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Abstract  
Background 
In many low-and middle-income countries, there is high maternal, infant and child 
mortality due in part to low contraceptive use and high unmet need for family 
planning. The aim of this overview of systematic reviews is to synthesise the 
findings of systematic reviews conducted in this area to assess the impact of various 
contraceptive methods and mixes of contraceptive methods on contraceptive 
prevalence, unwanted and unintended pregnancies, and unmet need (a desire to 
limit the number of children but not currently using any contraception) for family 
planning in developing countries/regions.  
Methods 
Eight databases (Bioline international, The Cochrane Library, Latin American and 
Caribbean Health Sciences Literature - LILACS, Popline, PubMed, Turning Research 
Into Practice, World Health Organisation Reproductive Health Library and Zetoc) 
were searched from 28 October 2010 to 08 December 2010. Cochrane and non-
Cochrane systematic reviews were included. Eligible reviews included studies whose 
participants were sexually active women or men from countries classified as 
‘developing’, ‘low-income’ or ‘middle-income’. Systematic reviews of any 
intervention (or combination of interventions) designed to increase contraceptive 
prevalence, reduce fertility or both were eligible. Data were extracted and 
synthesised narratively. A Measurement Tool to Assess Systematic Reviews, AMSTAR, 
was used to evaluate the quality of the included systematic reviews, and Grading of 
Recommendations, Assessment, Development and Evaluation (GRADE) was used to 
evaluate the quality of the body of evidence for each comparison. To aid the 
interpretation of the findings for a variety of settings, relevant contextual 
information was presented where possible.  
Results 
There were 22 systematic reviews included in this overview of reviews. The 
overview examined a range of contraceptive methods, including modern (terminal 
and spacing) and traditional methods (such as withdrawal and periodic abstinence 
which do not require contraceptive substances or devices and also do not require 
clinical procedures). However, the systematic reviews included did not address all 
the objectives of the overview. 
The results of the review are summarised below according to the objectives. 
Objective 1: To assess the impact of various contraceptive methods and mixes of 
contraceptive methods on contraceptive prevalence in developing countries/regions.  
There was no systematic review that met this objective.  
Objective 2: To assess the impact of various contraceptive methods and mixes of 
contraceptive methods on unwanted and unintended pregnancies in developing 
countries/regions. 
The body of evidence for the relative efficacy or effectiveness of a variety of 
contraceptive methods to prevent pregnancy in developing countries was generally 
rated as of low or moderate quality. There was, however, a number of comparisons 
(between different derivatives of the same contraceptive methods) for which the 
evidence was rated as of high or moderate quality. Evidence from systematic 
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reviews is lacking on the acceptability of contraceptive methods and their impact on 
prevalence and on unmet needs for family planning. The evidence for the relative 
effectiveness of a variety of contraceptive methods to prevent pregnancy in 
developing countries is generally of low quality. There is some high-quality evidence 
comparing different derivatives of the same contraceptive methods, although this is 
more often evidence of efficacy than evidence of effectiveness.  
Objective 3: To assess the impact of various contraceptive methods and mixes of 
contraceptive methods on unmet need for family planning in developing countries/regions. 
There was no systematic review that met this objective. 
Limitations and conclusions 
This overview of reviews could not identify any systematic reviews that could 
answer all the questions set out in the protocol, particularly those related to 
outcomes such as contraceptive prevalence and unmet need for contraception. This 
indicates lack of evidence either in the form of systematic reviews or in primary 
research. Thus, this overview of reviews points out the need to either undertake 
systematic reviews or RCTs (where these are possible) or non-RCT/observational 
studies (where RCTs are not possible). The overview of reviews, however, did 
provide an opportunity to compare the effectiveness of various contraceptive 
methods on outcome measures such as pregnancy and continuation. However much 
of the available evidence in this area is based on a limited number of poorly 
conducted studies comparing different formulations of the same type of 
contraceptive; there is a lack of evidence from well-designed studies comparing 
different types of contraceptives in developing country settings across a wider range 
of outcomes (e.g. to include birth spacing and unmet need for family planning). It 
was not possible to present evidence on the included outcomes for a number of 
types of contraception: male condoms, female condoms, diaphragms, vasectomy, 
skin patches and vaginal rings. The evidence examining traditional methods was 
particularly weak.  
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Executive summary  
Background 
Unintended pregnancies contribute towards accelerated population growth, and 
lead to closely spaced pregnancies and births, early childbearing and abortions. 
These in turn contribute to high maternal and infant mortality (Sedgh et al., 2006). 
Despite the existence of official family planning programmes, in many developing 
countries, contraceptive prevalence is low (United Nations, 2011) and women 
continue to have an unmet need for family planning (USAID, 2005). In general, 
access to a wide range of contraceptive methods is linked to higher levels of overall 
contraceptive prevalence (Ross et al., 2002; Magadi and Curtis, 2003). Factors such 
as policy, provider bias, history of a method within a country, properties of methods 
(e.g. effectiveness), acceptability and client characteristics also play a role in the 
methods utilised by the population (Sullivan et al., 2006). Hence, context is an 
important consideration and there is a need to examine the impact of different 
contraceptives (and combinations of contraceptives) on unmet need for family 
planning in the context of each developing country. Systematic reviews have been 
conducted in this area, but this evidence has not been brought together, and has 
not always been examined taking into account contextual factors. We therefore 
conducted an overview of systematic reviews to enable policy makers to identify 
those contraceptive methods (or range of contraceptive methods) likely to be most 
successful in the context of a particular country or region.  
Objectives 
Given the above background and conceptual framework, the specific objectives of 
the proposed overview of systematic reviews (OoR) are:  
 To assess the impact of various contraceptive methods and mixes of 
contraceptive methods on contraceptive prevalence in developing 
countries/regions. 
 To assess the impact of various contraceptive methods and mixes of 
contraceptive methods on unwanted and unintended pregnancies in developing 
countries/regions. 
 To assess the impact of various contraceptive methods and mixes of 
contraceptive methods on unmet need for family planning in developing 
countries/regions. 
Wherever possible, the review will try to provide findings for various regions: Sub-
Saharan Africa, North Africa, South Asia, Southeast Asia, West Asia, Latin America 
and the Caribbean.  
Methods  
This was an overview of Cochrane and non-Cochrane systematic reviews of 
randomised and non-randomised trials, observational studies and economic 
evaluations. Eligible reviews included studies whose participants were sexually 
active women or men from countries classified as ‘developing’, ‘low-income’ or 
‘middle-income’. Systematic reviews of any intervention (or combination of 
interventions) designed to increase contraceptive prevalence, reduce fertility or 
both (in order to prevent unwanted pregnancies; delay pregnancies; space 
pregnancies; limit fertility) were eligible. Primary outcomes of interest were 
What is the impact of contraceptive methods and mixes of contraceptive methods on contraceptive 
prevalence, unmet need for family planning, and unwanted and unintended pregnancies? 
4 
contraceptive prevalence, unwanted pregnancies, unintended pregnancies and 
unmet need for family planning. Secondary outcomes were initiation of 
contraceptive use, continuation of contraceptive use, adherence to contraception, 
time between pregnancies and time between births. Searches were carried out in 
the following databases: Bioline international, The Cochrane Library, LILACS, 
Popline, PubMed, TRIP, WHO Reproductive Health Library and Zetoc, from 28 
October 2010 to 08 December 2010, with no restriction on date. The search strategy 
included key words that could capture all studies on family planning and associated 
interventions, without limits on the primary and secondary outcomes. Titles and full 
texts were independently screened by two review authors. Data were extracted 
from included studies by two independent review authors using a data collection 
form designed for this review. Disagreements were resolved via a third author and 
discussion amongst the team. The AMSTAR tool was used to assess how well the 
included reviews were conducted. The GRADE approach (Grading of 
Recommendations, Assessment, Development and Evaluation) was used to assess the 
overall quality of the evidence in the included studies. The overall approach to 
synthesis was descriptive, and we did not seek to run a meta-analysis based on the 
pooled results from systematic reviews, as there was heterogeneity across the 
reviews. Data were interpreted with respect to the quality of the evidence.  
Details of the included reviews 
Twenty-two systematic reviews were included in this overview, twenty of which 
were Cochrane systematic reviews and two of which were articles in peer-reviewed 
journals. The systematic reviews can be grouped into ten types of contraception 
(examined at different levels): natural family planning, injectables, intrauterine 
devices, oral contraceptives, emergency contraception, sterilisation, spermicides, 
reversible contraception, and hormonal and non-hormonal contraception. The 
reviews assessed a wide variety of outcomes; however, of these only certain 
outcomes met the inclusion criteria for the overviews; continuation/ discontinuation 
of contraceptives and pregnancy. Within the included systematic reviews, data 
could be extracted from studies conducted in a number of developing countries 
(some of which were multi-centre: Argentina, Bangladesh, Brazil, Colombia, Chile, 
China, Ecuador, Egypt, Ghana, Guatemala, India, Indonesia, Kenya, Malaysia, 
Mexico, Nepal, Nigeria, Pakistan, Peru, the Philippines, Poland, Taiwan, Thailand, 
Turkey, Vietnam, Zambia) and over a wide range of dates (1973-2007).  
Synthesis results and conclusions 
Results 
The results are presented according to the objectives of the study. The majority of 
the individual studies included in the systematic reviews were randomised or non-
randomised trials. In many systematic reviews very little information is available 
about how individual studies (within systematic reviews) have recruited participants 
for various trials, how many have participated in the trials and how many have 
discontinued trials. This would have helped to examine the acceptability or 
effectiveness/efficacy of various contraceptive methods.  
Evidence from systematic reviews is lacking about the acceptability of contraceptive 
methods, and their impact on prevalence and on unmet needs for family planning. 
The relative effectiveness of a variety of contraceptive methods to prevent 
pregnancy in developing countries is generally of low quality. There is some high-
quality evidence comparing different derivatives of the same contraceptive method, 
although this is more often evidence of efficacy than evidence of effectiveness. 
Executive summary  
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Objective 1: To assess the impact of various contraceptive methods and mixes of 
contraceptive methods on contraceptive prevalence in developing countries/regions 
There was no systematic review that met this objective.  
Objective 2: To assess the impact of various contraceptive methods and mixes of 
contraceptive methods on unwanted and unintended pregnancies (and continuation and 
discontinuation of family planning methods) in developing countries/regions. 
The body of evidence for the relative effectiveness of a variety of contraceptive 
methods to prevent pregnancy in developing countries was generally rated as of low 
or moderate quality. There was, however, a number of comparisons (between 
different derivatives of the same contraceptive methods) for which the evidence 
was rated as of high or moderate quality.  
In the following paragraphs we present the efficacy or effectiveness of each modern 
and traditional family planning methods on pregnancy, and on continuation and 
discontinuation.  
Pregnancy  
MODERN CONTRACEPTIVE METHODS 
 Female sterilisation: There was only one systematic review dealing with female 
sterilisation; there was moderate-quality evidence from two RCT studies 
(number of participants: 724) demonstrating that rings and clips are equally 
efficacious to prevent pregnancy (Peto OR=1.09, 95%CI 0.22, 5.36), although 
evidence on other methods of tubal occlusion is of low quality.  
 The pill (oral contraception): Seven systematic reviews examining oral 
contraceptives contained data from developing countries and were included in 
this overview of reviews. For the majority of comparisons, the evidence suggests 
that there was no difference in effectiveness between a variety of oral 
contraceptive formulations and modes of administration, and for all 
comparisons, pregnancy rates were low in each group. However, the quality of 
evidence ranged widely, from very low to moderate, and follow-up was 
generally short. There is, however, moderate-quality evidence from two RCT 
studies (number of participants: 2,074) in the case of one oral contraceptive to 
favour a second-generation pill (monophasic norgestrel 0.3mg/EE 30mcg) over 
the first (monophasic norethindrone acetate 1.5mg/EE 30mcg) (RR=0.12, 95% CI 
0.02, 0.99) in preventing pregnancy.  
 Intrauterine devices: There is high-quality evidence from one systematic review 
to support the programmatic use of the TCU380A intrauterine device over the 
Multiload Cu375 device: (rate difference = 0.75, (95% CI 0.13, 0.37) at one year 
(2 RCT studies, 3,371 participants), and 1.50 (95% CI 0.09, 2.91), at two years 
follow-up (1 RCT study, 1,894 participants). 
 Injectables: Although moderate-quality evidence from one systematic review of 
two RCT studies (number of participants:4272) suggests that there is little to 
favour the use of two-monthly injections of NET-EN/E2V 50mg over three-
monthly injections of DMPA/E2c 5mg (Peto OR=0.75 (95%CI 0.67,0.84), there was 
no difference in the effectiveness of pregnancy prevention (one RCT study with 
3,915 participants: Peto OR = 1.95, 95% CI 0.53, 7.20). Where newer products 
are concerned, the evidence favours NET-EN/E2V over DMPA/E2C, since it is 
equally effective at reducing the risk of pregnancy. There are as yet insufficient 
data from developing countries to evaluate the comparison of the newer NET-
EN/E2V formulation against the ‘traditional’ DMPA 150 mg regimen. There is 
moderate-quality evidence from one systematic review of one RCT study that 
copper intrauterine devices (IUDs) are no more effective than depot 
What is the impact of contraceptive methods and mixes of contraceptive methods on contraceptive 
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progestogens to prevent pregnancy. 
 Implants: Low-quality evidence from one systematic review (number of 
participants: 1,219) suggests that the two implants Implanon and Norplant 
reduce the risk of pregnancy. 
 Emergency contraception (EC): There is moderate-quality evidence from one 
systematic review of 19 RCT studies that mid-dose mifepristone (25-50mg) is 
more effective than low-dose mifepristone (<25mg) for emergency contraception 
(RR= 0.66, 95% CI 0.47, 0.91; number of participants: 11432). There is no added 
benefit in combination formulations of mifepristone with other agents.  
 Foam/jelly (spermicides): The is moderate-quality evidence from one 
systematic review that there is no difference between a variety of spermicides: 
between Neo sampoon tablet (menfegol 60mg) and Ortho/Emko vaginal tablet 
(100mg of nonoxynol-9) (3 RCT studies; number of participants: 672); moderate 
quality evidence between Ortho vaginal tablet (100mg of nonoxynol-9) and Emko 
vaginal tablet (nonoxynol-9 (2 RCT studies; number of participants: 440); and 
moderate quality evidence between Neo sampoon tablet (menfegol 60mg) and 
Emko foam (nonoynol-9 8%) (2 RCT studies; number of participants: 620). There 
is  low-quality evidence that collatex sponge (nonoxynol-9 1.15mg) was no 
different from neo sampoon tablet (menfegol 60 mg) (one RCT study; number of 
participants: 1,299). 
TRADITIONAL METHODS 
 Periodic abstinence: The low-quality evidence reported by the systematic review 
on the comparison between the ovulation method and the symptothermal 
method (one systematic review, no information on number of participants) did 
not report any pregnancies occurring in either group and found relatively high 
discontinuation for both methods. 
 Lactational amenorrhea method (LAM): The evidence in this area was poor (two 
systematic reviews and two non-RTC studies; number of participants in these 
studies was 676 and 735 respectively), which made it difficult to draw any firm 
conclusions.  
Continuation and discontinuation 
MODERN METHODS 
 Oral contraception: Seven systematic reviews examining oral contraceptives 
contained data from developing countries and were included in this overview of 
reviews. For the majority of comparisons, the evidence suggested that there was 
no difference in discontinuation between a variety of oral contraceptive 
formulations and modes of administration. 
 Intrauterine devices: Four of the five comparisons provide moderate evidence 
of no difference in discontinuation. These are as follows: LNG-20 versus a non-
hormonal IUD ≤250mm2 (rate ratio at 2 years follow-up: 0.93, 95% CI: 0.80-1.07, 
1 study and 2118 participants), MLCu250 versus TCu380A (rate difference at 1 
year follow-up: −1.50 [−1.26, 4.26], 1 study and 2,043 participants) and also the 
TCu220 when compared with the TCu380A (rate difference at 1 year follow-up: 
−3.00, 95% CI: −7.21, 1.21, 1 study and 857 participants). Similarly, there is 
moderate evidence of no difference in discontinuation for the TCu200 versus the 
TCu380A (rate difference at 1 year follow-up: 1.00, 95% CI: −2.96, 4.96, 1 study 
and 1,678 participants). For the remaining comparison, there is low-quality 
evidence of no difference between LNG-20 versus subdermal implants (rate ratio 
at 1 year: 0.97, 95% CI: 0.72-1.31, 1 study and 200 participants). 
Executive summary  
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 Injectables: There is moderate-quality evidence that DMPA 25mg/E2C 5mg has 
lower discontinuation than NET-EN 50mg/E2V 5mg (Peto OR = 0.75, 95%CI: 0.67, 
0.84, 2 RCT studies and 4,272 participants). There is also moderate-quality 
evidence to suggest that there is no difference in discontinuation between 
administering DMPA 150mg IM every 3 months versus NET-EN 200mg IM every 2 
months (10 RCT studies and 2,467 participants). Additionally, there is low-
quality evidence suggesting that discontinuation is higher with DMPA 25mg/E2C 
5mg than with DMPA 150mg (1 RCT study and 360 participants), and with NET-EN 
50mg/E2V 5mg than with NET-EN 200mg (1 RCT study and 849 participants). 
 Implants: Low-quality evidence from one systematic review (number of 
participants: 1,219) suggests that the two implants Implanon and Norplant have 
no difference in discontinuation rates over a long period.  
 Spermicides: This review presents low-quality evidence to suggest that there is 
no difference in rates of discontinuation between collatex sponge (nonoxynol-9 
1.15mg) and Neo sampoon tablet (menfegol 60mg) (1 RCT study and 1,299 
participants), between Neo sampoon tablet (menfegol 60mg) and Emko foam 
(nonoxynol-9 8%) (2 RCT studies and 620 participants), nor between vaginal 
foaming tablets containing nonoxynol-9 (1.15mg) (2 RCT studies and 440 
participants) and those containing menfegol 60mg (3 RCT studies and 672 
participants).  
Gaps in the evidence: It was not possible to present evidence on the included 
outcomes for a number of types of contraception: male condoms, female condoms, 
diaphragms, vasectomy, skin patches or vaginal rings. 
TRADITIONAL METHODS 
 Periodic abstinence: The low-quality evidence reported by the systematic 
review for the comparison between the ovulation method and the 
symptothermal method (one systematic review, no information on number of 
participants) found relatively high discontinuation for both methods. 
 Lactational amenorrhea method (LAM): The evidence in this area was poor 
(two systematic reviews and two non-RTC studies; number of participants in 
these studies was 676 and 735 respectively), which made it difficult to draw any 
firm conclusions.  
Gaps in the evidence: It was not possible to present evidence on the included 
outcomes for the withdrawal method, and the quality of the evidence for other 
types of contraception was poor.  
Objective 3: To assess the impact of various contraceptive methods and mixes of 
contraceptive methods on unmet need for family planning in developing countries/regions. 
There was no systematic review that met this objective.  
Limitations and conclusions 
The overview of reviews (OoR) could not identify any systematic reviews that could 
address all the objectives, in particular, the impact of contraceptive methods and 
mixes of methods on contraceptive prevalence and unmet need for contraception. 
This indicates a lack of evidence either in the form of systematic reviews or in 
primary research. Thus, this OoR points out the need to either undertake systematic 
reviews or RCTs (where these are possible) or non-RCT/observational studies (where 
RCTs are not possible).  
This OoR, however, did provide an opportunity to compare the effectiveness of 
various contraceptive methods to prevent pregnancy and other outcome measures. 
What is the impact of contraceptive methods and mixes of contraceptive methods on contraceptive 
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Much of the available evidence in this area is based on a limited number of poorly 
conducted studies comparing different formulations of the same type of 
contraceptive. There is a lack of evidence from well-designed studies comparing 
different types of contraceptives in developing country settings across a wider range 
of outcomes (e.g. to include birth spacing and unmet need for family planning). 
Where the lack of evidence comparing different types of contraceptives is 
concerned, it is unclear if this is because primary studies do not exist or if it is due 
to the scope of existing systematic reviews.  
Existing systematic reviews provide little in the way of contextual information, for 
example on ease of access to family planning facilities (in the case of repeat-
administration contraceptives), which would help to inform users of the 
transferability of the findings across settings. Future reviews should consider 
providing as much contextual information as possible to aid interpretation for 
developing country settings.  
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1.  Background 
1.1  Aims and rationale for review 
Unintended pregnancies contribute towards accelerated population growth, and 
lead to closely spaced pregnancies and births, early child bearing, and abortions. 
These in turn contribute to high maternal and infant mortality (Sedgh et al., 2006). 
Despite the existence of official family planning programmes, in many developing 
countries, contraceptive prevalence is low (United Nations, 2009) and women 
continue to have an unmet need for family planning (USAID, 2005). In general, 
access to a wide range of contraceptive methods is linked to higher levels of overall 
contraceptive prevalence (Ross et al., 2002; Magadi and Curtis, 2003). Factors such 
as policy, provider bias, history of a method within a country, properties of methods 
(e.g. effectiveness), acceptability and client characteristics also play a role in the 
methods utilised by a population (Sullivan et al., 2006). Hence, context is an 
important consideration and there is a need to examine the impact of different 
contraceptives (and combinations of contraceptives) on unmet need for family 
planning in the context of developing countries (and regions). Systematic reviews 
have been conducted into family planning, but this evidence has not been brought 
together, and has not always been examined taking into account contextual factors. 
This overview of systematic reviews was conducted to enable policy makers to 
identify those contraceptive methods (or range of contraceptive methods) likely to 
be most successful in the context of a particular country or region.  
1.2  Definition and conceptual issues 
There is a large amount of terminology currently used in the field of family planning 
in developing countries. Some key definitions are provided below: 
Fertility: the reproductive performance of a woman. It also indicates the incidence 
of births in a population.  
Replacement level of fertility: in the absence of migration, the level of fertility 
and mortality in a population of interest to maintain existing population levels 
(approximately two children per women: Ross 2010).  
Desired fertility: total number of children desired by a woman or a couple. 
Actual fertility: the fertility level achieved by a woman or a couple.  
Contraceptive prevalence rate (CPR): the proportion of women of reproductive age 
(or their partners) who are using a contraceptive method at a given point in time 
(World Health Organization 2013). 
Family planning effort: quantification of the nature and strength of family planning 
efforts in a particular country (i.e. input into family planning). 
Method mix: the distribution of contraceptive methods used by a population (i.e. 
the percentage that uses each method). 
Skewed method mix: when a single method of contraception accounts for more 
than half of contraceptive use. 
Unintended pregnancies: pregnancies that are reported to have been either 
unwanted (i.e. they occurred when no children, or no more children, were desired) 
or mistimed/unplanned (i.e. they occurred earlier than desired). 
Unmet need for family planning: women of reproductive age who would prefer to 
avoid or postpone child bearing, but are not using any method of contraception. 
What is the impact of contraceptive methods and mixes of contraceptive methods on contraceptive 
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1.3  Policy and practice background  
In many developing countries (also termed low- and middle-income countries), 
official family planning programmes began during the 1960s with the aim of 
reducing high fertility i.e. high numbers of births per woman (Seltzer, 2002). 
However, in recent years, various demographic and health surveys (DHS) report that 
women in developing countries have lower desired fertility than actual fertility, i.e. 
women are having more children than they want. This indicates that there is still an 
unmet need for family planning i.e. there is a proportion of women of reproductive 
age who would prefer to avoid or postpone childbearing but who are not using any 
method of contraception. In 2000, an estimated 17 percent of married women (105 
million) had an unmet need for family planning in the developing world (USAID, 
2005), and there is considerable variation across countries, for example, 5 percent 
in Vietnam and 40 percent in Haiti (Khan et al., 2007).  
Indeed, despite official family planning programmes being in existence for more 
than 40 years, the contraceptive prevalence rate (CPR) is still low in many 
countries. The optimum level for contraceptive prevalence is regarded as 80-85 
percent, as this level is quite consistent with replacement level fertility. Although 
increased from the level seen in the 1960s (9 percent), according to the United 
Nations Population Division 2011), the contraceptive prevalence for the developing 
world in 2009 was 61.2 percent, and there were huge variations: it was only 2.8 
percent in Chad but 80 percent in Costa Rica, for example. There were also 
significant variations between regions: about 28 percent in Africa and 74 percent in 
South America (United Nations, 2011).  
An unmet need for family planning can have many undesired consequences in the 
areas of health, population growth and development. In developing countries, 
unintended pregnancies (either mistimed or unwanted at the time of conception) 
are one of the major consequences of an unmet need for contraception 
(Pallikadavath and Stones, 2006). This contributes towards accelerated population 
growth by unwanted fertility and closely spaced births. Further, unintended 
pregnancies often lead to closely spaced pregnancies and child births, early 
childbearing and abortions, which in turn lead to high maternal and infant mortality 
(Sedgh et al., 2006). Moreover, the need for family planning is generally high in 
societies where poverty, illiteracy and gender inequality are high (Nazar-
Beutelspacher et al., 1999). In such societies, unintended and repeat pregnancies 
make it difficult for women to participate in economic development and self-
development. This causes a cycle of ill health and poverty which, if uninterrupted, 
could transfer to future generations. Thus, there is a strong health rationale for 
addressing the unmet need for family planning services in developing countries and 
thereby contributing to the achievement of the United Nation’s Millennium 
Development Goals (MDGs), in particular goals 4 and 5: 
MDG 4. To reduce child mortality: 
Target 1. Reduce by two-thirds, between 1990 and 2015, the under-five mortality 
rate. 
MDG 5. To improve maternal health: 
Target 1. Reduce by three quarters the maternal mortality ratio.  
Target 2. Achieve universal access to reproductive health. 
1.4  Research background 
Studies have shown that countries in which all couples have easy access to a wide 
range of contraceptive methods have a more balanced methods mix and higher 
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levels of overall contraceptive prevalence than countries with limited access to 
various contraceptives (Ross et al., 2002; Magadi and Curtis, 2003). Further, Jain 
(1989) has estimated that the widespread addition of one method to options 
available in a country would be associated with an increase of 12 percent in 
contraceptive prevalence. A balanced method mix is also an indicator that there is 
no ‘systematic limitation of contraceptive choice’ (Sullivan et al. 2006). At the 
global level the most widely used contraceptive methods are female sterilisation (23 
percent), the IUD (15.1 percent) and the pill (7.2 percent) (United Nations, 2009). 
However, there are wide variations in the use of these methods within developing 
countries. For example, while sterilisation is the most popular contraceptive 
method in Brazil (40.1 percent) and India (37.3 percent), it is not widely used in 
Indonesia (3 percent) or Morocco (2.7 percent) (United Nations, 2009).  
A directive issued by the International Conference on Population and Development 
(ICPD) in 1996 recommended that countries should ‘Recognise that appropriate 
methods for couples and individuals vary according to their age, parity, family size 
preference and other factors, and ensure that women and men have information 
and access to the widest possible range of safe and effective family planning 
methods in order to enable them to exercise free and informed choice’ (United 
Nations Population Fund 1996: 53). It is since ICPD commitment that many countries 
have tried to provide a broad range of methods to their population. However, a 
study carried out using data from 1999 showed that this has not been achieved 
everywhere; about one-third of developing countries still had a skewed method mix, 
in which a single method accounted for more than half of contraceptive use 
(Sullivan et al., 2006).  
Contraceptive prevalence and method mix are influenced by a range of factors. 
According to Sullivan et al. (2006), these factors are: (1) policies and programmes: 
government promotion of certain methods at the expense of others, regulatory 
barriers, capacity and motivation to provide a range of methods; (2) provider bias: 
provider preference for specific methods; (3) history: length of time since the 
introduction of each method in a country; (4) the properties of the methods 
themselves: ease of distribution, high programme cost, side-effects, effectiveness; 
(5) client characteristics: knowledge of alternative methods, desire for limiting vs 
spacing, religious beliefs, personal preferences, age and life stage. For example, a 
strong relationship between the Family planning Programme Effort index (FPE)1 and 
contraceptive prevalence was noted in a study using 1999 FPE cycle data from 89 
countries. This study also showed that countries with high social and economic 
development had high contraceptive prevalence (Ross and Stover, 2001). In 
addition, the FPE and/or the particular social contexts of countries may lead to 
provision focusing on a particular contraceptive method. Historically in some 
countries, some contraceptive methods were given more importance than others 
either because of their effectiveness or ease of administration. Similarly, for 
religious reasons, some methods were less popular in some countries.  
This highlights the importance of context in assessing the suitability of different 
contraceptive methods (and combinations of methods) for developing countries. 
This is further supported by research which has been carried out to measure the 
‘ideal’ method mix in order to help focus family planning programmes. According to 
Choe and Bulatao (1992), contraceptive choices will be different at the different 
stages of the reproductive life cycle defined as: (1) before first marriage; (2) after 
first marriage but before first birth; (3) after first birth but before last birth; (4) 
                                            
1 A summary of family planning effort measured using policy, services, evaluation and method 
availability. 
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after last. Using the above framework Choe and Bulatao (1992) suggested an ‘ideal’ 
contraceptive mix for Indonesia and showed its potential benefit for improving 
family planning programmes through targeted interventions. However, there has 
been no consensus about the ‘optimal’ or ‘ideal’ method mix among the 
international reproductive health community, as reproductive needs are different 
for different countries (Sullivan et al., 2006).  
1.5  Conceptual framework 
A conceptual framework linking contraceptive prevalence and method mix with 
unmet need for family planning, unintended pregnancy and fertility is presented in 
Figure 1.1. According to the framework, family planning programmes and policies 
determine the number of contraceptive methods available for public use: the 
contraceptive choice mix. The range of contraceptives available to individuals may 
be more limited than those made available for public use, either affected by 
provider bias and/or an individual’s access to and acceptability of the family 
planning services provided.  
The acceptability of the contraceptives to which individuals have access will affect 
both whether they will choose to use any of the available methods (initiation of 
contraceptive use) and whether they continue with their chosen method 
(continuation of contraceptive use). It may also affect whether or not individuals 
adhere to their chosen contraceptive method (adherence). The context (e.g. client 
characteristics, length of time since introduction of each method and the properties 
of the methods) may affect the expectations and requirements that an individual 
has of particular contraceptive methods and hence the acceptability of each 
method. 
The acceptability of the contraceptives to which individuals have access will be 
reflected in the contraceptive prevalence and the method mix, i.e., fewer people 
may use contraceptives if there is a lack of acceptable accessible methods and 
there may be a greater skew towards contraceptives that are more acceptable (or 
more accessible). It will also be, more directly, reflected in the levels of unmet 
need for family planning, i.e., where individuals lack access to acceptable 
contraceptives, they will choose not to use the available method, even if they 
desire to space or limit their fertility. Further, the acceptability of the available 
contraceptives (individually and in combination) will combine with the known 
efficacy2 of the method to produce the effectiveness of both individual 
contraceptives and of the range of available contraceptives. 
The effect of an unmet need for family planning and of the effectiveness of the 
available contraceptive methods (individually and in combination) is reflected in 
rates of unintended and unwanted pregnancies, and the consequent rates of 
unintended/unwanted births (fertility). As discussed previously, unintended and 
unwanted pregnancies could have adverse health effects on mother and child; they 
could also accelerate population growth and slow down development by reinforcing 
poverty, illiteracy and gender inequality. An examination of rates of unintended and 
unwanted pregnancies may indicate where there is a greater need for acceptable 
spacing or terminal methods of contraception, i.e., unintended pregnancies may 
indicate that more acceptable spacing methods are required and unwanted 
pregnancies may indicate that more acceptable terminal methods are required.
                                            
2 Efficacy is the extent to which an intervention has the ability to bring about its intended effect under 
ideal circumstances, such as in a randomised clinical trial; effectiveness is the extent to which an 
intervention achieves its intended effect in the usual clinical setting. 
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Figure 1.1: Conceptual framework of the factors influencing 
contraceptive prevalence, method mix and unmet need for 
family planning 
 
Notes: Light grey shaded boxes = contextual factors; Blue shaded boxes = focus of 
this OoR; Unshaded boxes = consequences of unintended/unwanted pregnancies). 
EM= emergency contraception; LAM = lactational amenorrhea with support; ab= 
abstinence. The boxes with black borders indicate the interventions discussed, 
with numbers of participants. 
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1.6  Focus of this review 
The conceptual framework outlined above encompasses a wide range of factors 
which influence contraceptive prevalence, unmet need for family planning and 
unintended pregnancies and births. One key aspect of this framework for family 
planning policy development in developing countries is the impact of the type (and 
range) of contraceptives available to individuals on these outcomes. Although 
studies suggest that increasing the number of methods of contraception available to 
women (and their partners) increases contraceptive prevalence, it is important to 
examine the impact that the contraceptives individuals have access to (either 
individually or in combination) have on contraceptive prevalence or unmet need for 
family planning, and ultimately on rates of unintended and unwanted pregnancies.  
As previously discussed, research suggests that the acceptability of different 
methods may vary according to context, and therefore that different contraceptives 
(and ranges of contraceptives) may be more or less successful in different countries 
or regions. Hence, where possible, there is a need to examine the impact of 
different contraceptives (and combinations of contraceptives) on outcomes such as 
unmet need for family planning in this context. Systematic reviews have been 
conducted in this area, but this evidence has not been brought together, and has 
not always been examined taking into account contextual factors. We will therefore 
conduct an overview of systematic reviews to enable policy makers to identify those 
contraceptive methods (or range of contraceptive methods) likely to be most 
successful in the context of a particular country or region. Overviews of systematic 
reviews are intended primarily to summarise multiple systematic reviews of 
interventions, and have a similar structure to systematic reviews, except that they 
include reviews rather than primary studies as their unit of interest (Becker and 
Oxman 2008).  
1.7  Objectives  
The specific objectives of the proposed overview of systematic reviews (OoR) are:  
1. To assess the impact of various contraceptive methods and mixes of 
contraceptive methods on contraceptive prevalence in developing 
countries/regions. 
2. To assess the impact of various contraceptive methods and mixes of 
contraceptive methods on unwanted and unintended pregnancies in developing 
countries/regions. 
3. To assess the impact of various contraceptive methods and mixes of 
contraceptive methods on unmet need for family planning in developing 
countries/regions. 
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2.  Methods used in the review 
2.1  User involvement 
2.1.1  Approach and rationale 
Consumer involvement in OoRs and systematic reviews can help to ensure that 
reviews address topics and outcomes salient to a particular population. Due to time 
constraints, it was not possible to engage in a wide consultation with relevant 
stakeholders to inform the scope of the OoR. In order to ensure the salience and 
scope of the OoR, we have established a multidisciplinary review team including Dr 
Saseendran Pallikadavath, who has experience of conducting global health research 
in India and Brazil, and Professor William Stones, who is the Puribai Kanji Professor 
and Chair, Department of Obstetrics and Gynaecology, Aga Khan University, Nairobi, 
Kenya. Further, we have sought peer review from the South African Cochrane 
Centre and the UK Cochrane Centre.  
2.2  Identifying and describing reviews 
2.2.1  Defining relevant reviews: inclusion and exclusion criteria 
For this OoR, we included Cochrane and non-Cochrane systematic reviews of 
randomised and non-randomised trials, observational studies and economic 
evaluations on the effects of methods (and mixes of methods) of contraception on 
(1) contraceptive prevalence, (2) unwanted pregnancies, (3) unintended 
pregnancies and (4) unmet need for family planning. The included systematic 
reviews may have incorporated a full range of study designs. 
Systematic reviews were eligible where participants were sexually active women or 
men from countries classified as ‘developing’, ‘low-income’ or ‘middle-income’ 
countries by the author(s) of the review; or those classified as low-and middle-
income countries according to the World Bank classification of countries based on 
gross national income (GNI)3 at the time the study was conducted. Reviews that 
included studies with participants from ‘high-income’ or ‘developed’ countries were 
eligible, but only when it was possible to use the data from the studies conducted in 
‘developing’, ‘low-income’ or ‘middle-income’ countries separately.  
These inclusion criteria were broad in order to ensure that the OoR included all 
relevant systematic reviews. For example, although we acknowledge that family 
planning services in developing countries are typically targeted at ‘currently 
married’ women aged 15-49 years, it was feasible that systematic reviews in the 
area may have taken a broader eligibility criterion, and we sought to include these 
in the OoR.  
This overview included systematic reviews of any intervention (or combination of 
interventions) designed to increase contraceptive prevalence, reduce fertility or 
both (in order to prevent unwanted pregnancies, delay pregnancies, space 
pregnancies or limit fertility). Systematic reviews which have examined the use of 
contraception for other purposes (e.g. condoms to reduce the transmission of 
infectious disease) or included studies which have done so were included in the OoR 
provided that one of the relevant outcomes had been assessed.  
Our primary outcome measures were: contraceptive prevalence; unwanted 
                                            
3 http://data.worldbank.org/about/country-classifications 
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pregnancies; unintended pregnancies; and unmet need for family planning. 
Secondary outcome measures were: initiation of contraceptive use; continuation of 
contraceptive use; adherence to contraception; time between pregnancies; and 
time between births. 
Full details of the inclusion and exclusion criteria can be found in Appendix 2.1. 
2.2.2  Identification of potential reviews: search strategy 
Since this overview includes both Cochrane and non-Cochrane systematic reviews, 
searches were conducted of a variety of electronic databases in the field of 
healthcare, reproductive health, demography, population studies, population 
geography and family planning. Searches were made of the following databases 
during the period 28 October 2010 to 8 December 2010: Cochrane Library, PubMed, 
Bioline International, Popline, WHO Reproductive Health Library, LILACS, Turning 
Research Into Practice (TRIP) database and Zetoc (The British Library's Electronic 
Table of Contents).  
Further details and the search strategies can be found in Appendix 2.2. No language 
or date restrictions were employed. Advice was sought from an information 
specialist to ensure that rigorous search strategies were employed. Search results 
were imported into reference management software and duplicates were removed 
prior to screening for relevance. We did not attempt to update any existing 
systematic reviews which were out of date to see if any new RCTs or non-RCTs had 
been published. Protocols and ongoing systematic reviews were not included in this 
overview of reviews. 
2.2.3  Screening reviews: applying inclusion and exclusion criteria 
Titles were independently screened by two review authors. For those titles deemed 
potentially eligible (and where there was disagreement between review authors), 
both the titles and abstracts were reviewed. These were independently screened by 
two review authors and rated as either ‘exclude’ or ‘potentially eligible’. 
Disagreements were resolved by discussion between the two review authors. Full 
reports of abstracts were obtained for citations classified as potentially eligible, and 
where there was doubt about eligibility or disagreement between review authors 
that could not be resolved by discussion. The full reports were assessed 
independently by two review authors to establish their eligibility for inclusion in the 
OoR using the study eligibility form in Appendix 2.3. They were then classified as 
either ‘excluded’, ‘included’ or ‘subject to clarification’. Disagreements were 
resolved by discussion between the two review authors. Other authors were brought 
in where disagreements could not be resolved, and a resolution was achieved by 
discussion amongst the review team. At each stage of screening, all titles, 
abstracts, and full reports were screened by one review author (HM), with the 
second independent screening shared amongst the rest of the team (SP, TD, AD, 
WS); this provided a level of consistency and helped identify duplicate publications 
of the same report. 
2.2.4  Characterising included reviews  
Data were extracted from included reviews using a data collection tool designed for 
this review (Appendix 2.4). In general, the data collection form sought information 
on the following: general information (e.g. review identification, authors, contact 
details and date of last update), objectives, inclusion and exclusion criteria, 
participants, interventions, comparison interventions, length of interventions, 
length of follow-up, included studies, countries in which the included studies were 
conducted, included study designs, outcomes for which data were reported, 
comparisons performed, methods and results of study-level quality assessment, 
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summary of results for each relevant outcome, and review quality assessment. 
Source page numbers were included for ease of reference and, where information 
was missing or unclear, this was marked as such on the form.  
Due to time constraints, data were extracted individually by review authors and 
verified upon data inputting. The authors of the original systematic reviews were 
contacted for any missing data or for clarification where necessary.  
2.2.5  Identifying and describing reviews: quality assurance process 
There were a number of ways in which the quality of the identification and 
description of studies was ensured. Firstly, the team consisted of a number of 
review authors with a range of expertise and backgrounds. Secondly, the protocol 
for the OoR was subject to peer review by both the UK and the South African 
Cochrane Centres, and advice was sought from an information specialist to ensure 
that robust search strategies were employed. Thirdly, all stages of screening (title, 
title and abstract, full text) were completed independently by two review authors, 
who then compared their decisions and came to a consensus. Finally, both the study 
eligibility and data collection forms were piloted for ease of use and clarity. Notes 
sheets were provided for additional information (e.g. the World Bank’s 
classifications of countries by income) to ensure that decisions were informed by 
clear and transparent information. 
2.3  Methods for synthesis  
2.3.1  Assessing the quality of the reviews 
Included reviews 
The quality of included reviews was independently assessed by two review authors 
using the AMSTAR tool (Shea et al., 2007). Full details can be found in Section E of 
Appendix 2.4. Any disagreements were resolved by discussion between the assessors 
and by bringing in a third review author. Where disagreements could not be resolved 
through discussion amongst the review team, a two-thirds majority informed the 
final decision. Where items were graded as ‘Can’t answer’, the authors of the 
original systematic review were contacted for clarification. 
Quality of evidence in the studies included in the reviews 
The GRADE approach was used to assess the overall quality of the evidence in the 
included reviews (GRADE working group, 2004). This approach defines quality of 
evidence as ‘the extent to which one can be confident that an estimate of effect is 
correct’. The quality of evidence was graded in the following stages according to 
the listed criteria: 
 High = Randomised trials or double-upgraded observational studies 
 Moderate = Downgraded randomised trials or upgraded observational studies 
 Low = Double-downgraded randomised trials or observational studies 
 Very low = Triple-downgraded randomised trials or downgraded observational 
studies or case studies/case reports 
A study is downgraded if there is: 
 A serious (-1) or very serious (-2) limitation to study quality 
 an important inconsistency (-1) 
 some (-1) or major (-2) uncertainty about directness 
 imprecise or sparse data (-1) 
 high probability of reporting bias (-1). 
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A study is upgraded if: 
 there is strong evidence of association – a significant risk ratio of >2 (<0.5) based 
on consistent evidence from two or more observational studies, with no 
plausible confounders (+1) 
 there is very strong evidence of association – a significant risk ratio of >5 (<0.2) 
based on direct evidence with no major threats to validity (+2) 
 there is evidence of a dose-response gradient (+1) 
all plausible confounders would have reduced the effect (+1). 
2.3.2  Overall approach to and process of synthesis 
The overall approach to synthesis was descriptive, and we did not seek to run a 
meta-analysis based on the pooled results obtained from the systematic reviews 
because of heterogeneity between reviews. However, where appropriate, pooled 
results of individual systematic reviews were presented. Our approach was to map 
the current evidence against the taxonomy of interventions detailed in section 2.2. 
This mapping additionally enabled an assessment of areas in which there was a lack 
of systematic review evidence. Further, in synthesising the evidence, information 
was sought on contextual factors and on intervention characteristics that might 
explain the extent to which the intervention or outcomes are sustained. For each 
country included in the final OoR the following was recorded:  
 GDP (Gross Domestic Product), at the time of the study(s). 
 A description of the current family planning programme as follows: 
o Family planning effort 
o Contraceptive methods available 
o Methods of delivery of family planning services (e.g. community based, 
home visits, incentives, social marketing) 
o Method mix (the distribution of contraceptive methods used by a 
population) 
 Contraceptive prevalence rate 
 Total fertility rate (TFR) 
 Average ideal number of children (AINC). 
At the study level, for each outcome, and where possible (i.e. where description 
was provided in the systematic review), the following contextual factors were also 
mapped: access to family planning services, including distance factors (e.g. distance 
to family planning services, lack of transportation), health-system factors (e.g. 
provider bias, staffing shortages and lack of availability of preferred methods) and 
client/community factors (e.g. prohibitive cost of products/services, lack of client 
awareness, cultural factors).  
2.3.3  Selection of studies for synthesis (if not all studies that were described are 
included in the synthesis)  
All studies meeting the inclusion criteria were included in the synthesis.  
2.3.4  Selection of outcome data for synthesis 
Outcome data were only extracted where the outcome met our inclusion criteria 
and it was possible to extract the data from developing countries separately. Data 
were extracted using a data collection form to ensure that the relevant information 
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was extracted uniformly across reports (see the data collection tool in Appendix 
2.4). Where available, we extracted the pooled effect estimates of meta-analyses 
(with confidence intervals where provided) conducted within included systematic 
reviews. If this information was not available, we presented the findings according 
to the statistical information available in each review. The systematic review 
authors were contacted to provide additional information or clarification as 
appropriate.  
2.3.5  Process used to combine/synthesise data 
Data were interpreted with respect to the quality of the evidence and critique of 
the included systematic reviews. We aimed to present the best available evidence, 
to help inform policy. Where systematic reviews of RCTs and those of RCT and non-
RCTs had examined the same intervention and outcome, a judgement was made 
about whether to include the non-RCT data. This decision was primarily informed by 
the quality of the non-RCT evidence and whether this evidence conflicted with that 
provided by RCT evidence. For example, where there was good-quality non-RCT 
evidence (i.e. upgraded or double-upgraded observational studies) this was 
included. However, where observational studies that had not been upgraded 
conflicted with evidence from good-quality RCT evidence, this evidence was not 
included. Such decisions are documented in Chapter 4. Where we found only low-
quality non-RCT evidence, this is presented as the best available evidence, but the 
limitations with regard to the interpretation of such evidence are discussed. 
Where possible, to further enable comparisons, statistical reports of outcomes have 
been standardised across included reviews. Attention was also paid to whether 
reviews had treated pregnancy as an event or a non-event4, in order to ensure that 
the findings were correctly interpreted and presented consistently alongside those 
from different reviews. Attention was also paid to studies that had been included in 
more than one review, to avoid unit of analysis errors. If a comparison was 
examined by more than one systematic review and there was an overlap between 
included studies, data were extracted from both reviews and duplicate study data 
removed. If there was any discrepancy in the data presented from a study contained 
in more than one systematic review, the original paper was inspected. 
Given the time available and the additional statistical support that would be 
required, where systematic reviews did include all potential information on direct 
comparisons, we did not seek to undertake additional statistical analyses of indirect 
comparisons. In this case, we have noted the lack of available evidence for each 
potential direct comparison. 
2.4  Deriving conclusions and implications 
Where possible, data from the included systematic reviews have been presented in 
an overview of Reviews table (the equivalent of the Summary of Findings tables in 
systematic reviews – Becker and Oxman 2008) under the following headings: 
outcomes, assumed risk (with comparator), corresponding risk (with intervention), 
relative effect, number of participants and studies, quality and comments. Data 
were managed using RevMan 5. 
                                            
4 If pregnancy is treated an event in one study and a non-event in another study the results when they 
are combined will be different. To avoid this all pregnancy were treated as an event.  
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3.  Search results 
3.1  Studies included from searching and screening 
The screening process is described in Figure 3.1. Of the 12,680 citations identified 
by the searches, 203 were identified as duplicates and removed. Due to the large 
number of citations and high volume of irrelevant records (the TRIP database 
required free-text searching and proved to yield results with low specificity), an 
initial screen of titles was performed independently by two review authors. As a 
result 889 titles and abstracts (where review authors agreed the reference was 
potentially eligible or disagreed about eligibility) were screened for potential 
relevance to the overview. Of these, 141 were identified as potentially eligible and 
the full-text retrieved for screening. Of these 22 were included in the review. 
Figure 3.1: Filtering of papers from searching to map to synthesis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2  Details of the included reviews 
Twenty-two systematic reviews were included in this overview, twenty of which 
were Cochrane systematic reviews and two of which were articles in peer-reviewed 
journals. The systematic reviews can be grouped into ten types of contraception 
(examined at different levels): natural family planning, injectables, intrauterine 
devices, oral contraceptives, emergency contraception, sterilisation, spermicide, 
reversible contraception, and hormonal and non-hormonal contraception. The 
included reviews assessed a wide variety of outcomes; however, of these, only the 
following met the inclusion criteria for the overview: continuation/discontinuation 
of contraceptives and pregnancy. Details of the included reviews are provided in 
Appendix 3.1.  
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4.  Synthesis results  
4.1  Further details of the reviews included in the synthesis 
The majority of the systematic reviews included in this overview of reviews 
compared different formulations within one category of contraceptives (e.g. 
different formulations of the contraceptive pill: Cheng5 2008; Draper 2006; Edelman 
2005; French 2004; Gallo 2008; Gallo 2011; Grimes 2004; Grimes 2005; Grimes 
2010a; Grimes 2010b; Halpern 2010; Kejuan 2007; Kulier 2007; Lawrie 2011; Maitra 
2004; Power 2007; Van der Wijden 2003; Van Vliet 2006a, b; Wen 2009). Only one of 
the included systematic reviews compared one type of contraceptive with another 
(Hofmeyr 2010). The studies included in the systematic reviews were predominately 
RCTs. Within the included systematic reviews, data could be extracted from studies 
conducted in a number of developing countries (some of which were multi-centre: 
Argentina, Bangladesh, Brazil, Chile, China, Colombia, Egypt, Ecuador, Ghana, 
Guatemala, India, Indonesia, Kenya, Malaysia, Mexico, Nepal, Nigeria, Pakistan, 
Peru, the Philippines, Poland, Taiwan, Thailand, Turkey, Vietnam, Zambia) and over 
a wide range of dates (1973-2007).  
We had originally planned to map the findings in relation to a number of contextual 
factors, primarily access to family planning services, including: distance factors 
(e.g. distance to family planning services, lack of transportation); health-system 
factors (e.g. provider bias, staffing shortages and lack of availability of preferred 
methods); and client/community factors (e.g. prohibitive cost of products/services, 
lack of client awareness, cultural factors). However, only a handful of reviews 
reported any contextual information for (at least some of) the included comparisons 
and this predominantly focused on the location of delivery of services and the 
profession of those delivering them (Cheng 2008, French 2004, Gallo 2008, Grimes 
2004, Grimes 2010a, Halpern 2010, Hofmeyr 2010, Kulier 2007). Additionally, no 
reviews focused on the effectiveness and/or acceptability of contraceptives within 
different settings (e.g. developing countries). Appendices 4.1, 4.2 and 4.3 provide 
further information about the reviews included in the synthesis.  
4.2 Quality of included reviews 
All the included reviews had ‘a priori’ research questions and inclusion criteria. 
Eleven of the 22 conducted duplicate study selection and data extraction (Cheng, 
2008; Draper 2006; Grimes 2010a, b; Halpern 2010; Kejuan 2007; Lawrie 2011; 
Maitra 2004; Power 2007; Van der Wijden 2003; Van Vliet 2006a; Wen 2009). 
However, in one of these reviews, the second author confirmed the eligibility of the 
reports selected rather than screening independently (Grimes 2010b); in two others, 
this was the case for data extraction (Van der Wijden 2003; Van Vliet 2006b); and a 
further review carried out data extraction by one autheor for  articles not published 
in Chinese (Cheng 2008). Six included reviews reported conducting single-author 
study eligibility screening and duplicate data extraction (Edelman, 2005; French 
2004; Gallo 2008; Grimes 2005; Kulier 2007; O’Brien 2005). An additional review 
reported duplicate data extraction but did not report on screening study eligibility 
(Hofmeyr 2010) and a further review reported single-author eligibility screening for 
titles and abstracts but failed to mention the procedure for full-text screening 
(Gallo 2011). One review made no mention of the procedure for screening or data 
                                            
5 Since all the reviews were multi-authored, et al. has been omitted in references to the included 
systematic reviews. 
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extraction (Grimes 2004). 
Nineteen reviews conducted comprehensive literature searches (Cheng 2008; Draper 
2006; Edelman 2005; French 2004; Gallo 2008, 2011; Grimes 2004, 2010a; Halpern 
2010; Hofmeyr 2010; Kejuan 2007; Lawrie 2011; Maitra 2004; O’Brien 2005; Power 
2007; Van der Wijden 2003; Van Vliet 2006a, b; Wen 2009). The literature searches 
of three reviews were not comprehensive: in two, no dates were provided (Grimes 
2010b; Grimes 2005); in another, the search was not supplemented by further 
information (Kulier 2007). The status of publication was used as an inclusion 
criterion in seven reviews (Draper 2006; Gallo 2011; Grimes 2004; Hofmeyr 2010; 
Kejuan 2007; Kulier 2007; O’Brien 2005). All except two reviews provided a list of 
included and excluded studies: Kejuan (2007) and Power (2007) failed to report 
excluded studies. The characteristics of the included studies were provided in all 
but one review (Kejuan 2007), which provided incomplete information. The 
scientific quality of the included studies was assessed and documented in all 
reviews. This assessment was used appropriately in formulating conclusions in all 
but two reviews (French 2004; Kejuan 2007).  
The methods used to combine the findings of the studies were appropriate in fifteen 
of the included reviews (Cheng 2008; Draper, 2006; Gallo 2011; Grimes 2004, 2005, 
2010a, b,; Kejuan 2007; Halpern 2010; Hofmeyr 2010; Lawrie 2011; O’Brien 2005; 
Power 2007; Van der Wijden 2003; Van Vliet 2006a, b; Wen 2009). In five reviews, 
the methods used to combine reviews were not appropriate: three did not test for 
homogeneity of pooled results (Edelman 2005; Gallo 2008; Maitra 2004) and one 
occasionally used fixed-effects models regardless of the high size of I2 (Kulier 2007). 
It was not possible to judge this for one review (French 2004) because the methods 
did not clearly reflect the presentation of the results; fixed-effects models were 
used to pool data with heterogeneity (which is not consistently reported) and it was 
not clear how the authors decided whether to use fixed- or random-effects models. 
Most reviews (n=17) did not assess the likelihood of publication bias (Edelman 2005; 
French 2004; Gallo 2008, 2011; Grimes 2004, 2010b, 2011; Halpern 2010; Kejuan 
2007; Kulier 2007; Lawrie 2011; Maitra 2004; O’Brien 2005; Power 2007; Van der 
Wijden 2003; Van Vliet 2006a, b). However, many reviews conducted narrative 
syntheses where data pooling was not possible. All except two reviews (Draper 2006; 
Kejuan 2007) made statements regarding conflict of interest.  
4.3  Synthesis: quality assurance results 
At each stage of screening, all titles, abstracts and full reports were screened by 
one review author (HM), with the second independent screening shared amongst the 
rest of the team (SP, TD, AD, WS); this provided a level of consistency and helped 
identify duplicate publications of the same report. In the case of titles, 
disagreement was resolved by reviewing the abstracts. At all other stages, 
disagreements were resolved by discussion between the two relevant review 
authors. Other authors were brought in where disagreements could not be resolved, 
and a resolution was achieved by discussion amongst the review team. The full 
reports were assessed independently by two review authors to establish their 
eligibility for inclusion in the OoR using the study eligibility form in Appendix 2.3. 
Data extraction was also conducted using a pre-specified format (see the data 
collection tool in Appendix 2.4).  
4.4  Syntheses of evidence 
Syntheses of evidence are presented according to the objectives of the overview. No 
systematic reviews covered unmet needs, contraceptive prevalence or economic 
evaluations; other outcomes met our inclusion criteria. Figure 4.1, ‘funnel of 
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attrition’ for various contraceptives, is provided to help readers understand various 
data points used in the analysis. The outer layer in the circle shows how many 
women were recruited (i.e. initially agreed to participate) in various studies 
included in the overview. If we had had information about the size of the target 
population, it would have been possible to estimate the general acceptability of 
each contraceptive method. However, this information was not available and 
therefore the evidence presented in this OoR is mainly evidence of efficacy rather 
than evidence of effectiveness. The second layer in the attrition funnel is the 
number of women who actually participated in the various trials. If we know how 
many women were recruited then we can find out the participation rate (another 
measure of acceptance). For many methods, we do not know further details, such as 
how many were discontinued and whether or not these women were included in the 
calculation of pregnancy rates. Therefore, these rates could reflect either the 
efficacy or the effectiveness of the methods investigated.  
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Figure 4.1: Funnel of attrition for various contraceptive methods 
 
 
 
 
 
 
No systematic reviews were found which addressed Objectives 1 and 3. Therefore, 
the remainder of this chapter describes the results for Objective 2: To assess the 
impact of various contraceptive methods and mixes of contraceptive methods on 
unwanted and unintended pregnancies in developing countries/regions. 
The body of evidence for the relative effectiveness of a variety of contraceptive 
methods to prevent pregnancy in developing countries was generally rated as low or 
moderate. There was, however, a number of comparisons (between different 
derivatives of the same contraceptive methods) for which the evidence was rated as 
being of high or moderate quality.  
4.4.1 Pregnancy 
4.4.1.1 Terminal methods 
1. FEMALE STERILISATION  
The analysis presented in this section is based on 1,297 women who participated in 
the trials from a total number of 1,327 women who initially agreed to participate. 
As these results are based on the number of women who remained in the trials until 
they had been sterilised, outcomes can be interpreted as the efficacy of female 
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sterilisation to prevent pregnancies. Since only very few women dropped out after 
recruitment into the study, the acceptability of female sterilisation was very high 
(98 percent). One included systematic review examined female sterilisation (Lawrie 
2011); four of the comparisons contained data from developing countries and could 
be included in the overview (Appendix 4.2, Table 4.2a). One comparison (including 
data from two RCT studies and 724 participants) examined the number of 
pregnancies in a group sterilised using tubal rings versus those sterilised using tubal 
clips.  
No difference was found in the number of pregnancies between groups (Peto OR = 
1.09, 95% CI 0.22, 5.36). The quality of the body of evidence for this comparison 
was given a GRADE rating of moderate. No differences in numbers of pregnancies 
were found in the remaining three comparisons (each containing one study): 
modified Pomeroy versus electrocoagulation (Peto OR = 4.47, 95% CI 0.07, 286.78; 
295 participants), tubal ring versus electrocoagulation (Peto OR = 0.0, 95%CI 0.0, 
0.0; 160 participants) and modified Pomeroy versus clip (Peto OR = 8.28, 95% CI 
0.16, 419.87; 148 participants).  
It should, however, be noted that the body of evidence for all comparisons was 
graded as very low; for two of these comparisons the confidence intervals were 
extremely wide and for the other there were no pregnancies in either group. The 
results outlined above obtained from developing countries are comparable with the 
results obtained from developing and developed countries combined, indicating no 
difference in the effectiveness of different female sterilisation procedures on 
preventing pregnancy. The implication for policy and practice is that failure rates 
are very low for all methods of female sterilisation.  
2. MALE STERILISATION 
No systematic reviews examining male sterilisation met the eligibility criteria for 
this overview of reviews. 
4.4.1.2 Spacing/temporary methods 
1. THE PILL  
Overall 15,201 women agreed to participate in various trials included in the 
systematic reviews that were included in the overview. Of this, 3,502 discontinued 
and the analysis is based on the remaining 11,699 women who completed the trial. 
Therefore, the results refer to the efficacy of various types of pills rather than their 
effectiveness to prevent pregnancy. Of the included systematic reviews, seven 
examined the impact of oral contraception on pregnancy and discontinuation of the 
method (Edelman 2005; Gallo 2011; Grimes 2010b; Kejuan 2007; Maitra 2004; Van 
Vliet 2006a, b: see Appendix 4.2, Tables 4.2b and 4.2c). Within these reviews, 17 
comparisons contained (extractable) data from developing countries examining 
pregnancy as an outcome. Fifteen comparisons contained extractable, relevant, 
data examining discontinuation as an outcome. Data on continuation was reported 
for a further comparison. 
For the pregnancy outcome, two comparisons found significant differences between 
the intervention and comparison oral contraceptive regimen, although the quality of 
the evidence for these varied. One review (Maitra 2004), interested in progestogens 
in combined oral contraceptives (COCs), identified moderate-quality evidence (using 
pooled data from two studies, comprising 2,074 participants) that monophasic 
norgestrel 0.3mg/EE 30mcg (Lo-femenal; second-generation OC) was more effective 
at preventing pregnancy than was monophasic norethindrone acetate 1.5mg/EE 
30mcg (Lo-estrin: first-generation OC: RR = 0.12, 95%CI: 0.02, 0.99).  
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A further review (Edelman 2005) examined continuous or extended cycles versus 
cyclic use of combined hormonal contraception. This review identified low-quality 
evidence, from a single study (900 participants), which indicated that 28-day cycle 
(cyclic) vaginal administration of 50µg ethinyl estradiol and 250µg levonorgestrel 
resulted in fewer pregnancies than did continuous administration (1 year: Peto OR = 
0.14, 95% CI 0.02, 0.97). In addition, a review predominantly of RCTs (Grimes 
2010b; one study, 518 participants), which was interested in progestin-only pills for 
contraception, reported fewest pregnancies in the group taking levonorgestrel 
150/ethinyl estradiol 30mg, followed (in order of effectiveness) by norethisterone 
1mg/mestraw 150mg then levonorgestrel 30mg and finally, norethisterone 350mg.  
For seven comparisons, no significant differences were identified between different 
types of oral contraception, although it should be noted that the quality of the 
evidence was rated as either low or very low in all cases. From the review 
comparing various triphasic OCs versus monophasic OCs (Van Vliet 2006b) these 
were as follows: triphasic LNG 50-70-125µg/EE 30-40-30µg versus monophasic LNG 
150µg/EE 30µg (followed up at both 6 and 12 cycles: data from one and three 
studies respectively: respective risk ratios were 0.65 [95%CI 0.11, 3.78; one study, 
189 participants] and 1.00 [95%CI 0.06, 16.01; three studies, 3010 participants]); 
triphasic LNG 50-70-125µg/EE 30-40-30µg versus monophasic NET 600µg/EE 35µg 
(data from one study, 186 participants, RR = 0.94, 95%CI: 0.13, 6.52); and triphasic 
GTD 50-70-100µg/EE 30-40-30µg versus monophasic DSG 150µg/EE 30µg (data from 
one study, 168 participants, RR = 1.00, 95%CI: 0.06, 15.73).  
With regard to COCs containing 20µg estrogen versus those containing >20µg (from 
Gallo 2011, RCT) no significant differences were reported for the following 
comparisons: EE 20µg + desogestrel 150µg versus EE 30µg + gestodene 75µg (data 
from one study, 416 participants, RR = 2.97 (95%CI: 0.12, 72.52)) and monophasic 
desogestrel 150µg + EE 30µg versus monophasic gestodene 75µg + EE 30µg (data 
pooled from three studies, 1,730 participants, RR = 1.13 (95%CI: 0.07, 18.02)). One 
review (Grimes 2010b, RCT), which was interested in progestin-only pills for 
contraception, reported findings from a very small study (97 participants) in which 
there was no difference in pregnancy rate between low-dose mifepristone and 
levonorgestrel (OR = 0.71 (95%CI: 0.07-6.95)). Finally the evidence from a review of 
once-a-month contraceptive pills (Kejuan 2007, one study, 712 participants) found 
that the pearl indices for Quin-Lg and Quin-Lng were 2.9 and 1.8 respectively.  
For the additional six comparisons (number of participants: 313-1,200; no 
information for one comparison), no pregnancies occurred in the either the 
intervention or the comparison groups. All comparisons contained data from single 
studies only. In the review comparing triphasic versus monophasic oral 
contraceptives (Van Vliet 2006b, RCT, one study, 1,200 participants) this was the 
case for the comparison between triphasic LNG 50-70-125 µg/EE 30-40-30 µg and 
monophasic NET 400 µg/EE 35 µg. In the review comparing COCs containing 20µg 
estrogen versus those containing >20µg (Gallo 2011, RCT one study, 416 
participants), this refers to the comparison between EE 20µg + gestodene 75µg and 
EE 30µg + gestodene 75µg. For the comparison between monophasic NE 
(norethindrone) 0.4mg + EE 35mcg and monophasic LNG (levonorgestrel) 150mcg + 
EE 30mcg (monophasics) reported by a review interested in progestogens in COCs 
(Maitra 2004, RCT, one study, 150 participants) this was also the case.  
Furthermore, in a review which compared biphasic and triphasic oral contraceptives 
(Van Vliet 2006a, RCT, one study, 1,199 participants), this occurred in both the 
comparison between biphasic levonorgestrel/EE (preparation Alpha) and triphasic 
levonorgestrel/EE (preparation Gamma), and the comparison between biphasic 
levonorgestrel/EE (preparation Beta) and triphasic levonorgestrel/EE (preparation 
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Gamma). Finally, one review (Grimes 2010b: progestin-only pills for contraception; 
RCT; one study) reported on a study comparing progestin-only pills started six weeks 
post-partum versus a six-month post-partum commencement, in which there were 
similarly no pregnancies in either group.  
Annex 2, Table 4.2k provides pre- and/or post-coital hormonal contraception to 
prevent pregnancy. One pill of Chinese –versus Hungarian- made tablet of LNG 0.75 
mg taken as oons as possible after the first coitus and no longer than 8 hours after. 
A second tablet was taken 24 hours regardless of whether another coital exposure 
had occurred during that time. There was no significant difference between the two 
types and the average Pearl Index was 16.1 (1 study and 361 participants). One dose 
quinestanol acetate within 24 hours of intercourse in 0.5 mg, 0.6 mg, 0.75 mg, 0.8 
mg, 1.5 mg and 2.0 mg showed increading Pearl Index with decrease in doses (1 
study and 2,792 participants). Quinestanol acetate within 24 hours of intercourse in 
0.2 mg, 0.3 mg, 0.4 mg, 0.5mg, 0.75 mg and 0.8mg also showed higher Perl Index 
for lower doses (1 study and 317 participants). Progestogens before/after coitus was 
examined in one review (1 study and 1,805 participants). Pearl Index for 
Retroprogestogen 30-40mg was 4.5; Ethynodiol 0.5 was 36.9, Norgestrienone 0.5mg 
was 2.6, Clogestone 1.0 mg was 2.5. One review examined Clogestone 1.0 mg 5/6 
hours prior to intercourse (Pearl Index 17); two clogestone 0.6 one before and one 
after coitus (Pearl Index 15) and two clogestone 1.0 mg one before and one after 
coitus (Pearl Index 15).   
 
2. THE INTRAUTERINE DEVICE (IUD), INCLUDING IMMEDIATE POST-PARTUM AND POST-ABORTION 
INSERTION  
This analysis is based on 24,643 women. It was not possible to separate out how 
many were contacted, how many agreed, and how many dropped out from the 
study. It is, therefore, difficult to ascertain whether the results pertain to the 
effectiveness or the efficacy of the method to prevent pregnancy. Of the included 
systematic reviews, five examined the impact of intrauterine devices on pregnancy 
and discontinuation of the method (French 2004; Grimes 2010a; Kulier 2007; O’Brien 
2005; Wen 2009: see Appendix 4.2, Tables 4.2d and 4.2e). Within these reviews, 16 
comparisons contained extractable data from developing countries and examined 
pregnancy and/or discontinuation/continuation as outcomes.  
 Within the included systematic reviews, there was high-quality evidence that, at 
both one and two years follow-up, TCu380A was more effective at pregnancy 
prevention than MLCu375 (rate difference: 0.75 [0.13, 0.37; 2 RCT studies and 3371 
participants] and 1.50 [95%CI: 0.09, 2.91, 1 RCT study and 1,894 participants] 
respectively). This was supported by moderate-quality evidence from a different 
systematic review (RR: 0.25 [95%CI: 0.08, 0.75, 4 studies and 3,617 participants]). 
Furthermore, there was moderate quality of evidence to suggest that TCu380A was 
more effective than MLCu250 (rate difference: 1.00 [95%CI: 0.24, 1.76, 1 study and 
2,043 participants]). Within TCu IUDs, moderate-quality evidence suggested that 
TCu220 was more effective than TCu380A at two years follow-up (rate difference: 
−1.00 [95%CI: −1.98, −0.02, 1 study and 954 participants]). However, it should be 
noted that, as presented below, this was not the case at one and three years follow-
up. 
For five comparisons, there was moderate-quality evidence to suggest that there 
were no differences in effect between the following types of IUD: LNG-20 
intrauterine system versus non-hormonal IUD >250mm2 (rate ratio at 3 years: 0.11, 
95%CI: 0.01, 2.12, 1 study and 2,118 participants) and versus a non-hormonal IUD 
≤250mm2 (rate ratios: −0.90 [95%CI: −2.01, −0.21, 1 study and 2,118 participants] 
(year 1 and 2), −0.56 [95%CI: −1.30, 0.18, 1 study and 2,118 participants]  year 3); 
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TCu380S versus TCu380A (rate differences: 0.10 [95%CI: −0.33, 0.53, 1 study and 
1,568 participants], −0.18 [95%CI: −0.73, 0.37, 1 study and 1568 participants], −0.90 
[−95%CI: 2.21, 0.41, 1 study and 1,568 participants] at one, two and three years 
respectively); TCu220 versus TCu380A (rate differences: −0.20 [95%CI: −1.47, 1.07, 2 
studies and 1,811 participants] and −0.70 [95%CI: −1.84, 0.44, 1 study and 954 
participants] at one and three years respectively); and also for TCu200 versus 
TCu380A (rate differences: 1.06 [95%CI: −0.90, 3.02, 3 studies and 2,842 
participants], 0.72 [95%CI: −1.65, 3.09, 3 studies and 2,842 participants] and 0.60 
[95%CI: −0.93, 2.13, 1 study and 964 participants] at one, two and three years 
respectively). 
Finally, three comparisons provided low-quality evidence of no difference between 
the following types of IUD: LNG-20 intrauterine system versus subdermal implants 
(rate ratios: 3.01 [95%CI: 0.13, 75.56, 1 study and 200 participants], 3.06 [95%CI: 
0.12, 75.56, 1 study and 200 participants] and 3.00 [95%CI: 0.12, 73.53, 1 study and 
200 participants] at one, two and three years respectively); TCu220 versus the 
MLCu375 (rate difference: 0.44, 95%CI: -1.17, 2.05, 1 study and 768 participants); 
and also TCu380A versus the GyneFix frameless IUD (rate difference: -0.34, 95%CI: -
1.01, -0.33, 1 study and 606 participants). One review (Grimes 2010a, 
predominantly RCTs) also examined the immediate post-partum insertion of 
intrauterine devices. This review reported low-quality evidence of no difference 
between the immediate post-partum insertion of Delta T versus Delta loop (12-
month pregnancy rates per 100 women of 0 and 2.1 respectively, 1 study and 400 
participants). 
3. INJECTABLES  
Data for this method comes from 15,826 women who had accepted injectables as a 
contraceptive method. No data is available on dropout from the studies. Therefore, 
the results may be interpreted as efficacy or effectiveness of injectables to prevent 
pregnancy. Two of the included systematic reviews examined injectables (Draper 
2006; Gallo 2008: see Appendix 4.2, Table 4.2f); five of the comparisons contained 
relevant data from developing countries and could be included in the overview. For 
two comparisons, extractable data were available for pregnancy and 
discontinuation; an additional comparison had extractable data for pregnancy only 
and the remaining two for discontinuation only. 
There was moderate-quality evidence to suggest that there was no difference 
between the number of pregnancies that occur with NET-EN 50mg/E2V 5mg and 
DMPA 25mg/E2C 5mg. Additionally, there was low-quality evidence suggesting that 
NET-EN 50mg/E2V 5mg was equally as effective as NET-EN 200mg and non-hormonal 
IUDs (from Gallo 2008). 
4. INTRAUTERINE DEVICES VERSUS INJECTABLES  
One included systematic review examined intrauterine devices compared with 
injectables for contraception (Hofmeyr 2010: see Appendix 4.2, Table 4.2g). The 
number of women who completed the trial and were included in the analysis was 
482. Although there were discontinuation and dropouts from the trial, it was not 
possible to extract that information from the systematic reviews. Therefore, the 
results may be interpreted as efficacy or effectiveness to prevent pregnancy. One of 
the comparisons contained relevant data from developing countries and could be 
included in the overview. This review pooled results from two studies to examine 
pregnancy in copper-containing intrauterine devices versus depot progestogen. For 
discontinuation, the two studies were reported separately (due to heterogeneity).  
There is moderate-quality evidence to suggest that there were fewer pregnancies 
with copper-containing intrauterine devices than with depot progestogens (RR: 0.47, 
95%CI: 0.25, 0.85, 1 study and 937 participants). 
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5. IMPLANTS  
One included systematic review examined implants for contraception (Power 2007: 
see Appendix 4.2, Table 4.2h). The number of women included in this analysis was 
1,219. It was not possible to extract data on the number of women who dropped 
out; the results may thus be interpreted as efficacy or effectiveness. One of the 
comparisons contained relevant data from developing countries and could be 
included in the overview. Narrative synthesis was provided for this comparison; no 
meta-analyses were conducted.  
This review reported low-quality evidence from three systematic reviews (3 studies 
and 1,219 participants) which indicated no differences in effectiveness for 
pregnancy prevention between Implanon versus Norplant; there were no 
pregnancies in either group.  
6. THE FEMALE CONDOM 
No systematic reviews examining female condoms met the eligibility criteria for this 
overview of reviews. 
7. THE MALE CONDOM 
No systematic reviews examining male condoms met the eligibility criteria for this 
overview of reviews. 
8. EMERGENCY CONTRACEPTION (EC)  
One included systematic review examined emergency contraception (Cheng 2008: 
Appendix 4.2, Table 4.2i). The results are based on 31,480 women. There was no 
dropout reported in this study, so the results can be interpreted as efficacy of 
emergency contraception to prevent contraception. No information is available to 
calculate the effectiveness or acceptability of this method. Eighteen of the 
comparisons contained relevant data from developing countries and could be 
included in the overview.  
For six comparisons, there were significant differences between the intervention 
and comparison emergency contraceptive regimens, although the quality of the 
evidence for these varied. There is moderate-quality evidence that mid-dose 
mifepristone (25-50mg) is more effective than low-dose mifepristone (<25mg) (RR: 
0.66, 95%CI: 0.47, 0.91, 19 RCT studies and 11,432 participants). Five further 
comparisons offered low- to very low-quality evidence to favour one emergency 
contraceptive regime over another. These comparisons suggested the following 
differences: IUD as more effective than expectant management (RR: 0.09, 95%CI: 
0.03, 0.26, 1 study and 300 participants), mid-dose (25-50mg) and low-dose (<25mg) 
mifepristone as more effective than levonorgestrel (RR: 2.01 [95%CI: 1.27, 3.17, 15 
studies and 3,743 participants] and RR: 2.05 [95%CI: 1.11, 3.81, 7 studies and 1,647 
participants] respectively), and high dose (>50mg) as more effective than low-dose 
(<25mg) mifepristone (RR: 0.19, 95%CI: 0.04, 0.90, 4 studies and 1,726 
participants). There were also lower numbers of pregnancies in groups taking 
mifepristone than in those taking anordrin (RR: 0.26, 95%CI: 0.11, 0.63, 7 studies 
and 1,035 participants). 
For twelve comparisons there were no significant differences between the 
intervention and comparison emergency contraceptive regimens. Again, the quality 
of the evidence for these varied. There is moderate-quality evidence to suggest that 
there is no difference in effectiveness at pregnancy prevention between a split dose 
of levonorgestrel given 24 hours apart and one given 12 hours apart (RR: 0.98, 
95%CI: 0.53, 1.82, 1 study and 2,060 participants) nor between a split dose (given 12 
hours apart) and a single dose (RR: 0.54, 95%CI: 0.16, 1.85, 1 study and 1,118 
participants). For the remaining comparisons, there was low- to very low-quality 
evidence of no difference in effectiveness. This includes levonorgestrel versus 
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anordrin (RR: 0.67, 95%CI: 0.11, 3.89, 1 study and 172 participants) and a variety of 
comparisons between doses of mifepristone: a low dose of <25mg versus a low dose 
of ≤10mg (RR: 1.04, 95%CI: 0.07, 16.37, 1 study and 220 participants), a mid-dose of 
>50mg versus a mid-dose of 25mg (RR: 0.72, 95%CI: 0.41, 1.27, 13 studies and 3,123 
participants) and a high dose (>50mg) versus a mid-dose (25-50mg) (RR: 0.83, 95%CI: 
0.39, 1.77, 8 studies and 1,890 participants).  
Further, there was very low-quality evidence of no difference in effectiveness 
between mifepristone and danazol (RR: 0.20, 95%CI: 0.02, 1.67, 1 study and 241 
participants). Similarly, when comparing mifepristone alone with mifepristone 
combined with other agents there was low- to very low-quality evidence of no 
effect. The additive agents were as follows: anordrin (RR: 1.32, 95%CI: 0.72, 2.41, 5 
studies and 3,038 participants]), MTX (RR: 3.00 [95%CI: 0.13, 71.92, 1 study and 100 
participants), tamoxifen (RR: 3.00, 95%CI: 0.31, 28.60, 1 study and 400 participants) 
and misoprostol (RR: 3.49, 95%CI: 0.73, 16.65, 1 study and 599 participants). 
Similarly, there was very low-quality evidence of no difference in effectiveness 
between mifepristone and Cu-IUD (RR: 1.51, 95%CI: 0.06, 36.67, 1 study and 185 
participants). 
9. THE DIAPHRAGM 
No systematic reviews examining the diaphragm met the eligibility criteria for this 
overview of reviews. 
10. FOAM/JELLY (SPERMICIDES)  
One included systematic review examined spermicides (Grimes 2005). The results 
are based on 3,031 women who completed the trial in various studies included in 
the systematic review. No information is available on dropouts. Five of the 
comparisons contained relevant data from developing countries and could be 
included in the overview (Appendix 4.2, Table 4.2j). All comparisons were reported 
narratively; no meta-analyses were conducted.  
There was moderate evidence of no effect for three comparisons: between Neo 
sampoon tablet (menfegol 60mg) and Ortho/Emko vaginal tablet (100mg of 
nonoxynol-9), Ortho vaginal tablet (100mg of nonoxynol-9) and Emko vaginal tablet 
(nonoxynol-9) The 12 moth rates were 15.2 for menfegol and 22.5 for Ortho (3 RCT 
studies and 672 participants), and also between Neo sampoon tablet (menfegol 
60mg) and Emko foam, life table rates were same(nonoynol-9 8 percent, 2 RCT 
studies and 620 participants). There was low-quality evidence to suggest that there 
was no difference in the efficacy for pregnancy prevention of collate sponge life 
table pregnancy rates  (nonoxynol-9 1.15mg and Neo sampoon tablet (menfegol 
60mg, 1 RCT study and 1,299 participants).  
4.4.1.3 Traditional methods 
1. PERIODIC ABSTINENCE 
One included systematic review examined fertility awareness-based methods for 
contraception (Grimes 2004). The results are based on 566 women who completed 
the trial in various studies included in the systematic review. No information is 
available on dropouts. One of the comparisons contained relevant data from 
developing countries and could be included in the overview (see Appendix 4.2, 
Table 4.2l). This comparison was reported narratively; no meta-analyses were 
conducted.  
The systematic review reported a comparison between the ovulation method and 
the symptothermal method. However, the evidence for this comparison was of very 
low quality and there were no pregnancies in either group. 
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2. WITHDRAWAL  
No systematic reviews examining withdrawal met the eligibility criteria for this 
overview of reviews. 
3. LACTATIONAL AMENORRHEA METHOD (LAM) 
One included systematic review examined the lactational amenorrhea method (Van 
der Wijden 2003). The  results are based on 1,411 women; no information is 
available on dropouts. Two of the comparisons contained relevant data from 
developing countries and could be included in the overview (see Appendix 4.2, 
Table 4.2l). All comparisons were reported narratively; no meta-analyses were 
conducted, and the quality of the evidence for all comparisons was very low.  
One study compared LAM with support versus LAM without support. The life-table 
pregnancy rate was 0.45 in the LAM with support group (one pregnancy in 1,671 
woman-months accumulated, 1 study and 676 participants) and there were no 
pregnancies in the LAM without support group. Another study compared LAM with 
support with controls who used non-hormonal IUDs two months post-partum and on-
demand feeding. No women became pregnant in the IUD group and the life-table 
pregnancy rate for those using LAM with support was 2.45 after 6 months (1 study 
and 735 participants, using the standard definition of amenorrhea).  
4.4.2 Discontinuation 
4.4.2.1 Terminal methods 
1. FEMALE STERILISATION  
As female sterilisations are terminal methods, once a woman accepts sterilisation, it 
is very rarely reversed. The systematic reviewed included in this overview did not 
examine reversal of female sterilisation.  
2. MALE STERILISATION 
No systematic reviews examining male sterilisation met the eligibility criteria for 
this overview of reviews. 
4.4.2.2  Spacing/temporary methods 
1. THE PILL  
Overall 15,201 women agreed to participate in various trials included in the 
systematic reviews included in the overview; 3,502 dropped out from the studies. Of 
the included systematic reviews, seven examined the impact of oral contraception 
on pregnancy and discontinuation of the method (Edelman 2005; Gallo 2011; Grimes 
2010b; Kejuan 2007; Maitra 2004; Van Vliet 2006a, b: see Appendix 4.2, Tables 4.2b 
and 4.2c). Within these reviews, 17 comparisons contained extractable data from 
developing countries examining pregnancy as an outcome. Fifteen comparisons 
contained extractable and relevant data examining discontinuation as an outcome. 
Data on continuation was reported for a further comparison. 
For discontinuation, there were significant differences identified between the 
intervention and comparison oral contraceptive regimens. One review (Maitra 2004, 
predominantly RCTs), interested in progestogens in COCs, identified moderate-
quality evidence that (using pooled data from two studies) there was lower 
discontinuation for monophasic norgestrel 0.3mg/EE 30mcg (second-generation OC) 
than for monophasic norethindrone acetate 1.5mg/EE 30mcg (Lo-estrin: first-
generation OC: RR = 0.79, 95%CI 0.69, 0.91; 2,074 participants). This review also 
identified low-quality evidence from one study that monophasic NE (norethindrone) 
0.4mg + EE 35mcg had lower discontinuation than monophasic LNG (levonorgestrel) 
150mcg + EE 30mcg (RR = 0.79, 95%CI 0.66, 0.94; 1,199 participants). 
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For two comparisons, there was moderate evidence of no difference between the 
intervention OC and the comparison OC. The first was reported by a review 
comparing various triphasic OCs versus monophasic OCs (Van Vliet 2006b, RCT; 1 
study and 189 participants), which found no difference in discontinuation between 
triphasic LNG 50-70-125mcg/EE 30-40-30mcg and monophasic NET 400mcg/EE 
35mcg. The second was reported by the review concerned with progestogens in 
COCs (Maitra 2004, predominantly RCTs, 3 studies and 1,730 participants), which 
found no difference in discontinuation between monophasic desogestrel 150mcg + 
EE30mcg and monophasic gestodene 75mcg + EE30mcg. 
Furthermore, there was low-quality evidence of no difference for eleven 
comparisons. The included review (Van Vliet 2006b, predominantly RCTs) that 
compared various triphasic OCs versus monophasic OCs reported five such 
comparisons: triphasic LNG 50-70-125 µg/EE 30-40-30 µg versus monophasic LNG 150 
µg/EE 30 µg (follow-up = 6 cycles; one study and 189 participants); triphasic LNG 50-
70-125 µg/EE 30-40-30 µg versus monophasic LNG 150 µg/EE 30 µg (follow-up = 12 
cycles; 3 studies and 3010 participants); triphasic LNG 50-70-125 µg/EE 30-40-30 µg 
versus monophasic NET 600 µg/EE 35 µg (1 study and 186 participants); triphasic 
GTD 50-70-100 µg/EE 30-40-30 µg versus monophasic DSG 150 µg/EE 30 µg (follow-
up = 6 cycles; 1 study and 168 participants); and triphasic GTD 50-70-100 µg/EE 30-
40-30 µg versus monophasic DSG 150 µg/EE 30 µg (follow-up = 12 cycles; 1 study and 
168 participants).  
A further review (Edelman 2005, RCT; 1 study and 900 participants), which 
examined continuous or extended cycles versus cyclic use of combined hormonal 
contraception, reported one such comparison: 28-day cycle (cyclic) vaginal 
administration of 50µg ethinyl estradiol and 250µg levonorgestrel versus 1 year 
(continuous) administration. Another (Gallo 2008: COCs containing 20µg estrogen 
versus those containing >20µg), reported two comparisons with low-quality evidence 
for no difference: EE 20µg + desogestrel 150µg vs EE30µg + gestodene 75µg (1 study 
and 416 participants) and EE 20µg + gestodene 75µg vs EE 30µg + gestodene 75µg (1 
study and 150 participants). Two comparisons examining biphasic versus triphasic 
OCs (Van Vliet 2006a, predominantly RCTs) gave low-quality evidence of no 
difference: biphasic levonorgestrel/EE (preparation Alpha) versus triphasic 
levonorgestrel/EE (preparation Gamma) (1 study and 313 participants) and biphasic 
levonorgestrel/EE (preparation Beta) versus triphasic levonorgestrel/EE (preparation 
Gamma) (1 study and 298 participants). Finally, a comparison between 
norethisterone and levonorgestrel 150 + ethinyl estradiol combination pill also 
provided low-quality evidence of no effect (Grimes 2010b, RCT, 1 study and 1,199 
participants). 
Annex 2, Table 4.2k provides pre- and/or post-coital hormonal contraception to 
prevent pregnancy. One dose quinestanol acetate within 24 hours of intercourse in 
0.5 mg, 0.6 mg, 0.75 mg, 0.8 mg, 1.5 mg and 2.0 mg. The mean duration of use was 
4.8 month/cycles (1 study and 2,792 participants). Quinestanol acetate within 24 
hours of intercourse in 0.2 mg, 0.3 mg, 0.4 mg, 0.5mg, 0.75 mg and 0.8mg. Mean 
duration was 4.2 monthsn (1 study and 317 participants). Progestogens before/after 
coitus was examined in one review. Retroprogestogen 30-40mg was 4.5; Ethynodiol 
0.5 was 36.9, Norgestrienone 0.5mg was 2.6, Clogestone 1.0 mg was 2.5. The mean 
duration of use was 5.5 months (1 study and 1,805 participants). One review 
examined Clogestone 1.0 mg 5/6 hours prior to intercourse; two clogestone 0.6 one 
before and one after coitus and two clogestone 1.0 mg one before and one after 
coitus. Mean duration of use for this was 5.4 months (1 study and 756 participants).   
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2. THE INTRAUTERINE DEVICE (IUD), INCLUDING IMMEDIATE POST-PARTUM AND POST-ABORTION 
INSERTION  
This analysis on the discontinuation of use of an intrauterine device is based on 
24,643 women who participated in various trials. Of the included systematic 
reviews, five examined the impact of intrauterine devices on pregnancy and 
discontinuation of the method (French 2004; Grimes 2010a; Kulier 2007; O’Brien 
2005; Wen 2009: see Appendix 4.2, Tables 4.2d and 4.2e). Within these reviews, 16 
comparisons contained extractable data from developing countries and examined 
pregnancy and/or discontinuation/continuation as outcomes.  
Four of the five comparisons that could be extracted for this overview provide 
moderate evidence of no difference in discontinuation. These are as follows: LNG-20 
versus a non-hormonal IUD ≤250mm2 (rate ratio at 2 years follow-up: 0.93 [95%CI: 
0.80-1.07, 1 study and 2,118 participants]); MLCu250 versus TCu380A (rate 
difference at 1 year follow-up: −1.50, 95%CI: −1.26, 4.26, 1 study and 2,043 
participants) and also the TCu220 when compared with the TCu380A (rate 
difference at 1 year follow-up: −3.00, 95%CI: −7.21, 1.21, 1 study and 857 
participants). Similarly, there was moderate evidence of no difference in 
discontinuation for the TCu200 versus the TCu380A (rate difference at 1 year follow-
up: 1.00, 95%CI: −2.96, 4.96, 1 study and 1,678 participants). For the remaining 
comparison, there was low-quality evidence of no difference between LNG-20 versus 
subdermal implants (rate ratio at 1 year: 0.97, 95%CI: 0.72-1.31, 1 study and 200 
participants). 
3. INJECTABLES  
Data for the analysis of discontinuation of injectables were taken from 15,826 
women who participated in various studies included in the systematic reviews. Two 
of the included systematic reviews examined injectables (Draper 2006; Gallo 2008: 
see Appendix 4.2, Table 4.2f); five of the comparisons contained relevant data from 
developing countries and could be included in the overview. For two comparisons, 
extractable data were available for pregnancy and discontinuation; an additional 
comparison had extractable data for pregnancy only and the remaining two for 
discontinuation only. 
There was moderate-quality evidence that DMPA 25mg/E2C 5mg had lower 
discontinuation than NET-EN 50mg/E2V 5mg (from Gallo 2008: Peto OR = 0.75, 
95%CI: 0.67, 0.84, 2 RCT studies and 4272 participants). There was also moderate-
quality evidence to suggest that there was no difference in discontinuation between 
administering DMPA 150mg IM every 3 months versus NET-EN 200mg IM every 2 
months (from Draper 2006, 10 RCT studies and 2,467 participants). Additionally, 
there was low-quality evidence suggesting that discontinuation was higher with 
DMPA 25mg/E2C 5mg than with DMPA 150mg (1 RCT study and 360 participants), and 
with NET-EN 50mg/E2V 5mg than NET-EN 200mg (1 RCT study and 849 participants) 
(from Gallo 2008). 
4. INTRAUTERINE DEVICES VERSUS INJECTABLES  
One included systematic review examined intrauterine devices compared with 
injectables for contraception (Hofmeyr 2010: Appendix 4.2, Table 4.2g). The 
number of women included in this analysis was 482. Due to heterogeneity, the two 
studies reporting discontinuation were reported separately. Both provided 
moderate-quality evidence; however, the studies provided conflicting results. One 
compared copper-containing intrauterine devices with depot progestogen only and 
found lower discontinuation with the IUD (RR: 0.17, 95%CI: 0.07, 0.39, 1 RCT study 
and 338 participants). However, an alternative study, comparing copper-containing 
intrauterine devices with mixed hormonal contraception (depot progestogen and/or 
OC), found lower discontinuation with the mixed hormonal contraception (RR: 4.20, 
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95%CI: 3.06, 5.78, 1 study and 599 participants). 
5. IMPLANTS  
See Section 4.4.4.3 on continuation. 
6. THE FEMALE CONDOM 
No systematic reviews examining female condoms met the eligibility criteria for this 
overview of reviews. 
7. THE MALE CONDOM 
No systematic reviews examining male condoms met the eligibility criteria for this 
overview of reviews. 
8. EMERGENCY CONTRACEPTION (EC)  
One included systematic review examined emergency contraception (Cheng 2008: 
Appendix 4.2, Table 4.2i). The results presented in this section are based on 31,480 
women, and 18 of the comparisons contained relevant data from developing 
countries and could be included in the overview.  
9. THE DIAPHRAGM 
No systematic reviews examining the diaphragm met the eligibility criteria for this 
overview of reviews. 
10. FOAM/JELLY (SPERMICIDES)  
One included systematic review examined spermicides (Grimes 2005). The results 
presented for the discontinuation of spermicides is based on the 3,303 women were 
recruited for trials. Five of the comparisons contained relevant data from 
developing countries and could be included in the overview (Appendix 4.2, Table 
4.2j). All comparisons were reported narratively; no meta-analyses were conducted.  
This review presented low-quality evidence to suggest that there is no difference in 
rates of discontinuation between: collatex sponge (nonoxynol-9 1.15mg) and Neo 
sampoon tablet (menfegol 60mg) (1 RCT study and 1,299 participants); Neo sampoon 
tablet (menfegol 60mg) and Emko foam (nonoxynol-9 8 percent) (2 RCT studies and 
620 participants); Neo sampoon tablet (menfegol 60mg) and vaginal foaming tablets 
containing nonoxynol-9 (1.15mg) (2 RCT studies and 440 participants); and those 
containing menfegol 60mg versus Ortho or Emko vaginal tablet (100mg of 
monoxynol-9)  (3 RCT studies and 672 participants). As the results of these 
comparisons were presented narratively, there are conflicting findings for some 
comparisons.  
For example, the review presented low-quality evidence that suggested similar 
discontinuation rates between Neo sampoon tablet (menfegol 60mg) and 
Ortho/Emko vaginal tablet (nonoxynol-9 100mg) (2 RCT studies and 440 
participants); however, it also presented low-quality evidence to suggest that there 
was significantly lower discontinuation due to discomfort for Neo sampoon tablet 
(menfegol 60mg) than for Ortho vaginal tablet (100mg of nonoxynol-9) (3 RCT 
studies and 672 participants), which was significantly lower than for Emko vaginal 
tablet (100mg of nonoxynol-9) (2 RCT studies and 440 participants). Similarly, the 
review also presented conflicting low-quality evidence for the relative 
discontinuation rates for Ortho vaginal tablet (nonoxynol-9 100mg) compared with 
the Emko vaginal tablet (nonoxynol-9 100mg) (2 RCT studies and 440 participants). 
One RCT study suggested no difference in discontinuation, while another suggested 
lower discontinuation for Ortho vaginal tablet (nonoxynol-9 100mg).  
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4.4.2.3 Discontinuation: traditional methods 
1. PERIODIC ABSTINENCE 
One included systematic review examined fertility awareness-based methods for 
contraception (Grimes 2004); one of the comparisons contained relevant data from 
developing countries and could be included in the overview (see Appendix 4.2, 
Table 4.2l). This comparison was reported narratively; no meta-analyses were 
conducted.  
The low-quality evidence reported by the systematic review for the comparison 
between the ovulation method and the symptothermal method suggests that there 
is relatively high discontinuation for both methods. There was high drop-out before 
the beginning of the observation period (but after randomisation); 53 percent of 
couples in the ovulation method group dropped out, as did 61 percent of those in 
the symptothermal method group. During follow-up, 31 percent of couples in the 
ovulation method group discontinued compared with 30 percent of those in the 
symptothermal method group. 
2. WITHDRAWAL  
No systematic reviews examining withdrawal met the eligibility criteria for this 
overview of reviews. 
3. LACTATIONAL AMENORRHEA METHOD (LAM) 
Discontinuation was not reported for any comparisons included in this overview of 
reviews. 
4.4.3 Continuation 
4.4.3.1 Terminal methods 
1. FEMALE STERILISATION  
The systematic reviews included in this overview did not examine continuation of 
female sterilisation as this is a terminal family planning method.  
2. MALE STERILISATION 
No systematic reviews examining male sterilisation met the eligibility criteria for 
this overview of reviews. 
4.4.3.2 Spacing/temporary methods 
1. THE PILL  
Overall 15,201 women agreed to participate in various trials included in the 
systematic reviews that were included in the overview. Of these, 3,502 
discontinued. Of the included systematic reviews, seven examined the impact of 
oral contraception on pregnancy and discontinuation of the method (Edelman 2005; 
Gallo 2011; Grimes 2010b; Maitra 2004; Kejuan 2007; Van Vliet 2006a, b: see 
Appendix 4.2, Tables 4.2b and 4.2c). Within these reviews, 17 comparisons 
contained extractable data from developing countries examining pregnancy as an 
outcome. Fifteen comparisons contained extractable and relevant data examining 
discontinuation as an outcome. Data on continuation was reported for a further 
comparison. 
Two comparisons reported continuation rather than discontinuation. Both provided 
low-quality evidence. One (Grimes 2010b, 1 study and 200 participants) involved 
progestin-only pills started six weeks post-partum versus a six-month post-partum 
commencement, in which there was similar continuation in each group. The second 
(from Kejuan 2007, 1 study and 712 participants) involved Quin-Ng versus Quin-Lng 
where the one- and two-year net cumulative continuation rates for Quin-Lng pills 
were 87 and 78 per 100 respectively, and for Quin-Lng pills, 74 and 64 per 100 
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respectively. The difference between the two pills appeared to be due to 
discontinuation for side effects other than bleeding problems. 
2. THE INTRAUTERINE DEVICE (IUD), INCLUDING IMMEDIATE POST-PARTUM AND POST-ABORTION 
INSERTION 
Of the included systematic reviews, five examined the impact of intrauterine 
devices on pregnancy and discontinuation of the method (French 2004; Grimes 
2010a; Kulier 2007; O’Brien 2005; Wen 2009: see Appendix 4.2, Tables 4.2d and 
4.2e). Within these reviews 16 comparisons contained extractable data from 
developing countries and examined pregnancy and/or discontinuation/continuation 
as outcomes.  
For one comparison there was moderate-quality evidence to suggest that 
continuation was higher with TCu380S than with TCu380A (rate difference at 1 year: 
−5.50, 95%CI: − 9.11, − 1.89, 1 study and 1,568 participants). When comparing the 
immediate post-partum insertion of TCu200 versus progestasert, there was low-
quality evidence to suggest that there was higher continuation with the TCu200 
regardless of method of insertion: 12-month continuation rates (per 100 women) for 
hand insertion were 86.3 for the Tcu 200 and 59.9 for the progestasert and for 
instrument insertion were 86.1 and 57.2 respectively (1 study and 400 participants). 
Low-quality evidence from a different review indicates higher continuation in 
Gynefix frameless IUD than in TCu380A at two and three years follow-up: 
continuation rates (SE) at 3 years were 90.7(1.7) in the GyneFix group and 85.3(2.0) 
in the TCu380A group (1 study and 606 participants).  
There was moderate-quality evidence of no difference in continuation between 
MLCu375 and TCu380A (rate difference: −2.20, 95%CI: −5.39, 0.99, 1 study and 1477 
participants) and also between TCu200 and TCu380A (rate difference: −3.00, 95%CI: 
−12.84, 6.84, 1 study and 200 participants). With regard to the immediate post-
partum insertion of IUDs, there was low-quality evidence of no difference in 
continuation between Delta T and Delta loop: 12-month continuation rates per 100 
women were 93.3 for the Delta Loop and 90.7 for Delta T (1 study and 246 
participants); and between TCu200 and IPCS-52mg: 12-month continuation rates per 
100 women were 73.8 for the Tcu 200 and 57.3 for the IPCS-52 (1 study and 400 
participants). 
3. INJECTABLES  
Two of the included systematic reviews examined injectables (Draper 2006; Gallo 
2008: see Appendix 4.2, Table 4.2f), but data were reported only on 
discontinuation, not on continuation.  
4. INTRAUTERINE DEVICES VERSUS INJECTABLES  
One included systematic review examined intrauterine devices compared with 
injectables for contraception (Hofmeyr 2010: Appendix 4.2, Table 4.2g), but data 
were reported only on discontinuation, not on continuation.  
5. IMPLANTS  
One included systematic review examined implants for contraception (Power 2007: 
see Appendix 4.2, Table 4.2h). The number of women included in this analysis was 
1,219. One of the comparisons contained relevant data from developing countries 
and could be included in the overview. Narrative synthesis was provided for this 
comparison; no meta-analyses were conducted.  
With regard to continuation, low-quality evidence indicated no significant 
differences between Implanon and Norplant at one, two, three and four years 
follow-up (3 studies and 1,219 participants). At 1 year, 91.6 percent continued to 
use Implanon and 92.4 percent continued to use Norplant; at 2 years, the 
continuation figures were 82.5 percent and 81.4 percent respectively; at 3 years, 
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67.4 percent and 72.5 percent; and at 4 years, 17.1 percent and 16.9 percent.  
6. THE FEMALE CONDOM 
No systematic reviews examining female condoms met the eligibility criteria for this 
overview of reviews. 
7. THE MALE CONDOM 
No systematic reviews examining male condoms met the eligibility criteria for this 
overview of reviews. 
8. EMERGENCY CONTRACEPTION (EC)  
One included systematic review examined emergency contraception (Cheng 2008: 
see Appendix 4.2, Table 4.2i), but no data were reported on continuation. 
9. THE DIAPHRAGM 
No systematic reviews examining the diaphragm met the eligibility criteria for this 
overview of reviews. 
10. FOAM/JELLY (SPERMICIDES)  
One included systematic review examined spermicides (Grimes 2005), but data were 
reported only on discontinuation, not on continuation.  
4.4.3.3 Traditional methods 
1. PERIODIC ABSTINENCE 
The analysis is based on 1,411 women who participated in trials. One included 
systematic review examined fertility awareness-based methods for contraception 
(Grimes 2004), but data were reported only on discontinuation, not on continuation.  
2. WITHDRAWAL  
No systematic reviews examining withdrawal met the eligibility criteria for this 
overview of reviews. 
3. LACTATIONAL AMENORRHEA METHOD (LAM) 
The analysis is based on 1,411 women participated in the trials. One included 
systematic review examined the lactational amenorrhea method (LAM: Van der 
Wijden 2003), but no data were reported on continuation.  
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5.  Conclusions and recommendations  
Overall, this OoR could not answer questions on the impact of various contraceptive 
methods and mixes of contraceptive methods on contraceptive prevalence and 
unmet need for family planning (objectives 1 and 3). This is because there were no 
systematic reviews available to include in the OoR, a restriction imposed by the OoR 
methodology. Therefore, the OoR predominantly focuses on various contraceptive 
methods on preventing pregnancy. In general, the quality of the evidence for the 
comparisons examined with this overview of reviews was low. In part, this was due 
to inconsistent reporting of risk of bias within systematic reviews, which limited the 
ability to make confident assessments of the quality of the evidence. However, 
there were several comparisons for which there was moderate evidence and this 
section will focus predominantly on these. Where there are important gaps in the 
evidence, or where there are important implications when evidence is of low 
quality, these will also be discussed. This section is arranged with commentary in 
relation to each contraceptive method in turn, highlighting findings of potential 
importance for policy and programming, and identifying topics that should be a 
focus for further research in each case. 
5.1 Sterilisation in developing countries 
Where female sterilisation is concerned, included studies examined sterilisation 
conducted in a number of circumstances; immediately post-partum (including after 
a Caesarean section), delayed post-partum, post-abortion and interval.6 There is 
good evidence to suggest that rings and clips are equally effective for tubal 
occlusion; both have a very low failure rate. Thus, consideration of costs, 
infrastructure issues and the risk and severity of side effects might usefully inform 
programme decisions. Studies comparing these methods with others (Modified 
Pomeroy and electrocoagulation) suggested that failure rates were very low for all 
methods; however, the quality of the evidence was poor and event rates (i.e., 
incidences of subsequent pregnancy) were zero in all groups. For all comparisons, 
the follow-up periods were short. Hence, longitudinal research making direct 
comparisons between the full range of methods (on a number of outcomes) would 
be informative.  
Such research would also allow a fuller investigation of the relative effectiveness 
(and risk of side effects) of conducting sterilisation in a variety of circumstances in 
developing countries, as only one study has currently done so (Yan et al. 1990; 
conducted in Taiwan). As Caesarean delivery rates increase in the developing world, 
there is an increasing number of women who are likely to undergo repeat Caesarean 
for subsequent births and request the convenience of tubal ligation at the same 
time (Ghoshal et al. 2003). Post-partum tubal ligation is not favoured in developed 
countries because of concern about the small risk of venous thromboembolism 
following surgery in the puerperium,7 but it remains popular in many developing 
countries because of a desire to reduce costs and avoid further hospital admission 
for an interval procedure. 
In the case of South India, there is a concern that very widespread recourse to 
                                            
6 i.e. more than six weeks after birth. 
7 The period of about six weeks after childbirth during which the reproductive organs return to their 
original non-pregnant state. 
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female sterilisation at a low mean age may have adverse consequences such as 
regret and request for reversal or recourse to assisted conception (Singh et al. 
2012). These concerns are set against the advantages of limiting family size such as 
opportunities for education and employment. An examination of these issues within 
longitudinal research (in any developing country) might help to build a fuller picture 
of the advantages and disadvantages of sterilisation for individuals, communities 
and populations. 
A systematic review has been conducted comparing minilaparotomy versus 
laparoscopic approaches to sterilisation, which may be informative for policy 
makers, as some of the included studies were conducted within developing 
countries. However, this review focused on morbidity and mortality as outcomes, 
and consequently did not fall within the scope of this overview of reviews (Kulier et 
al. 2004). It is also important to highlight that although there are systematic reviews 
on male sterilisation (e.g. Cook 2007a, b), these were not included in this overview. 
For one review, this was because the data for developing countries could not be 
extracted separately, and for the other, it was because the outcomes examined 
(azoospermia) did not meet the inclusion criteria. A systematic review of the 
literature on this topic within developing countries would probably provide greater 
understanding of the effectiveness and acceptability of male sterilisation in this 
context. 
5.2 Oral contraception in developing countries  
A number of systematic reviews were included which compared a wide variety of 
different oral contraceptive preparations (biphasic versus triphasic, triphasic versus 
monophasic, 20µg versus >20µg oestrogen, progestogens in combined oral 
contraceptives, progestin-only pills) and modes of administration (continuous or 
extended cycle versus cyclic use, once-a-month pills). For the majority of 
comparisons, the evidence suggested that there was no difference in effectiveness 
or discontinuation between a variety of oral contraceptive formulations and modes 
of administration, and for all comparisons, pregnancy rates were low in each group. 
However, the quality of evidence ranged widely, from very low to moderate, and 
follow-up was generally short. Thus, at present there is little to recommend one 
preparation over another and the choice of preparations to be included in 
programming might be more usefully informed by availability in countries and cost.  
There was, however, good evidence (from studies conducted in Malaysia, Egypt, 
Thailand, Mexico and the Philippines) to suggest that in the case of one oral 
contraceptive preparation, the second-generation pill (monophasic norgestrel 
0.3mg/EE 30mcg) decreased the risk of pregnancy by 88 percent and the risk of 
discontinuation by 21 percent when compared with the first generation (monophasic 
norethindrone acetate 1.5mg/EE 30mcg). It is difficult to make a statement about 
the extent to which this is true of all second- versus first-generation oral 
contraceptives, since the quality of the evidence for the other comparisons was low. 
Further research would help to elucidate this. However, at least for the above 
preparation, these findings suggest that policy and programming should be focused 
on procurement and supply chain logistics to allow access to the second-generation 
preparation. Moreover, the cost-effectiveness analyses underpinning procurement 
decisions should incorporate discontinuation evidence. This evidence may lead to 
procurement of more expensive but better tolerated preparations as part of a ‘pill 
mix’, for example to offer a ‘second line’ preparation for those experiencing 
problems with the basic pill preparation. In general, public family planning 
programmes in developing countries have yet to offer more than one combined pill 
preparation.  
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Although this overview did not seek to make indirect comparisons, and the quality 
of evidence is generally low, looking across studies, discontinuation rates vary 
widely. This might be reflective of differences in study design and execution, but 
might also reflect population/cultural differences in acceptance of different oral 
contraceptives. Studies were conducted over a wide range of countries and regions. 
The overview of reviews methodology is not best suited to exploration of the 
different rationales for ‘discontinuation’ in detail. In a mature family planning 
programme, method switching is expected and can be seen as a marker of a 
balanced programme offering informed choice from a range of methods. On the 
other hand, it may simply represent dissatisfaction with the method or with the 
programme. Reference to contextual studies of ‘reasons for discontinuation’ is 
required to obtain a nuanced understanding of these issues. It may be that certain 
programmes experience more discontinuation and would be better able to make use 
of ‘low discontinuation’ pill preparations than other programme settings where 
discontinuation is less prevalent. This is an appropriate topic for operations 
research. 
This overview was not able to examine reviews of alternative routes of 
administration of oral contraceptive hormones, such as transdermal and vaginal ring 
preparations, in developing country settings. Although a systematic review has been 
conducted comparing skin patches and vaginal rings with oral contraceptives (Lopez 
et al. 2010) it was not included in the overview because only one included study was 
conducted in a developing country (Thailand), and this did not meet our inclusion 
criteria for outcomes. Data from developed countries suggests that these two 
alternative delivery routes are no more effective than oral contraceptives, although 
the patch had higher discontinuation rates when compared with oral contraceptives 
(Lopez et al. 2010). Further studies investigating the effectiveness, acceptability 
and economics of providing access to newer technology delivery systems for 
combined hormonal contraception in developing countries is recommended.  
5.3 Intrauterine devices in developing countries 
The overview identified evidence from one systematic review which indicated a 75 
percent reduction (lower bound of confidence interval 25 percent reduction) in the 
risk of pregnancy with use of the TCu380A device compared with the Multiload 
Cu375 device, consistent with the widespread incorporation of the former device 
into programming. There are no appreciable differences between the two ‘T’ 
devices with 380 mm2 copper content. There is heterogeneity in findings of 
outcomes with devices with a lower copper content (TCu220), and overall there is a 
limited place for these devices. 
There is a dearth of comparative data regarding both pregnancy risk and 
discontinuation data for the levonorgestrel-releasing intrauterine system (LNG-IUS), 
although the single developing country study (conducted in India) included in this 
overview is a large one. It appears unlikely that further primary research or reviews 
will uncover major differences of programmatic significance in pregnancy rates, and 
the basis for considering inclusion of the LNG-IUS in programmes is to increase the 
scope for intrauterine contraception for women with heavy menstrual bleeding, for 
whom a copper device would be unsuitable. As such, it has an important place, 
given the high prevalence of menstrual disorders. 
Post-partum intrauterine device insertion was addressed in the overview (including 
insertion immediately after Caesarean section), but the overall quality of the 
evidence was low. Furthermore, those studies conducted in developing countries 
compared the effectiveness and (dis)continuation of different types of IUD 
administered immediately post-partum. Only one included study (conducted in 
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Turkey) compared immediate with delayed post-partum insertion. This is a vital 
topic from a programmatic perspective, since the opportunity to provide 
intrauterine contraception immediately post-partum avoids many of the practical 
constraints of interval insertion. Delayed post-partum insertion requires a repeat 
visit and internal examination, which may deter women from having an IUD. The 
primary literature is mainly from the 1970s and indicates a higher rate of expulsion 
compared with interval insertion (data not reviewed in this overview); for many 
women, a higher but not excessive expulsion rate may not be a barrier to this 
approach, with appropriate counselling. Good-quality studies comparing an 
immediate versus delayed post-partum insertion of IUDs in a developing country 
setting are required in order to provide a firm evidence base upon which to base 
policy.  
5.4 Injectables in developing countries 
This overview shows that pregnancy rate data for injectables are broadly 
uninformative for policy and programming, as event rates are extremely low with all 
the relevant products. There is no recommendation for further work on pregnancy 
rates, as the key policy and programming issues are continuation rates and, most 
importantly, the population level impact of substantial use of injectables on 
variables such as birth spacing. This overview was not able to address birth spacing, 
but other literature based on analysis of DHS data is available (Rutstein, 2011).  
A key finding of this overview is that there is moderate-quality evidence (from a 
multi-centre trial) to indicate that discontinuation rates do not differ between two 
commonly used injectables; three-monthly DMPA and two-monthly NET-EN. 
However, no data studies were conducted in developing countries from which to 
gain information about the relative effectiveness of these two methods. This means 
that, at present, programmatic decisions might be more usefully based on cost and 
availability; there is likely to be little benefit in offering both products together. 
Newer products featured in this overview include two combinations of progestogen 
with estradiol, which may have a more favourable adverse effect profile. There is a 
substantial effect favouring the NET-EN/E2V formulation, with a 25 percent lower 
risk of discontinuation compared to DMPA/E2C, and no difference in effectiveness of 
pregnancy prevention. There are as yet insufficient data from developing countries 
to evaluate the comparison of the newer NET-EN/E2V formulation against the 
‘traditional’ DMPA 150 mg regimen; this should be a high priority for further 
research, given the massive part played by DMPA in current family planning 
programming, especially in Africa, and its prominence in community-based 
distribution programming. It would also be of great interest to establish the impact 
of NET-EN/E2V on birth spacing and other population-level outcomes. 
There was also systematic review data comparing intrauterine contraception with 
injectables. In this comparison, the IUD was associated with a substantially lower 
risk of pregnancy, although the findings on discontinuation are contradictory. The 
former finding is perhaps unexpected and should be a topic for further research, 
given the moderate pooled sample size. The authors of the systematic review 
attribute the conflicting discontinuation rates to differences in acceptability across 
the two included studies. This highlights that acceptability of the IUD versus depot 
progestogens may differ across populations.  
5.5 Implants in developing countries 
The overview findings with regard to contraceptive implants are that pregnancy 
rates are similarly low with both Implanon and Norplant. Discontinuation rates are 
also similar between formulations and are consistent with typical reproductive 
behaviour and the product characteristics, with a fall off after three years. The 
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policy and programming implication is that the choice of formulation to be included 
in programmes should be based on cost and availability; there would seem to be 
little advantage in offering more than one formulation. No research priorities were 
identified in this area. 
5.6 Emergency contraception 
A number of comparisons in this overview relate to the potential introduction of 
mifepristone as an agent for use in emergency contraception. The overview 
indicates that mifepristone at various doses is superior to levonorgestrel, which is 
the current standard of care. Further comparisons are reported between different 
doses of mifepristone, and overall the dose of 25-50 mg is favoured. There is no 
added benefit in combination formulations of mifepristone with other agents. The 
future place of mifepristone for this purpose will depend on regulatory 
considerations in countries, given the drug’s use at higher doses for medical 
abortion and the potential for adverse effects on a continuing pregnancy (unlike 
levonorgestrel). 
5.7 Spermicides in developing countries 
A limited number of review findings were available for nonoxynol-9 and menfegol-
based products, and no substantial differences in efficacy or continuation data were 
identified. In the light of the adverse effects of surfactant products on the vaginal 
mucosa, with consequent risk of increasing the risk of HIV transmission it is unlikely 
that further research or programmatic emphasis will be appropriate. There is scope 
for basic research to identify novel potential spermicides that can be demonstrated 
not to cause vaginal or penile irritation or epithelial disruption. 
5.8 Pre- and post-coital hormonal contraception in developing countries 
The range of studies included in this section of the overview were of low 
methodological quality and/or included small numbers, making clear conclusions 
difficult to identify.  
5.9 Natural family planning in developing countries 
Much of the literature on natural methods was uninformative, in the case of the 
symptothermal method because of very high dropout rates. Lactational 
amenorrhoea studies were also uninformative. Given the very widespread use of 
‘natural’ methods and the programmatic emphasis being given to variations such as 
the Standard Days Method in settings where there may be religious or cultural 
objections to modern methods, there is a substantial gap in knowledge from 
comparative studies to inform policy and programming. A possible approach would 
be to undertake reviews with a wider range of outcome measures, especially 
operational variables such as counselling time and relative acceptability. 
5.10 Gaps in the evidence 
There are a number of important gaps in the evidence presented in this overview of 
reviews. Firstly, it is important to highlight a number of contraceptive methods for 
which systematic review data could not be included. As already highlighted, there 
are systematic reviews (comparing minilaparotomy versus laparoscopic approaches 
to sterilisation, on male sterilisation, and comparing skin patches and vaginal rings 
with oral contraceptives), which did not meet the inclusion criteria of the overview 
of reviews. In addition, no systematic reviews met the inclusion criteria examining 
the male or female condom, the diaphragm or the withdrawal method for 
contraception, and consequently no evidence can be discussed for these methods. 
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Secondly, it is important to note that many of the studies included in the systematic 
reviews compared variations within a contraceptive type, for example, copper-
containing versus non-copper-containing intrauterine devices. There is little 
information comparing one type of contraception (e.g. oral contraceptives) with 
another (e.g. injectables), or one mix of contraceptive types with another (for 
example, in a trial conducted across communities). It is difficult to be sure whether 
this reflects the focus of existing systematic reviews in this area, or whether it 
reflects a dearth of studies that make direct comparisons between types of 
contraceptives. Similarly, although it was within the scope of this overview to 
present data on a variety of outcomes, including birth spacing, in reality, systematic 
review outcomes tended to focus on pregnancy, (dis)continuation and side effects. 
Again, it is difficult to establish whether this reflects the scope of existing 
systematic reviews or of primary studies in the area. Moreover, the examination of 
side effects was not within the scope of this review. This should be considered when 
interpreting the findings. 
Finally, there were no systematic reviews that examined contraceptive method 
mixes, and contraceptive prevalence and unmet need. This gap in evidence did not 
allow this OoR to answer research objectives 1 and 3 set out in this study. This OoR, 
therefore, recommends that more systematic reviews or primary research are 
required to answer the association between contraceptive method mix and 
contraceptive prevalence.  
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Appendix 2.1: Inclusion and exclusion criteria 
Types of reviews 
For this OoR, we included Cochrane and non-Cochrane systematic reviews of 
randomised and non-randomised trials, observational studies, and economic 
evaluations on the effects of methods (and mixes of methods) of contraception (see 
Types of interventions below) on (1) contraceptive prevalence (2) unwanted 
pregnancies (3) unintended pregnancies and (4) unmet need for family planning. Our 
definition for a systematic review required that the review meets the following 
criteria (Green et al. 2008): 
 a clearly stated set of objectives with predefined eligibility criteria for studies; 
 an explicit, reproducible methodology; 
 a systematic search that attempts to identify all studies that would meet the 
eligibility criteria; 
 an assessment of the validity of the findings of the included studies, for example 
through the assessment of risk of bias; and 
 a systematic presentation, and synthesis, of the characteristics and findings of 
the included studies. 
Reviews that did not contain these elements were excluded from the OoR.  
A wide range of study designs were considered eligible for inclusion: 
Randomised controlled trials: 
 All types.  
Non-randomised trials: 
 Quasi-randomised controlled trials, for example, those in which allocation to 
groups was via a non-random method such as alternation. 
 Controlled before and after studies (CBA), for example, those in which one 
locality is matched to a second, and in one locality a new contraceptive method 
or combination of methods is implemented whilst the other locality stays the 
same, and both locations are measured concurrently before and after the 
intervention. 
 Interrupted time series (ITS), for example, those in which one locality is 
measured at a series of points in time prior to, and again after a new 
contraceptive method or combination of methods is implemented. A minimum of 
three time points before and three time points after the intervention is required 
in order to see a change in trend. This study type may or may not include a 
concurrent control arm. 
 Simple ‘before and after’ studies, for example, where only one locality is 
measured, once before and once after an intervention, and there is no 
concurrent control arm. These studies will be included in this review, but it is 
acknowledged they are subject to a lot of potential confounding. 
Observational studies: 
 Cohort studies, for example, where a group of people who have been exposed to 
one type of contraceptive method or combination of methods are followed-up 
prospectively, and compared to a concurrent group of people who have been 
exposed to a different type of contraceptive method mix. 
 Case-control studies, for example, where a group of people with desirable 
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outcomes are matched to a group of people with undesirable outcomes and a 
retrospective investigation takes place to examine the combination of 
contraceptive methods they were exposed to.  
 Longitudinal studies, for example, where a study of a single service area is 
followed up over a period of time before and after the implementation of a new 
contraceptive method or combination of contraceptive methods (akin to ITS). 
Economic evaluations: 
 Full economic evaluations: 
o Cost-effectiveness analyses 
o Cost-utility analyses 
o Cost-benefit analyses 
 Partial economic evaluations: 
o Cost-analyses 
o Cost description analyses 
o Cost-outcome analyses. 
Types of participants 
For this OoR, we included Cochrane and non-Cochrane systematic reviews of studies 
whose participants were sexually active women or men from countries classified as 
‘developing’, ‘low-income’ or ‘middle-income’ countries by the author(s) of the 
review, or those classified as low-and middle-income countries according to the 
World Bank classification of countries based on gross national income (GNI)8 at the 
time the study was conducted. Reviews that included studies with participants from 
‘high-income’ or ‘developed’ countries were eligible, but only when it was possible 
to use the data from the studies conducted in ‘developing’, ‘low-income’ or 
‘middle-income’ countries separately. Where the review had combined data from 
developing/low-income/middle-income and developed/high-income countries, and 
it was not possible to separate them, the systematic review was excluded. 
These inclusion criteria were broad in order to ensure that the OoR included all 
relevant systematic reviews. For example, although we acknowledge that family 
planning services in developing countries are typically targeted at ‘currently 
married’ women aged 15-49 years, it was feasible that systematic reviews in the 
area might have taken a broader eligibility criterion, and we sought to include these 
in the OoR.  
Types of interventions 
This overview included systematic reviews of any intervention (or combination of 
interventions) designed to increase contraceptive prevalence, reduce fertility or 
both (in order to prevent unwanted pregnancies, delay pregnancies, space 
pregnancies or limit fertility). Systematic reviews which have examined the use of 
contraception for other purposes (e.g. condoms to reduce the transmission of 
infectious disease) or included studies which have done so were included in the OoR 
provided that one of the relevant outcomes had been assessed.  
Any of the following interventions, either individually or in any combination (when 
offered as part of a service, to target individual preferences, needs, or both), were 
included:
                                            
8 http://data.worldbank.org/about/country-classifications 
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Modern contraceptive methods 
Terminal methods: 
 Female sterilisation (laparoscopic, minilaparotomy, combination with Caesarean 
section, Quinacrine). 
 Male sterilisation (vasectomy and non-scalpel vasectomy) 
Spacing or temporary methods: 
 The pill 
 The intrauterine device (IUD), including immediate post-partum and post-
abortion insertion  
 Injectables 
 Implants 
 The female condom 
 The male condom 
 Emergency contraception (EC) 
 The diaphragm 
 Foam/jelly 
Traditional methods 
 Periodic abstinence 
 Withdrawal  
 Lactational amenorrhea method (LAM). 
Where systematic reviews of randomised, non-randomised trials or observational 
studies (as defined in Types of Studies above) are concerned, the OoR included 
those that compared any of the above interventions (in any combination) with any 
comparison intervention (such as alternative methods or combinations of 
contraceptive methods, single methods of contraception, placebo, lack of family 
planning, etc.). 
Types of outcome measure 
Our primary outcome measures were: 
 Contraceptive prevalence (measured as the proportion of women of reproductive 
age (or their partners) who were using a contraceptive method at a given point 
in time9).  
 Unwanted pregnancies (unplanned pregnancies which were not desired by the 
woman: this could be measured either as number of unwanted pregnancies10 or 
as proportion of women who had an unwanted pregnancy). 
 Unintended pregnancies (unplanned pregnancies which were more closely 
spaced than desired by the woman: measured either as number of unintended 
pregnancies   or as proportion of women who had an unintended pregnancy ).  
                                            
9 These outcome measures could be presented by systematic reviews as risk ratios, odds ratios, risk 
difference/absolute risk reductions or number needed to treat. If necessary, we sought to standardise 
these statistics to risk ratios. 
10 These outcome measures would be presented by systematic reviews as a rate ratio and, where 
necessary, we sought to standardise to a risk ratio. 
9 
9 10 
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 Unmet need for family planning (measured as the proportion of women of 
reproductive age who preferred to avoid or postpone child bearing, but were not 
using any method of contraception  ). 
The following secondary outcome measures were included: 
 Initiation of contraceptive use (measured as the proportion of women (or their 
partners) initiating the use of contraceptives  ). 
 Continuation of contraceptive use (measured as either the proportion of women 
(or their partners) who had continued contraceptive use throughout the period 
of the study   or as time-to-event11). 
 Adherence to contraception (measured in a number of ways including number of 
missed pills, number of times they had intercourse without contraception  ).  
 Time between pregnancies (measured as time-to-event data   ). 
Time between births (measured as time-to-event data  ) 
                                            
11 These outcome measures would be presented by systematic reviews as a hazard ratio and, where 
necessary, we sought to standardise to a risk ratio. 
9 
9 
9 
9 
11 
11 
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Appendix 2.2: Search strategy for electronic databases 
Bioline International 
Date of searches = 1 November 2010 - 18 November 2010 
Free-text search using the following terms: 
Family planning  
Contraception  
Contraceptive  
Population control  
Planned parenthood  
Birth control  
Birth regulation  
Population regulation  
Population regulating  
Fertility regulation  
Fertility regulating  
Birth space  
Birth spacer  
Birth spacing  
Birth spacings  
Fertility control  
Sterilisation  
Vasectomy  
Minilaparotomy  
Quinacrine  
Chemical occlusion  
Vas plugs  
Vas excision  
Fascial interposition  
Spacing method  
Spacing methods  
The pill  
Intrauterine device  
Intra-uterine device  
Intrauterine devices  
Intra-uterine devices  
IUD  
Injectable  
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Injectables  
Condom  
Condoms  
Emergency contraception  
Morning after pill  
Morning-after pill  
Abortion  
Withdrawal method  
Lactational amenorrhea  
Natural family planning  
Rhythm method  
Calendar method  
Symptothermal method  
Symptothermal methods  
Sympto-thermal method  
Sympto-thermal methods  
Symptothermic method  
Symptothermic methods  
Sympto-thermic method  
Sympto-thermic methods  
Cervical mucus method  
Fertility awareness  
Billings method 
Basal body temperature method  
Personal hormone monitoring  
Coitus interruptus  
Vaginal sponge  
Cervical cap  
Vaginal ring  
Intrauterine system  
Intrauterine systems  
Intra-uterine system  
Intra-uterine systems  
Vaginal diaphragm  
Latex diaphragm  
Spermicide  
Spermicides  
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Barrier method  
Pregnancy prevention  
Abstain sex intercourse 
Abstinence sex intercourse  
Abstain sexual intercourse  
Abstinence sexual intercourse  
The Cochrane Library 
Date of search = 18 November 2010 
1. Contraception [MeSH] 
2. Contraception:ti,ab 
3. Contraceptive devices [MeSH] 
4. Contraceptive agents [MeSH] 
5. Contraceptive:ti,ab 
6. “Family planning”:ti,ab 
7. Family planning policy [MeSH] 
8. Family planning services [MeSH] 
9. “Population control”[MeSH Terms] 
10. “Planned parenthood”:ti,ab 
11. “Birth control”:ti,ab 
12. “Birth regulation”:ti,ab 
13. Population NEXT regulati*:ti,ab 
14. Fertility NEXT regulati*:ti,ab 
15. Birth NEXT spac*:ti,ab 
16. “Fertility control” :ti,ab 
17. Sterilisation:ti,ab  
18. Vasectomy:ti,ab  
19. Minilaparotomy:ti,ab 
20. “Quinacrine/therapeutic use”[MeSH] 
21. “chemical occlusion”:ti,ab 
22. “Vas plugs”:ti,ab 
23. “Vas excision”:ti,ab 
24. “Fascial interposition”:ti,ab 
25. Spacing NEXT method*:ti,ab 
26. “The pill” :ti,ab 
27. Intrauterine device:ti,ab 
28. Intra-uterine device:ti,ab 
29. IUD:ti,ab 
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30. Injectable*:ti,ab 
31. Condom:ti,ab 
32. “Emergency contraception”:ti,ab 
33. Morning after pill:ti,ab 
34. Morning-after pill:ti,ab 
35. Abortion:ti,ab 
36. “Withdrawal method” :ti,ab 
37. "Natural family planning":ti,ab 
38. “Rhythm method”:ti,ab 
39. “Calendar method”:ti,ab 
40. Symptothermal NEXT method*:ti,ab 
41. Sympto-thermal NEXT method*:ti,ab 
42. Symptothermic NEXT method*:ti,ab 
43. Sympto-thermic NEXT method*:ti,ab 
44. “Cervical mucus method”:ti,ab 
45. “Fertility awareness” NEXT method*:ti,ab 
46. “Billings method”:ti,ab 
47. “Basal body temperature method”:ti,ab 
48. “Personal hormone monitoring”:ti,ab 
49. “Coitus interruptus”:ti,ab 
50. “Vaginal sponge”:ti,ab 
51. “Cervical cap”:ti,ab 
52. “Vaginal ring”:ti,ab 
53. Intrauterine NEXT system*:ti,ab 
54. Intra-uterine NEXT system*:ti,ab 
55. Vaginal diaphragm*:ti,ab 
56. Latex diaphragm*:ti,ab 
57. Spermicide*:ti,ab 
58. “Barrier method”:ti,ab 
59. Pregnan* NEXT prevent*:ti,ab 
60. Abstinence OR Abstain:ti,ab 
61. Sex OR Sexual:ti,ab 
62. #60 AND #61 
63. Intercourse :ti,ab 
64. #62 AND #63 
65. Amenorrhea [MeSH] 
66. Amenorrhoea:ti,ab 
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67. Amenorrhea:ti,ab 
68. Lactational :ti,ab 
69. Method :ti,ab 
70. #65 OR #66 OR #67  
71. #68 AND #69 AND #70 
72. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 
OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 
OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 
OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 
OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 
OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #64 OR #71 
73. Animals[MeSH Terms]  
74. Humans[MeSH Terms]  
75. #73 AND #74 
76. #73 NOT #75 
77. #72 NOT #76 
LILACS 
Date of search = 18 November 2010 
Language restrictions = English only 
1. Subject descriptor="contraception" or "contraceptive devices" or 
"contraceptive agents" or "family planning" or "family planning policy" or 
"family planning services" or "population control" or "quinacrine" 
2. contracepti$ or "family planning" or "population control" or "planned 
parenthood" or "birth control" or "birth regulation" or "fertility control" or 
sterilisation or vasectomy or minilaparotomy or "chemical occlusion" or "vas 
plugs" or "vas excision" or "fascial interposition" or "the pill" or iud or 
injectabl$ or condom$ or "emergency contraception" or "morning after pill" 
or “morning-after pill” or abortion or "withdrawal method" or "lactational 
amenorrhea" or "natural family planning" or "rhythm method" or "calendar 
method" or "cervical mucus method" or "fertility awareness" or "billings 
method" or "basal body temperature method" or "personal hormone 
monitoring" or "coitus interruptus" or "vaginal sponge" or "cervical cap" or 
"vaginal ring" or spermicide$ or “barrier method” 
3. (population and regulati$) or (fertility and regulati$) or (birth and spac$) or 
(spacing and method$) or (intrauterine and devic$) or (intra-uterine and 
devic$) or (symptothermal and method$) or (sympto-thermal and method$) 
or (symptothermic and method$) or (sympto-thermic method$) or 
(intrauterine and system$) or (intra-uterine and system$) or (vaginal and 
diaphragm$) or (latex and diaphragm$) or (pregnan$ and prevent$) or 
(abstain and sex$ and intercourse) or (abstinence and sex$ and intercourse) 
4. #1 OR #2 OR #3 
5. #4 AND Publication type = Meta-analysis 
6. #4 AND Publication type = Review 
7. Title = meta-analysis or search$ 
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8. Abstract = meta-analysis or search$ 
9. #7 OR #8 
10. #4 AND #9#5 OR #6 OR #10 
11. #11 (Language restriction English) 
Popline 
Date of search = 19 November 10 
((Family planning/Population control/Planned parenthood/Birth control/Birth 
regulation/Population regulati*/Fertility regulati*/Birth spac*/Fertility 
control/Sterilisation/Vasectomy/Minilaparotomy/ 
Quinacrine/Chemical occlusion/Vas plugs/Vas excision/Fascial interposition/Spacing 
method*/The pill/ Intrauterine device*/Intra-uterine 
device*/IUD/Injectable*/Condom/Emergency contraception/Morning after 
pill/Morning-after pill/Abortion/Withdrawal method/Lactational amenorrhea 
method/Natural family planning/Rhythm method/Calendar method/ Symptothermal 
method*/Sympto-thermal method*/ 
Symptothermic method*/Sympto-thermic method*/Cervical mucus method/Fertility 
awareness method*/ 
Billings method/Basal body temperature method/Personal hormone 
monitoring/Coitus interruptus/Vaginal sponge/Cervical cap/Vaginal ring/ 
Intrauterine system*/Intra-uterine system*/Vaginal diaphragm*/Latex 
diaphragm*/Spermicide*/Barrier method/Pregnan* 
prevent*)/((Abstinence/Abstain)&(Sex/Sexual)))&(Meta-analysis/Review/Search*) 
PubMed 
Date of search = 22 November 2010 
1. Contraception [Tiab] 
2. Contraception [MeSH Terms] 
3. Contraceptive devices [MeSH Terms] 
4. Contraceptive agents [MeSH Terms] 
5. “Contraceptives” [Tiab] 
6. “Contraceptive” [Tiab] 
7. “Family planning” [Tiab] 
8. Family planning policy [MeSH Terms] 
9. Family planning services [MeSH Terms] 
10. “Population control”[MeSH Terms] 
11. “Population control” [Tiab] 
12. Planned parenthood [Tiab] 
13. “Birth control” [Tiab] 
14. Birth regulation [Tiab] 
15. Population regulati* [Tiab] 
16. Fertility regulati* [Tiab] 
17. Birth spac* [Tiab] 
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18. “Fertility control” [Tiab] 
19. Sterilisation [Tiab] 
20. Vasectomy [Tiab] 
21. “Minilaparotomy” [Tiab] 
22. “Quinacrine/therapeutic use”[MeSH] 
23. “chemical occlusion” [Tiab] 
24. Vas plugs [Tiab] 
25. Vas excision [Tiab] 
26. “Fascial interposition” [Tiab] 
27. Spacing method* [Tiab] 
28. “The pill” [Tiab] 
29. Intrauterine device* [Tiab] 
30. Intra-uterine device* [Tiab] 
31. IUD [Tiab] 
32. Injectable* [Tiab] 
33. Condom [Tiab] 
34. Emergency contraception [Tiab] 
35. Morning after pill [Tiab] 
36. Morning-after pill [Tiab] 
37. Abortion [Tiab] 
38. “Withdrawal method” [Tiab] 
39. Lactational amenorrhea method [Tiab] 
40. Natural family planning [Tiab] 
41. “Rhythm method” [Tiab] 
42. “Calendar method” [Tiab] 
43. Symptothermal method* [Tiab] 
44. Sympto-thermal method* [Tiab] 
45. Symptothermic method* [Tiab]  
46. Sympto-thermic method* [Tiab] 
47. “Cervical mucus method” [Tiab] 
48. “Fertility awareness method” [Tiab] 
49. “Fertility awareness methods” [Tiab] 
50. “Billings method” [Tiab] 
51. “Basal body temperature method” [Tiab] 
52. “Personal hormone monitoring” [Tiab] 
53. “Coitus interruptus” [Tiab] 
54. “Vaginal sponge” [Tiab] 
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55. “Cervical cap” [Tiab] 
56. “Vaginal ring” [Tiab] 
57. Intrauterine system* [Tiab] 
58. Intra-uterine system* [Tiab] 
59. Vaginal diaphragm* [Tiab] 
60. Latex diaphragm* [Tiab] 
61. Spermicide* [Tiab] 
62. “barrier method” [Tiab] 
63. Pregnan* prevent* [Tiab] 
64. Abstinence [Tiab] 
65. Abstain [Tiab] 
66. #64 OR #65 
67. Sex [Tiab] 
68. Sexual [Tiab] 
69. #67 OR #68 
70. #66 AND #69 
71. Intercourse [Tiab] 
72. #70 AND #71 
73. #1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 
OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 
OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 
OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40 OR #41 OR #42 
OR #43 OR #44 OR #45 OR #46 OR #47 OR #48 OR #49 OR #50 OR #51 OR #52 
OR #53 OR #54 OR #55 OR #56 OR #57 OR #58 OR #59 OR #60 OR #61 OR #62 
OR #63 OR #72 
74. Animals[MeSH Terms] NOT (Humans[MeSH Terms] AND Animals[MeSH Terms]) 
75. #73 NOT #74 
76. Meta-analysis[publication type] 
77. Meta-analysis [Title/abstract] 
78. Meta-analysis [MeSH Terms] 
79. Review[Publication Type] 
80. Search*[Title/Abstract] 
81. #76 OR #77 OR #78 OR #79 OR #80 
82. #75 AND #81 
TRIP Database 
Date of search = 3-8 December 2010  
Publication type = systematic reviews 
Searched the following free-text terms: 
 Contracepti*  
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 “Family planning”  
 “Population Control”  
 “Planned parenthood”  
 “Birth control”  
 “Birth regulation”  
 “Population regulation”  
 “population regulating”  
 “ Fertility regulati*”  
 “Birth spac*”  
 “Fertility control”  
 Sterilisation  
 Vasectomy  
 Minilaparotomy  
 Quinacrine  
 “Chemical occlusion”  
 “Vas plugs”  
 “Vas excision”  
 “Fascial interposition”  
 “Spacing method*”  
 “The pill”  
 “Intrauterine device*”  
 “Intra-uterine device*”  
 IUD  
 Injectable*  
 Condom  
 “Emergency contraception”  
 “Morning after pill”  
 “Morning-after pill”  
 Abortion  
 “Withdrawal method”  
 “Lactational amenorrhea method”  
 “Natural family planning”  
 “Rhythm method”  
 “Calendar method”  
 “Symptothermal method*”  
 “Sympto-thermal method*”  
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 “Symptothermic method*”  
 “Sympto-thermic method*”  
 “Cervical mucus method”  
 “Fertility awareness method*”  
 “Billings method”  
 “Basal body temperature method”  
 “Personal hormone monitoring”  
 “Coitus interruptus”  
 “Vaginal sponge”  
 “Cervical cap”  
 “Vaginal ring”  
 “Intrauterine system*”  
 “Intra-uterine system*”  
 “Vaginal diaphragm*”  
 “Latex diaphragm*”  
 Spermicide*  
 “Barrier method”  
 Pregnan* prevent*  
 Sex* AND abstain AND intercourse  
 Sex* AND abstinence AND intercourse 
WHO Reproductive Health Library 
Date of search = 28-29 October 2010 
As the WHO Reproductive Health Library contains only a small number of reviews, 
those indexed under the following headings were added (by hand) into the main 
reference management database: 
Fertility regulation: 
 Contraception (and associated Cochrane Reviews) 
 Induced abortion (and associated Cochrane Reviews) 
 Adolescent sexual and reproductive health (and associated Cochrane Reviews) 
 HIV (and associated Cochrane Reviews) 
Zetoc (British Library’s table of contents) 
Date of search = 18 November 10 
 Contracepti* and Meta-analysis (title) 
 Contracepti* and Review (title) 
 Contracepti* and Search (title) 
 “Family planning” and Review (title) 
 Population regulati* and Review (title) 
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 “Birth control” and Review (title) 
 Population regulati* and Review (title) 
 Fertility regulati* and Review (title) 
 Fertility regulati* and Search (title) 
 Birth spac* and Meta-analysis (title) 
 Birth spac* and Review (title) 
 “Fertility control” and Review (title) 
 “Fertility control” and Search (title) 
 Sterilisation and Review (title) 
 Vasectomy and Meta-analysis (title) 
 Vasectomy and Review (title) 
 Spacing method* and Review (title) 
 Minilaparotomy and Review (title) 
 Quinacrine and Review (title) 
 “the pill” and Meta-analysis (title) 
 “the pill” and Review (title) 
 “the pill” and Search (title) 
 Intrauterine device* and Meta-analysis (title) 
 Intrauterine device* and Review (title) 
 Intra-uterine device* and Review (title) 
 IUD and Meta-analysis (title) 
 IUD and Review (title) 
 Injectable* and Meta-analysis (title) 
 Injectable* and Review (title) 
 Injectable* and Search (title) 
 Condom* and Meta-analysis (title) 
 Condom* and Review (title) 
 “Emergency contraception” and Meta-analysis (title) 
 “Emergency contraception” and Review (title) 
 Abortion and Meta-analysis (title) 
 Abortion and Review (title) 
 Abortion and Search (title) 
 “Lactational amenorrhea method” and Search (title) 
 “Calendar method” and Review (title) 
 “Vaginal ring” and Review (title) 
 Intrauterine system* and Meta-analysis (title) 
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 Intrauterine system* and Review (title) 
 Intrauterine system* and Search (title) 
 Intra-uterine system* and Meta-analysis (title) 
 Intra-uterine system* and Review (title) 
 Spermicide* and Meta-analysis (title) 
 Spermicide* and Review (title) 
 Spermicide* and Search (title) 
 Pregnan* prevent* and Meta-analysis (title) 
 Pregnan* prevent* and Review (title) 
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Appendix 2.3: Study eligibility form and notes 
OVERVIEW OF REVIEWS: SYSTEMATIC REVIEW ELIGIBILITY FORM 
If the answer to any of the below questions is no then the report will be excluded 
and no further questions need be answered. 
 Yes Unclear No 
  Next question  Exclude 
Methods used in review     
Is there a clearly stated set of objectives with pre-defined 
eligibility criteria for studies? 
   
Is there an explicit, reproducible methodology?    
Is there a systematic search that attempts to identify all studies 
that would meet the eligibility criteria? 
   
Is there an assessment of the validity of the findings of the 
included studies, for example through the assessment of risk of 
bias? 
   
Is there a systematic presentation, and synthesis, of the 
characteristics and findings of the included studies? 
   
    
Participants12     
Does the systematic review include studies whose participants are 
sexually active women or men? 
   
Setting16    
Does the systematic review include studies conducted in countries 
either defined by the review as developing, low-income, middle-
income or low-middle-income or defined by the World Bank 
Classification [Note 1] as lower income, lower-middle-income or 
upper-middle-income economies? 
   
Is it possible to extract the data from studies conducted in 
developing countries separately from those conducted in 
developed countries? 
   
Intervention16    
Does the systematic review include studies which include one or a 
combination of interventions designed to increase contraceptive 
prevalence, reduce fertility or both (in order to prevent unwanted 
pregnancies; delay pregnancies; space pregnancies; limit fertility)? 
[Note 2] 
 
 
 
 
 
 
Outcomes16    
Does the systematic review include studies which measure an 
outcome related to contraceptive use, unwanted pregnancy or 
births, or unmet need for family planning? [Note 3] 
 
 
 
 
 
 
 
                                            
12 According to the inclusion and exclusion criteria detailed in the systematic review 
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STUDY DESIGNS  
To be included in the Overview of Reviews the systematic review must include one 
or more of the following study designs. 
 Yes Unclear No 
Randomised Controlled Trial (RCT)    
A trial in which the participants were definitely assigned 
prospectively to one or two (or more) alternative forms of 
health care using a process of random allocation. 
   
Controlled Clinical Trial (CCT)    
A trial in which participants were either definitely or possibly 
assigned prospectively to one or two (or more) alternative 
forms of healthcare using a quasi-random method of allocation 
(e.g. alternation, date of birth). 
   
Controlled Before and After Study (CBA)    
A study in which one locality is matched to a second, and in one 
locality a new contraceptive method or combination of methods 
is implemented whilst the other stays the same, and both 
locations are measured concurrently before and after the 
intervention. 
   
Interrupted Time Series (ITS)    
A study in which one locality is measured at series of points in 
time prior to, and again after, a new contraceptive method or 
combination of methods is implemented. A minimum of three 
time points before and three time points after the intervention 
is required in order to see a change in trend. This study type 
may or may not include a concurrent control arm. 
   
Before and After Study     
A study in which only one locality is measured, once before and 
once after an intervention, and there is no concurrent control 
arm.  
   
Cohort Study    
A study in which a group of people who have been exposed to 
one type of contraceptive method or combination of methods 
are followed-up prospectively, and compared to a concurrent 
group of people who have been exposed to a different type of 
contraceptive method mix. 
   
Case Control Study    
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A study in which a group of people with desirable outcomes are 
matched to a group of people with undesirable outcomes and a 
retrospective investigation takes place to examine the 
combination of contraceptive methods they were exposed to. 
 
 
 
   
Longitudinal Study    
A study of a single service area which is followed up over a 
period in time before and after the implementation of a new 
contraceptive method or combination of contraceptive methods 
(akin to ITS). 
   
Economic Evaluation    
Any of the following: Full economic evaluations: cost-
effectiveness analyses, cost-utility analyses, cost-benefit 
analyses. Partial economic evaluations: cost-analyses, cost 
description analyses, cost-outcome analyses. 
   
 
FINAL DECISION: Include  Subject to 
clarification 
 Exclude  
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NOTES 
[1] 2008 World Bank list of economies:  
Lower income economies [INCLUDED] 
Afghanistan, Bangladesh, Benin, Burkina Faso, Burundi, Cambodia, Central African 
Republic, Chad, Comoros, Congo, Dem. Rep, Eritrea, Ethiopia, Gambia, The, Ghana, 
Guinea, Guinea-Bissau, Haiti, Kenya, Korea, Dem Rep., Kyrgyz Republic, Lao PDR, 
Liberia, Madagascar, Malawi, Mali, Mauritania, Mozambique, Myanmar, Nepal, Niger, 
Rwanda, Senegal, Sierra Leone, Somalia, Tajikistan, Tanzania, Togo, Uganda, 
Uzbekistan, Vietnam, Yemen, Rep., Zambia, Zimbabwe  
Lower-middle-income economies [INCLUDED] 
Albania, Angola, Armenia, Azerbaijan, Belize, Bhutan, Bolivia, Cameroon, Cape 
Verde, China, Congo, Rep., Côte d'Ivoire, Djibouti, Ecuador, Egypt, Arab Rep., El 
Salvador, Georgia, Guatemala, Guyana, Honduras, India, Indonesia, Iran, Islamic 
Rep., Iraq, Jordan, Kiribati, Kosovo, Lesotho, Maldives, Marshall Islands, Micronesia, 
Fed. States, Moldova, Mongolia, Morocco, Nicaragua, Nigeria, Pakistan, Papua New 
Guinea, Paraguay, Philippines, Samoa, São Tomé and Principe, Solomon Islands, Sri 
Lanka, Sudan, Swaziland, Syrian Arab Republic, Thailand, Timor-Leste, Tonga, 
Tunisia, Turkmenistan, Ukraine, Vanuatu, West Bank and Gaza. 
Upper-middle-income economies [INCLUDED] 
Algeria, American Samoa, Argentina, Belarus, Bosnia and Herzegovina, Botswana, 
Brazil, Bulgaria, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican Republic, 
Fiji, Gabon, Grenada, Jamaica, Kazakhstan, Latvia, Lebanon, Libya, Lithuania, 
Macedonia, FYR, Malaysia, Mauritius, Mayotte1, Mexico, Montenegro, Namibia, 
Palau, Panama, Peru, Poland, Romania, Russian Federation, Serbia, Seychelles, 
South Africa, St. Kitts and Nevis, St. Lucia, St. Vincent and the Grenadines, 
Suriname, Turkey, Uruguay, Venezuela, RB  
High-income economies [EXCLUDED] 
Andorra, Antigua and Barbuda2, Aruba, Australia, Austria, Bahamas, The, Bahrain, 
Barbados3, Belgium, Bermuda, Brunei Darussalam, Canada, Cayman Islands, Channel 
Islands, Croatia4, Cyprus5, Czech Republic6, Denmark, Equatorial Guinea7, Estonia8, 
Faeroe Islands, Finland, France, French Polynesia, Germany, Greece9, Greenland, 
Guam10, Hong Kong SAR, China, Hungary11, Iceland, Ireland, Isle of Man12, Israel, 
Italy, Japan, Korea, Rep.13, Kuwait, Liechtenstein, Luxembourg, Macao SAR14, China, 
Malta15, Monaco, Netherlands, Netherlands Antilles16, New Caledonia17, New 
Zealand, Northern Mariana Islands18, Norway, Oman19, Portugal, Puerto Rico20, 
Qatar, San Marino, Saudi Arabia21, Singapore, Slovak Republic22, Slovenia23, Spain, 
Sweden, Switzerland, Trinidad and Tobago24, United Arab Emirates, United 
Kingdom, United States, Virgin Islands (U.S.)  
PLEASE NOTE CHANGES IN STATUS (Records from 1987 to 2008): 
1. This was classified as a high-income economy in 1990 only 
2. This was not classified as a high-income economy from 1987-2001, 2003-2004 
3. This was classified as a high-income economy in 1989, 2000, 2002, 2006-2008 only 
4. This was not classified as a high-income economy until 2008 
5. This was not classified as a high-income economy in 1987 
6. This was not classified as a high-income economy until 2006 
7. This was not classified as a high-income economy until 2007 
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8. This was not classified as a high-income economy until 2007 
9. This was not classified as a high-income economy until 1996 
10. This was classified as a high-income economy in 1987-89 and 1995-2008 only 
11. This was not classified as a high-income economy until 2007 
12. This was classified as a high-income economy in 1987-89 and 2002-2008 only 
13. This was classified as a high-income economy in 1995-97 and 2001-2008 only 
14. This was not classified as a high-income economy until 1994 
15. This was classified as a high-income economy in 1989, 1998, 2000 and 2002-2008 
only 
16. This was not classified as a high-income economy until 1994 
17. This was not classified as a high-income economy until 1995 
18. This was classified as a high-income economy in 1995-2001 and 2007-2008 only 
19. This was not classified as a high-income economy until 2007 
20. This was classified as a high-income economy in 1989 and 2002-2008 only 
21. This was classified as a high-income economy in 1987-89 and 2004-2008 only 
22. This was not classified as a high-income economy until 2007 
23. This was not classified as a high-income economy until 1997 
24. This was not classified as a high-income economy until 2006 
COUNTRIES NO LONGER IN EXISTENCE: 
Czechoslovakia, Serbia and Montenegro, the USSR and Yugoslavia were not classified 
as high-income economies at any date. 
[2] List of contraceptive methods: 
 Female sterilisation (laparoscopic, minilaparotomy, combination with Caesarean 
section, Quinacrine) 
 Male sterilisation (Vasectomy and non-scalpel vasectomy) 
 The pill 
 The intrauterine device (IUD), including immediate post-partum and post-
abortion insertion 
 Injectables 
 Implants 
 The female condom 
 The male condom 
 Emergency contraception (EC) 
 The diaphragm 
 Foam/jelly 
 Periodic abstinence 
 Withdrawal 
 Lactational amenorrhea method (LAM) 
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[3] List of outcomes: 
Primary: 
 Contraceptive prevalence (the proportion of women of reproductive age (or 
their partners) who are using a contraceptive method at a given point in time) 
 Unwanted pregnancies (unplanned pregnancies which are not desired by the 
woman) 
 Unintended pregnancies (unplanned pregnancies which are more closely spaced 
than desired by the woman) 
 Unmet need for family planning (the proportion of women of reproductive age 
who prefer to avoid or postpone child bearing, but are not using any method of 
contraception) 
Secondary: 
 Initiation of contraceptive use (likely to be measured as the proportion of 
women (or their partners) initiating the use of contraceptives) 
 Continuation of contraceptive use (likely to be measured as either the 
proportion of women (or their partners) who have continued contraceptive use 
throughout the period of the study or as time-to-event) 
 Adherence to contraception (could be measured in a number of ways including 
number of missed pills, number of times had intercourse without contraception) 
 Time between pregnancies (likely to be measured as time to event data) 
 Time between births (likely to be measured as time to event data) 
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OVERVIEW OF REVIEWS: SYSTEMATIC REVIEW DATA COLLECTION FORM 
Impact of Contraceptive Methods and Mixes of Contraceptive Methods on 
Contraceptive Prevalence, Unmet Need for Family Planning, and Unwanted and 
Unintended Pregnancies. 
Throughout data collection please include the page number(s) from which 
information has been obtained. 
A. Notes 
 
 
B. Questions for authors? E.g. to ask for missing information or clarification. 
 
 
C. General Information  
Type of report (e.g. journal 
article) 
 
Author contact details  
Date searches conducted  
Date review published    Exclude (review withdrawn) 
Date of last update  
Date this form completed  
 
D. VERIFICATION OF SYSTEMATIC REVIEW ELIGIBILITY Done Not 
done 
Not 
clear 
Did this review use an explicit, reproducible methodology 
(including a systematic search strategy and assessment of the 
validity of findings of included studies) to produce a systematic 
presentation, and synthesis, of the findings of included 
studies? 
   
Were participants sexually active women or men?    
Does it include at least one study conducted in a developing 
country? 
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Is it possible to extract the data from studies conducted in 
developing countries separately from those conducted in 
developed countries? 
   
Do the included studies examine methods of contraception 
(individually or in combination) as an intervention? 
   
Do the included studies measure an outcome related to 
contraceptive use, unwanted pregnancy or births, or unmet 
need for family planning? 
   
Does the review include studies using at least one of the 
following study designs13: 
   
RCT    
CCT     
CBA     
ITS    
Before and After Study    
Cohort Study    
Case Control Study    
Longitudinal Study    
Economic Evaluation    
Are relevant and interpretable data presented and obtainable?    
 
E. QUALITY ASSESSMENT OF SYSTEMATIC REVIEW See additional notes for further 
guidance 
 
 
Yes No Can’t 
answer* 
N/A Notes 
Was an ‘a priori’ design 
provided? 
     
Was there duplicate study 
selection and data extraction? 
     
Was a comprehensive literature 
search performed? 
     
Was the status of publication 
(i.e. grey literature) used as an 
inclusion criterion? 
     
Was a list of studies (included 
and excluded) provided? 
     
Were the characteristics of the 
included studies provided? 
     
                                            
13 See additional notes for definitions (available from the review authors on request) 
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Was the scientific quality of the 
included studies assessed and 
documented? 
     
Was the scientific quality of the 
included studies used 
appropriately in formulating 
conclusions? 
     
Were the methods used to 
combine the findings of studies 
appropriate? 
     
Was the likelihood of publication 
bias assessed? 
     
Was the conflict of interest 
stated? 
     
*If can’t answer ticked please note in ‘Questions for Authors’ 
F. DATA EXTRACTION: Methods of the systematic review 
In this section please record the inclusion and exclusion criteria of the review. This 
can be found in the methods section and should not include information about the 
included studies (e.g. that found in ‘Description of studies’ sections or similar). 
 Inclusion criteria Exclusion criteria 
Participants  
 
 
 
Settings (e.g. limited 
to any particular 
countries) 
 
 
 
 
Intervention  
 
 
 
Comparison/Control  
 
 
 
Outcomes - primary  
 
 
 
 
Outcomes - 
secondary 
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G. DATA EXTRACTION: Relevant comparisons conducted and outcomes for which possible to extract developing countries data  
Please tick the boxes for all outcomes for which we can extract the developing countries data separately (i.e. in a review that includes meta-
analysis those outcomes for which all contributing studies were conducted in a developing country, in a narrative review those for which the 
contribution of studies conducted in developing countries is clear).  
Comparisons (please complete for each comparison) Outcomes (please tick)  
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C6  V           
C7  V           
C8  V           
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H. DATA EXTRACTION: Measurement of outcomes  
For those outcomes where it is possible to extract the developing countries data separately please complete the following information about how 
the outcomes were measured. Please tick N/A for outcomes where it is not possible to extract this data. 
Outcome N/A Measured as: Summary statistic presented:14 
RiR OR RD/ARR NNT RaR15 HR19 Other 
Contraceptive 
prevalence  
   Proportion of women of reproductive age (or their 
partner) who are using a contraceptive method at a 
given point in time 
       __________ 
 Other____________________________________________
_ 
        
Unwanted 
pregnancies16  
  Proportion of women who had an unwanted pregnancy.        __________ 
 Number of unintended pregnancies.         
 Other____________________________________________
_ 
        
Was pregnancy treated as an event  or non-event?          
Unmet need 
for family 
planning 
  Proportion of women of reproductive age who prefer to 
avoid or postpone child bearing, but are not using any 
method of contraception. 
       __________ 
 Other____________________________________________
_ 
        
Initiation of 
contraceptive 
use  
  Proportion of women (or their partners) initiating the 
use of contraceptives 
        
 Other____________________________________________
_ 
        
Continuation of 
contraceptive 
use 
  Proportion of women (or their partners) who have 
continued contraceptive use throughout the period of 
the study 
       __________ 
                                            
14 For abbreviations see additional notes (available from the review authors on request) 
15 Will need standardising to risk ratio 
16 Unplanned pregnancies not desired by the woman 
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 Time-to-event         
 Other____________________________________________
_ 
        
Adherence to 
contraception  
  Number of missed pills        __________ 
 Number of times had intercourse without contraception         
 Other____________________________________________
_ 
        
Time between 
pregnancies  
  Time-to-event        __________ 
 Other____________________________________________
_ 
        
Time between 
births 
  Time-to-event        __________ 
 Other____________________________________________
_ 
        
 
I. DATA EXTRACTION: Results for outcomes relevant to OoR (where meta-analyses have been undertaken). Please complete one table per outcome 
Outcome (please tick only one): 
 Contraceptive prevalence   Unwanted pregnancies  Unmet need for family 
planning 
 Initiation of contraceptive 
use  
 Continuation of contraceptive 
use 
 Adherence to 
contraception  
 Time between pregnancies   Time between births 
 
What is the impact of contraceptive methods and mixes of contraceptive methods on contraceptive prevalence, unmet need for family planning, and unwanted and unintended 
pregnancies? 
78 
C17 Risk in 
compariso
n group18  
Risk in 
interventio
n group22 
Relative 
risk  
(95% CI) 
E.g. 
Pooled 
odds ratio 
Number of 
participant
s (studies) 
Studies included (Author 
et al., year) 
Countries in which 
included studies conducted 
Length of follow up 
(Please tally 
number of studies 
for each time 
period) 
Additional 
comments 
       < 6 mths   
6 mths – 1 
year 
 
> 1year  
       < 6 mths   
6 mths – 1 
year 
 
> 1year  
  
 
     < 6 mths   
6 mths – 1 
year 
 
> 1year  
  
 
     < 6 mths   
6 mths – 1 
year 
 
> 1year  
 
                                            
17 Please complete the comparison number here using the number assigned to them in Section G. Please do not complete for comparison where it is not possible to extract data 
related to this outcome. 
18 e.g. n/N had unwanted pregnancies 
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J. DATA EXTRACTION: Results for outcomes relevant to OoR (where meta-analyses have not been undertaken) Complete one table per outcome 
Outcome (please tick only one): 
 Contraceptive prevalence   Unwanted pregnancies  Unmet need for family 
planning 
 Initiation of contraceptive 
use  
 Continuation of contraceptive 
use 
 Adherence to 
contraception  
 Time between pregnancies   Time between births 
C19 Summary of findings Studies included (Study ID e.g. 
author, year) 
Countries in which included 
studies conducted 
  
 
 
 
  
  
 
 
 
  
  
 
 
 
  
  
 
  
                                            
19 Please complete the comparison number here using the number assigned to them in Section G. Please do not complete for comparison where it is not possible to extract data 
related to this outcome. 
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K. DATA EXTRACTION: For all types of analyses – further contextual information. Complete one table per outcome 
Outcome (please tick only one): 
 Contraceptive prevalence   Unwanted pregnancies  Unmet need for family planning  Initiation of contraceptive use  
 Continuation of contraceptive 
use 
 Adherence to 
contraception  
 Time between pregnancies   Time between births 
 
C20 How were family 
planning services 
provided? E.g. 
community-based, 
clinic-based. 
How accessible 
were the family 
planning services? 
E.g. distance to 
travel to access, 
transportation 
available to 
services. 
How were the 
family planning 
services staffed? 
E.g. nurse-led 
clinics 
Were there any 
issues regarding 
availability of 
contraceptive 
methods? 
How much did the 
service cost users? 
Were there any 
cultural factors 
which may have 
affected choice or 
availability of 
contraceptive 
methods? 
Who funded the 
family planning 
services (e.g. NGO, 
private sector)? 
  
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
  
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
  
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
                                            
20 Please complete the comparison number here using the number assigned to them in Section G. Please do not complete for comparison where it is not possible to extract data 
related to this outcome. 
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 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
 
 Not clear 
 
L. QUALITY OF EVIDENCE: for each comparison – as reported in the systematic review.21 
C22 Study design(s) – what 
study designs contributed 
to the evidence for this 
comparison RCTs, 
observational studies?  
Study quality – was there 
adequate allocation 
concealment, blinding and 
follow-up; were there any 
serious limitations? 
Consistency – was there 
similarity of estimates of 
effect across studies? 
Directness – how similar 
were the people, 
interventions and outcomes 
to those of interest? 
If reported – what was the 
grade assigned to the 
overall body of evidence? 
  
 
    
 Not reported 
  
 
    
 
 Not reported 
  
 
 
    
 
 Not reported 
  
 
 
    
 
 Not reported 
                                            
21 For further guidance see GRADE Working Group. (2004). Grading quality of evidence and strength of recommendations. BMJ, 328, 1490 – provided in additional notes. 
22 Please complete the comparison number here using the number assigned to them in Section G. Please do not complete for comparison where it is not possible to extract data 
related to this outcome. 
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 Appendix 3.1: Table of included reviews 
Cheng (2008) 
Review type Cochrane review 
Study design Predominantly RCTs  
Date assessed as up-to-date 17 February 2008 
Population Inclusion criteria: Women with regular menses requesting emergency contraception following 
unprotected intercourse. 
Exclusion criteria: Women attending clinics for ‘once a month’ contraception in the form of luteal 
phase contraceptives and menstrual regulation using mifepristone (RU 486) and prostaglandin 
analogues. 
Setting Not limited by setting. 
Interventions Inclusion criteria: Both intervention and comparisons as listed: 
1. Any regimen vs nothing/placebo 
2. Hormonal ECPs: comparisons of different regimens: 
• Levonorgestrel vs Yuzpe 
• Levonorgestrel vs mifepristone 
• Mifepristone vs Yuzpe 
• Mifepristone vs anordin 
• Mifepristone vs mifepristone +anordin 
• Mifepristone vs mifepristone + misoprostol 
• Mifepristone vs mifepristone + tamoxifen 
• Mifepristone vs danazol 
• Yuzpe vs high-dose oestrogen 
• Yuzpe vs danazol 
• CDB-2914 vs levonorgestrel 
• Drug/dose comparisons 
• Others 
3. IUD comparisons to ECPs 
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4. Combination treatments and comparisons of these with other treatments alone or in 
combination were considered for inclusion when such data were available, including different 
doses. 
Exclusion criteria: Similar interventions used by women as regular post-coital contraception. 
Comparisons of different delivery systems such as advance provision or over-the-counter delivery, 
and any kind of educational interventions. 
Comparison interventions N/A 
Outcomes for which data were 
reported 
Primary: Pregnancy rate in women receiving different regimens (or control). 
Secondary: 
1. Observed number of pregnancies (all women) 
2. Ectopic pregnancy 
3. Side effects: 
• Any side effect 
• Nausea 
• Vomiting 
• Headache 
• Dizziness 
• Fatigue 
• Breast tenderness 
• Diarrhoea 
• Spotting or bleeding 
• Others 
4. Menses (early or late). 
Review limitations  
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Draper (2006) 
Review type Cochrane review 
Study design Predominantly RCTs 
Date assessed as up-to-date 23 May 2006 
Population Inclusion criteria: Healthy women of reproductive age, of all ethnic groups who are using either of 
the injectable progestogen-only contraceptives IPCs i.e. DMPA or NET-EN. 
Setting Not limited by setting. 
Interventions Inclusion criteria: DMPA given at doses of 150mg IM every 3 months versus… 
Comparison interventions NET-EN given at doses of 200mg IM every 2 months. 
Outcomes for which data were 
reported 
Primary:  
 Cumulative discontinuation risks: overall risks and risks due to specific menstrual and non-
menstrual effects.  
 Contraceptive efficacy: accidental pregnancy as a reason for discontinuation.  
 Minor effects: Amenorrhea, menorrhagia, spotting, irregular bleeding, dysmenorrhoea. Non-
menstrual = headache, clinically significant weight change of 24kg, decreased libido, mood 
swings/depression, nausea, dizziness, vaginal discharge. Major effects: Increased HIV vaginal 
shedding, susceptibility to HIV and other sexually transmitted infections. 
Review limitations Review has not been recently updated. 
 
Edelman (2005) 
Review type  Cochrane review 
Study design Predominantly RCTs 
Date assessed as up-to-date 3 September 2009 
Population Inclusion criteria: Reproductive-age women using combined hormonal contraceptives for 
contraceptive purposes. 
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Exclusion criteria: Use of combined hormonal contraceptives for conditions such as endometriosis. 
Setting Not limited by setting. 
Interventions Inclusion criteria: Any type of combined hormonal contraceptive (pill, patch, ring) given in a 
continuous manner (>28 days active hormones). 
Comparison interventions Traditional cyclic use of combined hormonal contraceptive (21 days active hormone, placebo). 
Outcomes for which data were 
reported 
Primary: Study discontinuation, pregnancy, bleeding, endometrial thickness, adherence, satisfaction, 
adverse events. 
Review limitations  
 
French (2004) 
Review type  Cochrane review 
Study design Predominantly RCTs and CCTs 
Date assessed as up-to-date 14 July 2009 
Population Inclusion criteria: Women of reproductive years. 
Setting Not limited by setting. 
Interventions Inclusion criteria: Hormonally impregnated IUDs. 
Comparison interventions Hormonal IUDs; Barrier contraception; oral contraceptives; injectable contraceptives; subdermal 
implants; other implants. 
Outcomes for which data were 
reported 
Primary: Pregnancy due to method failure at 1, 2, 3, 4 and 5+ years. Continuation of method at 1 ,2, 
3, 4 and 5+ years. 
Secondary: Planned pregnancy after discontinuation at 1+2 years; failed removal; side effects; 
menstrual bleeding changes; adverse clinical events; reason for discontinuation. 
Review limitations  
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Gallo (2008) 
Review type Cochrane review 
Study design Predominantly RCTs 
Date assessed as up-to-date 31st October 2010 
Population Inclusion criteria: Reproductive-age women. 
Exclusion criteria: Contraindications to combination injectable contraceptive use. 
Setting Not limited by setting. 
Interventions Inclusion criteria: Combination injectable contraceptives (limited to formulations marketed at the 
time of the review). 
Comparison interventions Any other contraceptive method or placebo. 
Outcomes for which data were 
reported 
Primary: Measures of contraceptive efficacy, bleeding patterns, continuation, user preferences, side 
effects. 
Biochemical measures were excluded. 
Review limitations  
 
Gallo (2011) 
Review type Cochrane review 
Study design Predominantly RCTs 
Date assessed as up-to-date 2 November 2010 
Population Inclusion criteria: Women of reproductive age, irrespective of previous COC history. 
Exclusion criteria: Medical contraindications to COCs. 
Setting Not limited by setting although only English language reports included. 
Interventions Inclusion criteria: Any combined oral contraceptive (COC) containing ≥20µg of EE (ethinyl estradiol). 
Trial interventions had to be designed to be administered for a minimum of 3 consecutive cycles. 
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Exclusion criteria: If COC used primarily as treatment for non-contraceptive conditions e.g. acne, 
anovulation, dysmenorrhea, menorrhagia, pelvic pain or endometriosis. 
Comparison interventions COC containing >20µg EE. 
Outcomes for which data were 
reported 
Primary: Contraceptive effectiveness, bleeding patterns, side effects, trial discontinuation for 
bleeding-related reasons or other side-effects. 
Trials measuring only biochemical changes were excluded. 
Review limitations  
 
Grimes (2004) 
Review type Cochrane review 
Study design Predominantly RCTs 
Date assessed as up-to-date 1 November 2009 
Population Inclusion criteria: All couples included in the eligible trials. 
Setting Not limited by setting. 
Interventions Inclusion criteria: Any fertility awareness-based methods used to prevent pregnancy. These included 
but were not limited to the calendar method, the basal-body temperature method, the ovulation or 
Billings method, the symptothermal method and ovulation prediction devices that rely on assays. 
Interventions could include fertility awareness-based methods used with or without a barrier 
contraceptive or withdrawal. 
Comparison interventions Compared with placebo or another method, including an alternative fertility awareness-based 
method or fertility awareness-based methods used in conjunction with another contraceptive. 
Outcomes for which data were 
reported 
Primary: Pregnancy rates. 
Secondary: Continuation rates, acceptability. 
Review limitations In this review, there was poor reporting of data collection and analysis methods. The review has 
mixed the reporting of inclusion/exclusion criteria with the description of included studies. 
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Grimes (2005) 
Review type Cochrane review 
Study design Predominantly RCTs 
Date assessed as up-to-date 19 September 2010 
Population Inclusion criteria: All women included in eligible trials. 
Setting Not limited by setting. 
Interventions Inclusion criteria: Any commercially available spermicide used for prevention of pregnancy; 
spermicide alone. 
Exclusion criteria: Trials using spermicide for preventing STIs. 
Comparison interventions Different spermicide; same spermicide and barrier method; different dose of same spermicide; 
different formulation of same spermicide; another contraceptive. 
Outcomes for which data were 
reported 
Primary: Pregnancy. 
Secondary: Continuation rates, side effects, acceptability, changes to vaginal epithelium. 
Trials which only reported surrogate end-points, such as in-vitro effects on sperm motility, were 
excluded. 
Review limitations  
 
Grimes (2010a) 
Review type Cochrane review 
Study design Predominantly RCT 
Date assessed as up-to-date 31 March 2010 
Population Inclusion criteria: Post-partum women of any age 
Setting Not limited by setting 
Interventions Inclusion criteria: Insertion of any type of IUD within 10 minutes of passing the placenta. 
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Comparison interventions Different devices, different insertion techniques, immediate post-partum versus delayed insertion 
and versus interval insertion (>6 weeks after delivery). 
Outcomes for which data were 
reported 
Primary: Pregnancy; spontaneous expulsion; continuation with the method. 
Review limitations  
 
Grimes (2010b) 
Review type Cochrane review 
Study design Predominantly RCTs 
Date assessed as up-to-date 23 May 2011 
Population Inclusion criteria: Women requiring contraception with data in the eligible trials.  
Setting Not limited by setting. 
Interventions Inclusion criteria: Progestin-only pill. Any dose. 
Comparison interventions Other progestin-only pill; different dose of progestin-only pill; combined oral contraceptive; other 
contraceptives. 
Outcomes for which data were 
reported 
Primary: Pregnancy. 
Secondary: Side effects, including bleeding patterns; continuation rates. 
Trials measuring invalid surrogate end points, especially ovulation, were excluded. 
Review limitations  
 
Halpern (2010) 
Review type Cochrane review 
Study design Predominantly RCTs and CCTs 
Date assessed as up-to-date 19 October 2011 
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Population Inclusion criteria: Women who repeatedly used hormonal methods immediately before or after 
coitus to prevent pregnancy and who provided data in the eligible trials. 
Setting Not limited by setting. 
Interventions Inclusion criteria: Hormonal drug by mouth after or immediately before each act of intercourse and 
taken repeatedly during one or more menstrual cycles for contraception. 
Comparison interventions Not given. 
Outcomes for which data were 
reported 
Primary: Pregnancy. 
Secondary: All related side effects, including bleeding patterns, and discontinuation rates (if 
available). 
Review limitations  
 
Hofmeyr (2010) 
Review type Cochrane review 
Study design Predominantly RCTs 
Date assessed as up-to-date 7 February 2010 
Population Inclusion criteria: Women in the childbearing age group. Potential subgroup analyses included: parity 
(nulliparous, multiparous), STI risk (high, low), HIV status (positive, negative, unknown), types of 
copper IUDs or depot progestogens (injectables, implants, mixed hormonal).  
Setting Not limited by setting. 
Interventions Inclusion criteria: Copper-containing IUD. 
Comparison interventions Compared with depot progestogen contraception alone or compared to mixed hormonal 
contraception (including a depot progestogen). 
Outcomes for which data were 
reported 
Primary: Unintended pregnancy; discontinuation of the allocated method. 
Secondary: (1) time to unintended pregnancy (2) time to discontinuation of the allocated method (3) 
genital tract infection (within four weeks of initiation and long-term) (4) HIV seroconversion (5) oligo-
amenorrhea (6) menorrhagia (7) dysmenorrhea (8) weight gain (9) weight loss (10) nausea/vomiting 
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(11) surgical complications of IUD insertion (e.g. perforation of the uterus) (12) depression (13) bone 
fracture (14) bone mineral density (15) stroke (16) any adverse event possibly related to 
contraceptive method (17) involuntary infertility. 
Review limitations This review pooled data on two different comparison groups versus IUD. For this overview, the data 
have been extracted for the two comparison groups separately. Also in the text of the review it says 
that the data they are reporting are risk ratios but this is not the case: the results are actually 
presented as odds ratios (according to the forest plots). The results have been converted for this 
overview and are presented as risk ratios. Furthermore, for discontinuation, the groups have been 
presented incorrectly in the forest plot (data for the intervention group as control group data and 
vice versa). This has been corrected for presentation in this overview. 
 
Kejuan (2007) 
Review type Journal article 
Study design Predominantly RCTs and CCTs 
Date assessed as up-to-date 2007 
Population Inclusion criteria: Healthy Chinese women of child-bearing age. 
Setting China. 
Interventions Inclusion criteria: Pills containing quinestrol 3.0mg and norgestrel 12mg (Quin-Ng). 
Comparison interventions Quinestrol 3.0mg and levonorgestrel 6mg (Quin-Lng) with at least 3 months of subject use. 
Outcomes for which data were 
reported 
Primary: Side effects (nausea, vomiting, headache, leukorrhea, dizziness, changes in monthly 
bleeding patterns and dysmenorrhea, liver function, serum lipids and blood pressure), contraceptive 
effectiveness and continuation rates as proxies for acceptability. 
Secondary: Papers with data on associations between use of once-a-month pills and female cancers, 
cardiovascular disease and birth defects were specifically searched for. 
Review limitations Review has not been recently updated. 
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Kulier (2007) 
Review type Cochrane review 
Study design Predominantly RCTs 
Date assessed as up-to-date 19 August 2007 
Population Inclusion criteria: Women using copper IUDs for contraception, regardless of timing of insertion: 
immediate post-abortion/post-partum and unrelated to pregnancy. 
Setting Not limited by setting. 
Interventions Inclusion criteria: Any framed copper IUD. 
Comparison interventions Any other framed copper IUD. 
Outcomes for which data were 
reported 
Primary:  
Effectiveness: pregnancy rates (failures), ectopic pregnancy rates.  
Side-effects (side/adverse effects as reason for discontinuation): prolonged/heavy menstrual 
bleeding, intermenstrual bleeding, pain, bleeding and pain combined, infection, total medical 
removal rates.  
Expulsion rates.  
Non-medical (personal) removal rates.  
Overall discontinuation rates.  
Events at insertion: failed or difficult insertions, cervical injuries.  
Perforation rates. 
Review limitations Review has not been recently updated. 
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Lawrie (2011) 
Review type Cochrane review 
Study design Predominantly RCTs 
Date assessed as up-to-date 19 July 2010 
Population Inclusion criteria: Women requesting tubal sterilisation as an interval, post-abortion or post-partum 
procedure. 
Setting Not limited by setting 
Interventions Inclusion criteria: Techniques to interrupt tubal patency: partial salpingectomy, tubal clips, tubal 
silicone rings, electrocoagulation, other interventions, e.g. instillation of chemical agents, or 
insertion of micro-inserts or removal plugs into fallopian tubes. 
Comparison interventions Not given. 
Outcomes for which data were 
reported 
Primary: Failure rate (yearly incidence of unintended pregnancy) including extrauterine pregnancy, 
operative mortality, major and minor morbidity (procedure-related intestinal, vascular or bladder 
injuries, injury to other pelvic organs, blood transfusion, readmission), failure of technical approach 
(e.g. clip converted to partial salpingectomy).  
Secondary: Operative time, changes in menstrual bleeding pattern, post-operative pain (pain scores 
or use of analgesics), post-operative complications (wound infection, reoperation, urinary tract 
infection, pelvic inflammatory disease), length of hospital stay, difficulty of procedure, persistent 
pain, women's satisfaction, surgeons' satisfaction. 
Review limitations It is not clear how the review authors managed different lengths of follow-up. There is inconsistent 
reporting of risk of bias. There are differences between the Peto odds ratios reported in the text and 
those in the forest plots. Those from the forest plots are reported here. 
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Maitra (2004) 
Review type Cochrane review 
Study design Predominantly RCTs 
Date assessed as up-to-date 15 April 2008 - converted to new format (new search not conducted) 
Population Inclusion criteria: Women of reproductive age. 
Exclusion criteria: Biochemical change assessment trials; women prescribed OCs for non-
contraceptive purposes; crossover studies. 
Setting Not limited by setting. 
Interventions Inclusion criteria: Same phasic doses, grouped into 4 interventions: (1) monophasic low-dose 
estrogen (<50µg) COC containing a 3rd generation progestogen versus any monophasic low-dose 
oestrogen COC containing a second-generation progestogen (same for multiphasic preparations); (2) 
Any monophasic low-dose estrogen COC containing a third-generation progestogen versus any 
monophasic low-dose oestrogen COC containing a first-generation progestogen (same for multi-phasic 
preparations); (3) Any monophasic low-dose oestrogen COC containing a second-generation 
progestogen versus any monophasic low-dose oestrogen COC containing a first-generation 
progestogen (same for multiphasic preparations); (4) Comparisons between low-dose oestrogen OCs 
containing a certain type of progestogen. 
Exclusion criteria: Trials comparing monophasic with multiphasic OCs were not eligible even if the 
progestogens fell within the scope of this review. Interventions have to be applied for a minimum of 
6 months before a trial is considered for inclusion. 
Comparison interventions See inclusion criteria. 
Outcomes for which data were 
reported 
Primary: Contraceptive effectiveness, discontinuation rates, cycle control, side effects, satisfaction. 
Review limitations Information about what countries studies were conducted in was not clearly available. Several studies 
were large multicentre 'European' studies and could therefore have included countries such as 
Poland, Romania, Serbia, Bulgaria, Bosnia and Herzegovina or Belarus. As this information was not 
provided, outcome data from such studies were not included in the overview. 
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O'Brien (2005) 
Review type Cochrane review 
Study design Predominantly RCTs 
Date assessed as up-to-date 12 November 2004 
Population Inclusion criteria: Women requesting an IUD for contraceptive purposes. 
Setting Not limited by setting. 
Interventions Inclusion criteria: Frameless IUD or any classical IUD with a copper-bearing frame. 
Comparison interventions N/A 
Outcomes for which data were 
reported 
Primary: Pregnancy rates, ectopic pregnancy rate, expulsion rate, removal rate (for pain, bleeding, 
or pain and bleeding), pelvic inflammatory disease rate, continuation rate. 
Review limitations Review has not been recently updated. 
 
Power (2007) 
Review type Cochrane review 
Study design Predominantly RCTs and CCTs 
Date assessed as up-to-date 21 April 2007 
Population Inclusion criteria: Women of reproductive years seeking effective contraception. 
Exclusion criteria: Pregnant women. 
Setting Not limited by setting 
Interventions Inclusion criteria: Subdermal implants 
Comparison interventions (1) Non-hormonal IUDs; (2) Barrier contraceptives; (3) Oral contraceptives; (4) Injectable 
contraceptives; (5) Progestogen-releasing intrauterine systems (IUSs); (6) different subdermal 
implants (e.g. Norplant vs Implanon). 
Outcomes for which data were Primary: Pregnancy due to method failure at 1, 2, 3, 4, 5 years after starting contraceptive method. 
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reported Continuation of contraceptive method after 1, 2, 3, 4, 5 years of follow-up. 
Secondary: (1) Menstrual changes; (2) Hormonal side effects; (3) Adverse clinical effects; (4) Study 
withdrawals/reason for discontinuation 
Review limitations Review has not been recently updated. 
 
Van der Wijden (2003) 
Review type Cochrane review 
Study design Predominantly RCTs 
Date assessed as up-to-date 6 February 2008 
Population Inclusion criteria: Sexually active, healthy fertile women having recently given birth and practising 
the LAM contraception method only. LAM = lactational amenorrhea method (breastfeeding as 
contraception and supported to do so). 
Exclusion criteria: Not sexually active. 
Setting Not limited by setting 
Interventions Inclusion criteria: LAM as the only method of contraception. 
Comparison interventions Women who gave birth recently and used breastfeeding, but without support. 
Outcomes for which data were 
reported 
Primary: Number of women in a specific month who experienced menstruation or who became 
pregnant confirmed by: (1) physical examination; (2) pregnancy test. Amenorrhea was defined (p3); 
data were collected in life-table menstruation and pregnancy rates. 
Review limitations (1) Inconsistency between description of method and results; (2) Salami slicing noted in review: (a) 
Diaz presents data in 4 separate publications: 3 present intervention data only; 1 with similar data 
plus controls (p5); (b) Perez uses same cases in 2 publications, one paper with controls, one without. 
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Van Vliet (2006a) 
Review type Cochrane review 
Study design Predominantly RCTs 
Date assessed as up-to-date 24 November 2008 
Population Inclusion criteria: Healthy women of reproductive age who desired to use oral contraceptives for 
preventing pregnancy. 
Exclusion criteria: Contra-indications for oral contraceptive use. 
Setting Not limited by setting 
Interventions Inclusion criteria: Any biphasic oral contraceptive pill (both 21 and 28 pill package) when used to 
prevent pregnancy 
Exclusion criteria: 
1. Studies examining sequential pills (those containing estrogen alone early in the cycle, followed by 
estrogen plus progestin later in the cycle). 
2. Used as a treatment and not as a contraceptive. 
Comparison interventions Any triphasic oral contraceptive pill (both 21 and 28 pill packages) when used to prevent pregnancy. 
Outcomes for which data were 
reported 
Primary: Incidence of accidental pregnancy; spotting, breakthrough bleeding, amenorrhea, 
intermenstrual bleeding, discontinuation due to side effects. 
Secondary: Studies which focused primarily on metabolic outcome measures and follicular growth. 
Review limitations  
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Van Vliet (2006b) 
Review type Cochrane review 
Study design Predominantly RCTs 
Date assessed as up-to-date 24 November 2008 
Population Inclusion criteria: Healthy women of reproductive age starting or switching oral contraceptives for 
preventing pregnancy. 
Exclusion criteria: Contraindications for contraceptive use. 
Setting Not limited by setting. 
Interventions Inclusion criteria: Triphasic oral contraceptive pill used to prevent pregnancy (21 or 28-day 
packages), applied for a minimum of 3 consecutive cycles. 
Exclusion criteria: Triphasic OCs used as a treatment (e.g. for acne, dysmenorrhea or menorrhalgia). 
Comparison interventions Monophasic oral contraceptive pill used to prevent pregnancy (21 or 28- day package), applied for a 
minimum of 3 consecutive cycles, excluding monophasic OCs used as a treatment. 
Outcomes for which data were 
reported 
Primary: 
 Contraceptive efficacy (proportion of women pregnant) 
 Bleeding patterns 
 Trial discontinuation: 
o Proportion of women who discontinued within 3, 6 and 12 cycles of pill use 
o Proportion of women who discontinued due to bleeding disturbances or adverse events 
within 3, 6 and 12 cycles of pill use. 
Review limitations The authors noted generally poor quality of trials conducted to date and consequent limitations on 
conclusions. 
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Wen (2009) 
Review type Journal article 
Study design Predominantly RCTs 
Date assessed as up-to-date Not reported. 
Population Inclusion criteria: Participants were women using copper IUDs for contraception and without any 
contraindications, regardless of timing of insertion, whether immediate post-abortion/post-partum or 
unrelated to pregnancy. 
Exclusion criteria: Duplicates and articles with greater than 20% loss to follow-up in the first year. 
Setting Not limited by setting 
Interventions Inclusion criteria: Copper IUD TCu380A 
Comparison interventions Copper IUD MLCu375 
Outcomes for which data were 
reported 
Primary:  
Effectiveness: pregnancy rate, continuation rate, removal rate and expulsion rate. 
Safety: infection, pain, abnormal menstruation, uterine perforation and other adverse events. 
Review limitations  
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Appendix 4.1: Tables of further information 
Table 4.1a: Further information on sterilisation in developing countries 
Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
and study design 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
Pregnancy       
 Tubal ring vs Clip Lawrie 
2011 
Aranda 1985 (RCT), 
Argueta 1980 (RCT) 
Costa Rica; 
Costa Rica 
None reported  >1 year (Not 
reported for 
Aranda 1985) 
 Modified Pomeroy vs 
Electrocoagulation 
Lawrie 
2011 
Sitompul 1984 (RCT) Indonesia The intervention and 
comparison intervention 
were delivered at a 
university hospital. 
Not reported. 
 Tubal ring vs 
Electrocoagulation 
Lawrie 
2011 
Koetsawang 1978 (RCT) Thailand The intervention and 
comparison intervention 
were delivered at a 
hospital 
6-12 months 
 Modified Pomeroy vs 
Clip 
Lawrie 
2011 
Yan 1990 (RCT) Taiwan, China The intervention and 
comparison intervention 
were delivered at a 
general hospital. 
> 1 year 
Discontinuation N/A N/A N/A N/A N/A N/A 
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Table 4.1b: Further information on oral contraceptives in developing countries 
Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of follow-
up 
Pregnancy       
 Triphasic LNG 50-70-
125 µg/EE 30-40-30 
µg vs monophasic 
LNG 150 µg/EE 30 µg 
(follow-up = 6 cycles) 
Van Vliet 
2006b 
Chen 1987 (RCT) China None reported  6 cycles 
 Triphasic LNG 50-70-
125 µg/EE 30-40-30 
µg vs monophasic 
LNG 150 µg/EE 30 µg 
(follow-up = 12 
cycles) 
Van Vliet 
2006b 
Dunson 1993 (RCT), 
Ramos 1989 (RCT), 
Saxena 1992 (RCT) 
Sudan, Sri 
Lanka, Chile, 
Ecuador, 
Dominican 
Republic; 
Philippines; 
India 
None reported  12 cycles 
 Triphasic LNG 50-70-
125 µg/EE 30-40-30 
µg vs monophasic 
NET 600 µg/EE 35 µg 
Van Vliet 
2006b 
Chen 1987 (RCT) China None reported  6 cycles 
 Triphasic LNG 50-70-
125 µg/EE 30-40-30 
µg vs monophasic 
NET 400 µg/EE 35 µg 
Van Vliet 
2006b 
Ramos 1989 (RCT) Philippines None reported  12 cycles 
 Triphasic GTD 50-70-
100 µg/EE 30-40-30 
µg vs monophasic 
DSG 150 µg/EE 30 µg 
Van Vliet 
2006b 
Agoestina 1987 (RCT) Indonesia None reported  12 cycles 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of follow-
up 
 28-day cycle vs 1 
year cycle 
Edelman 
2005 
Coutinho 1995 (RCT) Brazil, China, 
Egypt 
None reported  6-12 months 
 EE 20µg + desogestrel 
150µg vs EE30µg + 
gestodene 75µg 
Gallo 2011 Teichmann 1995 (RCT) Poland None reported  12 cycles 
 EE 20µg + gestodene 
75µg vs EE 30µg + 
gestodene 75µg 
Gallo 2011 Taneepanichskul 2002 
(RCT) 
Thailand None reported  12 cycles 
  Monophasic 
norgestrel 0.3mg/EE 
30mg (Lo-femenal) vs 
Monophasic 
norethindrone 
acetate 1.5mg/EE 30 
mcg (Lo-estrin) 
(Second versus first-
generation OCs) 
Maitra 
2004 
Dunson (NG-NE) (RCT), 
Ramos (LNG-NE) (RCT) 
Malaysia, 
Egypt, 
Thailand, 
Mexico; 
Philippines. 
None reported  6-12 months 
  Monophasic 
desogestrel 150 mcg 
+ EE 30mcg vs 
Monophasic 
gestodene 75mcg + 
EE 30mcg 
(monophasics) 
Maitra 
2004 
Koetsawang 1977 (RCT), 
L. America 1994 (RCT), 
Halbe 1998 (RCT) 
Thailand; 
Brazil, 
Argentina, 
Chile, 
Colombia, 
Venezuela; 
Brazil. 
None reported  6-12 months 
 Monophasic NE 
(norethindrone) 
0.4mg + EE 35mcg vs 
Monophasic LNG 
Maitra 
2004 
Ramos (LNG-NE) (RCT) Philippines None reported  6-12 months 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of follow-
up 
(levonorgestrel) 
150mcg + EE 30mcg 
(monophasics) 
 Biphasic 
levonorgestrel/EE 
(preparation Alpha) 
vs triphasic 
levonorgestrel/EE 
(preparation Gamma) 
Van Vliet 
2006a 
Larranaga 1978 (RCT) Peru None reported  Not reported. 
 Biphasic 
levonorgestrel/EE 
(preparation Beta) vs 
triphasic 
levonorgestrel/EE 
(preparation Gamma) 
Van Vliet 
2006a 
Larranaga 1979 (RCT) Peru None reported  Not reported. 
 Low dose 
mifepristone v 
levonorgestrel 
Grimes 
2010b 
Lakha 2007 (RCT) Nigeria, South 
Africa, Hong 
KongUinted 
Kingdom 
None reported  Not reported. 
 Norethisterone v 
levonorgestrel 150+ 
ethinyl estradiol 
combination pill 
Grimes 
2010b 
Sheth 1982 (RCT) India, 
Yugoslavia 
None reported  Not reported. 
 Progestron only pill v 
6 months post-
partum 
Grimes 
2010b 
Were 1997 (RCT) Kenya None reported  Not reported. 
 Quin-Ng vs Quin-Lng Kejuan 
2007 
Weng et al. 1992 (RCT) China None reported  Not reported. 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of follow-
up 
Discontinuation       
 Triphasic LNG 50-70-
125 µg/EE 30-40-30 
µg vs monophasic 
LNG 150 µg/EE 30 µg 
(follow-up = 6 cycles) 
Van Vliet 
2006b 
Chen 1987 (RCT) China None reported  6 cycles 
 Triphasic LNG 50-70-
125 µg/EE 30-40-30 
µg vs monophasic 
LNG 150 µg/EE 30 µg 
(follow-up = 12 
cycles) 
Van Vliet 
2006b 
Dunson 1993 (RCT), 
Ramos 1989 (RCT), 
Saxena 1992 (RCT) 
Sudan, Sri 
Lanka, Chile; 
Philippines; 
India 
None reported  12 cycles 
 Triphasic LNG 50-70-
125 µg/EE 30-40-30 
µg vs monophasic 
NET 600 µg/EE 35 µg 
Van Vliet 
2006b 
Chen 1987 (RCT) China None reported  6 cycles 
 Triphasic LNG 50-70-
125 µg/EE 30-40-30 
µg vs monophasic 
NET 400 µg/EE 35 µg 
Van Vliet 
2006b 
Ramos 1989 (RCT) Philippines None reported  12 cycles 
 Triphasic GTD 50-70-
100 µg/EE 30-40-30 
µg vs monophasic 
DSG 150 µg/EE 30 µg 
(follow-up = 6 cycles) 
Van Vliet 
2006b 
Agoestina 1987 (RCT) Indonesia None reported  6 cycles 
 Triphasic GTD 50-70-
100 µg/EE 30-40-30 
µg vs monophasic 
Van Vliet 
2006b 
Agoestina 1987 (RCT) Indonesia None reported  12 cycles 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of follow-
up 
DSG 150 µg/EE 30 µg 
(follow-up = 12 
cycles) 
 28-day cycle vs 1 
year cycle 
Edelman 
2005 
Coutinho 1995 (RCT) Brazil, China, 
Egypt 
None reported  6-12 months 
 EE 20µg + desogestrel 
150µg vs EE30µg + 
gestodene 75µg 
Gallo 2011 Teichmann 1995 (RCT) Poland None reported  12 cycles 
 EE 20µg + gestodene 
75µg vs EE 30µg + 
gestodene 75µg 
Gallo 2011 Taneepanichskul 2002 
(RCT) 
Thailand None reported  12 cycles 
 Monophasic 
norgestrel 0.3mg/EE 
30mg (Lo-femenal) vs 
Monophasic 
norethindrone 
acetate 1.5mg/EE 30 
mcg (Lo-estrin) 
(Second versus first-
generation OCs) 
Maitra 
2004 
Dunson (NG-NE) (RCT), 
Ramos (LNG-NE) (RCT) 
Malaysia, 
Egypt, 
Thailand, 
Mexico; 
Philippines 
None reported  6-12 months 
 Monophasic 
desogestrel 150 mcg 
+ EE 30mcg vs 
Monophasic 
gestodene 75mcg + 
EE 30mcg 
(monophasics) 
Maitra 
2004 
Koetsawang 1977 (RCT), 
L. America 1994 (RCT), 
Halbe 1999 (RCT) 
Thailand; 
Brazil, 
Argentina, 
Chile, 
Colombia, 
Venezuela; 
Brazil 
None reported  6-12 months 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of follow-
up 
 Monophasic NE 
(norethindrone) 
0.4mg + EE 35mcg vs 
Monophasic LNG 
(levonorgestrel) 
150mcg + EE 30mcg 
(monophasics) 
Maitra 
2004 
Ramos (LNG-NE) (RCT) Philippines None reported  6-12 months 
 Biphasic 
levonorgestrel/EE 
(preparation Alpha) 
vs triphasic 
levonorgestrel/EE 
(preparation Gamma) 
Van Vliet 
2006a 
Larranaga 1978 (RCT) Peru None reported  Not reported. 
 Biphasic 
levonorgestrel/EE 
(preparation Beta) vs 
triphasic 
levonorgestrel/EE 
(preparation Gamma) 
Van Vliet 
2006a 
Larranaga 1978 (RCT) Peru None reported  Not reported. 
 Norethisterone v 
levonorgestrel 150+ 
ethinyl estradiol 
combination pill 
Grimes 
2010b 
Sheth 1982 (RCT) India, 
Yugoslavia 
None reported  Not reported. 
Continuation       
 Progestron only pill v 
6 months post-
partum 
Grimes 
2010b 
Were 1997 (RCT) Kenya None reported  Not reported. 
Appendix 4.1: Tables of further information 
107 
Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of follow-
up 
 Quin-Ng vs Quin-Lng Kejuan 
2007 
Weng et al. 1992 (RCT) China None reported  Not reported. 
 
Table 4.1c: Further information on intrauterine devices in developing countries 
Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
Pregnancy       
 TCu380A vs MLCu375 Wen 2009 Kong C 1993 (RCT), Fang 
KJ 2006 (RCT), Yang MM 
1999 (RCT), Wu DD 2005 
(RCT) 
China None reported  1 year 
 c-1 LNG-20 vs non 
hormonal IUD >250 
MM2 
French 
2004 
Baveja 1989 (RCT) India The intervention and 
comparison intervention 
were delivered at a family 
planning clinic. 
3 years 
 c-2 LNG-20 vs non-
hormonal ≤ 250 mm2 
IUD 
French 
2004 
Baveja, 1989 (RCT) India The intervention and 
comparison intervention 
were delivered at a family 
planning clinic. 
3 years 
 c-4: LNG-20 vs 
subdermal implants 
French 
2004 
Wang 1992 (RCT) China The intervention and 
comparison intervention 
were delivered at a family 
planning clinic. 
3 years 
 Immediate post-
partum insertion: 
Grimes 
2010a 
Kisnisci 1985 (RCT) Turkey The intervention and 
comparison intervention 
were delivered at a family 
Not reported. 
What is the impact of contraceptive methods and mixes of contraceptive methods on contraceptive prevalence, unmet need for family planning, and unwanted and unintended 
pregnancies? 
108 
Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
Delta T vs Delta loop planning clinic. 
 Immediate post-
partum insertion TCu 
380 A (hand 
insertion) vs Tcu 380 
A (instrument 
insertion) 
Grimes 
2010a 
Apelo 1985 (RCT) Philippines The intervention and 
comparison intervention 
were delivered at a family 
planning clinic. 
Not reported. 
 MLCu 375 vs Tcu380A 
(Follow-up = 1 year) 
Kulier 2007 Cole 1985C (RCT), 
Sastrawinata 1991 (RCT) 
Yugoslavia, 
Panama, Costa 
Rica, Egypt; 
Indonesia 
None reported  1 year 
 MLCu 375 vs Tcu380A 
(Follow-up = 2 years) 
Kulier 2007 Sastrawinata 1991(RCT) Indonesia None reported  2 year 
 MLCu250 vs Tcu 380A Kulier 2007 Farr 1994C (RCT) Sri Lanka, 
Thailand, 
Malaysia 
Family planning clinics. 
IUD insertion by 
physicians. 
Not reported. 
 TCu380S vs TCu380A 
(Follow-up = 1 year) 
Kulier 2007 Bahamondes 1999 (RCT) Brazil School of Medicine. 
Insertion by nurse, 
gynaecologist, resident or 
medical student in 
training. 
1 year 
 TCu380S vs TCu380A 
(Follow-up = 2 years) 
Kulier 2007 Bahamondes 1999 (RCT) Brazil School of Medicine. 
Insertion by nurse, 
gynaecologist, resident or 
medical student in 
training. 
2 years 
 TCu380S vs TCu380A Kulier 2007 Bahamondes 1999 (RCT) Brazil School of Medicine. 
Insertion by nurse, 
3 years 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
(Follow-up = 3 years) gynaecologist, resident or 
medical student in 
training. 
 Tcu220 vs Tcu 380A 
(Follow-up = 1 year) 
Kulier 2007 Baveja 1989 (RCT), Farr 
1994B (RCT) 
India; Mexico, 
Philippines 
Human reproductive 
research centres and 
family planning clinics. 
1 year 
 Tcu220 vs Tcu 380A 
(Follow-up = 2 years) 
Kulier 2007 Baveja 1989 (RCT) India Human reproductive 
research centres and 
family planning clinics. 
2 years 
 Tcu220 vs Tcu 380A 
(Follow-up = 3 years) 
Kulier 2007 Baveja 1989 (RCT) India Human reproductive 
research centres and 
family planning clinics. 
3 years 
 Tcu200 vs TCu380A 
(Follow-up = 1 year) 
Kulier 2007 Baveja 1989 (RCT), Farr 
1994A (RCT), Shrestha 
1995 (RCT) 
India; 
Cameroon, 
Chile, Egypt, El 
Salvador, 
Mexico, 
Pakistan; Nepal 
Human reproduction 
research centres. No 
information for Farr 
1994A. 
1 year 
 Tcu200 vs TCu380A 
(Follow-up = 2 years) 
Kulier 2007 Baveja 1989 (RCT), Farr 
1994A (RCT), Shrestha 
1995 (RCT) 
India; 
Cameroon, 
Chile, Egypt, El 
Salvador, 
Mexico, 
Pakistan; Nepal 
Human reproduction 
research centres. No 
information for Farr 
1994A. 
2 years 
 Tcu200 vs TCu380A 
(Follow-up = 3 years) 
Kulier 2007 Baveja 1989 (RCT) India Human reproduction 
research centres. No 
information for Farr 
1994A. 
3 years 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
 TCu220 vs MLCu375 
(Follow-up = 1 year) 
Kulier 2007 Ho 1992 (RCT) China MCH hospitals and family 
planning centres. IUD 
insertion by experienced 
physicians. 
1 year 
  TCu380A vs GyneFix 
frameless IUD 
O’Brien 
2005 
Wu 2000 (RCT) China None reported  Not reported. 
Discontinuation       
 c-1 LNG-20 vs non 
hormonal IUD >250 
MM2 
French 
2004 
Baveja 1989 (RCT) India The intervention and 
comparison intervention 
were delivered at a family 
planning clinic. 
3 years 
 c-2 LNG-20 v non-
hormonal ≤250 mm2 
IUD 
French 
2004 
Baveja, 1989 (RCT) India The intervention and 
comparison intervention 
were delivered at a family 
planning clinic. 
3 years 
 c-4: LNG-20 vs 
subdermal implants 
French 
2004 
Wang 1992 (RCT) China The intervention and 
comparison intervention 
were delivered at a family 
planning clinic. 
3 years 
 MLCu250 vs Tcu 380A 
(Follow-up = 1 year) 
Kulier 2007 Farr 1994C (RCT) Sri Lanka, 
Thailand, 
Malaysia 
Family planning clinics. 
IUD insertion by 
physicians. 
1 year 
 Tcu220 vs Tcu 380A 
(Follow-up = 1 year) 
Kulier 2007 Farr 1994B (RCT) Mexico, 
Philippines 
Family planning clinics. 1 year 
 Tcu200 vs TCu380A 
(Follow-up = 1 year) 
Kulier 2007 Farr 1994A (RCT) Cameroon, 
Chile, Egypt, El 
Salvador, 
No information. 1 year 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
Mexico, 
Pakistan 
Continuation       
 TCu380A vs MLCu375 Wen 2009 Kong C 1993 (RCT), Fang 
KJ 2006 (RCT), Yang MM 
1999 (RCT), Wu DD 2005 
(RCT) 
China None reported  1 year 
 Immediate post-
partum insertion: 
Delta T vs Delta loop 
Grimes 
2010a 
Kisnisci 1985 (RCT) Turkey The intervention and 
comparison intervention 
were delivered at a family 
planning clinic. 
Not reported. 
 Immediate post-
partum insertion by 
hand TCu 200 Vs 
progestasert 
Grimes 
2010a 
Lavin 1983 (RCT) Chile The intervention and 
comparison intervention 
were delivered at a family 
planning clinic. 
Not reported. 
 Immediate post-
partum insertion by 
instrument Tcu 200 
vs progestart  
Grimes 
2010a 
Lavin 1983 (RCT) Chile The intervention and 
comparison intervention 
were delivered at a family 
planning clinic. 
Not reported. 
 Immediate post-
partum insertion Tcu 
200 VS IPCS-52 mg 
Grimes 
2010a 
Apelo 1985 (RCT) Philippines The intervention and 
comparison intervention 
were delivered at a family 
planning clinic. 
Not reported. 
 MLCu 375 vs Tcu380A Kulier 2007 Cole 1985C (RCT) Yugoslavia, 
Panama, Costa 
Rica, Egypt 
None reported  Not reported. 
 TCu380S vs TCu380A Kulier 2007 Bahamondes 1999 (RCT) Brazil School of Medicine. 1 year 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
(Follow-up = 1 year) Insertion by nurse, 
gynaecologist, resident, or 
medical student in 
training. 
 Tcu200 vs TCu380A Kulier 2007 Shrestha 1995 (RCT) Nepal None reported  Not reported. 
 TCu380A vs GyneFix 
frameless IUD 
O’Brien 
2005 
Wu 2000 (RCT) China None reported  Not reported. 
 
Table 4.1d: Further information on injectables in developing countries 
Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
Pregnancy       
 NET-EN 50mg/E2V 
5mg vs DMPA 
25mg/E2C 5mg 
Gallo 2008 
 
Sang 1995 (RCT) 
 
China 
 
Not reported. Not reported. 
 NET-EN 50mg/E2V 
5mg vs NET-EN 200mg 
Gallo 2008 Indian Council 1990 
(RCT) 
 
India 
 
Not reported. Not reported. 
 NET-EN 50mg/E2V 
5mg vs Non-hormonal 
IUD 
Gallo 2008 Von Kesseru 2000 (RCT) 
 
Argentina 
 
Not reported. Not reported. 
Discontinuation       
 DMPA 150mg IM every 
3 months vs NET-EN 
Draper 
2006 
Salem (RCT),1988 
WHO Multinational trial, 
Egypt; 
Thailand; 
Not reported. Not reported. 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
200mg IM every 2 
months 
 1983 
  
Nigeria; 
Pakistan; 
Zambia; 
Philippines; 
Mexico; Brazil; 
Chile 
 NET-EN 50mg/E2V 
5mg vs DMPA 
25mg/E2C 5mg 
Gallo 2008 Sang 1995 (RCT), WHO 
1997 (RCT) 
 
China; China, 
Cuba, Indonesia 
Not reported.  
 DMPA 25mg/E2C 5mg 
vs DMPA 150mg 
Gallo 2008 Ruminjo 2005 (RCT) 
 
Kenya 
 
The intervention and 
comparison intervention 
were delivered at a family 
planning clinic. 
 
 NET-EN 50mg/E2V 
5mg vs NET-EN 200mg 
Gallo 2008 Indian Council 1990 
(RCT) 
 
India 
 
Not reported.  
 
Table 4.1e: Further information on intrauterine devices versus injectables in developing countries 
Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
Pregnancy       
 IUD vs depot 
progestogen 
Hofmeyr 
2010 
Feldblum 2005 (RCT), 
Stringer 2007 (RCT) 
Brazil, 
Guatemala, 
Egypt, 
Vietnam; 
Family planning clinics; 
primary clinics 
12 months; not 
reported 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
Zambia 
Discontinuation       
 IUD vs depot 
progestogen 
Hofmeyr 
2010 
Feldblum 2005 (RCT) Brazil, 
Guatemala, 
Egypt, Vietnam 
Family planning clinics 12 months 
 IUD vs Mixed 
hormonal 
contraception 
Hofmeyr 
2010 
Stringer 2007 (RCT) Zambia Primary clinics Not reported 
 
Table 4.1f: Further information on implants in developing countries 
Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
Pregnancy       
 Implanon vs Norplant 
(Follow-up = 1 year) 
Power 2007 Organon 34510 (RCT), 
Organon 34520 (RCT), 
Zheng 1991 (RCT) 
Indonesia, 
Thailand; 
Indonesia; 
China 
None reported. 1 year 
 Implanon vs Norplant 
(Follow-up = 2 years) 
Power 2007 Organon 34510 (RCT), 
Organon 34520 (RCT), 
Zheng 1991 (RCT) 
Indonesia, 
Thailand; 
Indonesia; 
China 
None reported. 2 years 
 Implanon vs Norplant 
(Follow-up = 3 years) 
Power 2007 Organon 34510 (RCT), 
Organon 34520 (RCT), 
Indonesia, 
Thailand; 
Indonesia; 
None reported. 3 years 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
Zheng 1991 (RCT) China 
 Implanon vs Norplant 
(Follow-up = 4 years) 
Power 2007 Organon 34510 (RCT), 
Organon 34520 (RCT), 
Zheng 1991 (RCT) 
Indonesia, 
Thailand; 
Indonesia; 
China 
None reported. 4 years 
Continuation       
 Implanon vs Norplant 
(Follow-up = 1 year) 
Power 2007 Organon 34510 (RCT), 
Organon 34520 (RCT), 
Zheng 1991 (RCT) 
Indonesia, 
Thailand; 
Indonesia; 
China 
None reported. 1 year 
 Implanon vs Norplant 
(Follow-up = 2 years) 
Power 2007 Organon 34510 (RCT), 
Organon 34520 (RCT), 
Zheng 1991 (RCT) 
Indonesia, 
Thailand; 
Indonesia; 
China 
None reported. 2 years  
 Implanon vs Norplant 
(Follow-up = 3 years) 
Power 2007 Organon 34510 (RCT), 
Organon 34520 (RCT), 
Zheng 1991(RCT) 
Indonesia, 
Thailand; 
Indonesia; 
China 
None reported. 3 years 
 Implanon vs Norplant 
(Follow-up = 4 years) 
Power 2007 Organon 34510 (RCT), 
Organon 34520 (RCT), 
Zheng 1991(RCT) 
Indonesia, 
Thailand; 
Indonesia; 
China 
None reported. 4 years 
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Table 4.1g: Further information on emergency contraception in developing countries 
Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which 
respective 
studies 
conducted 
Contextual information Length of follow-
up 
Pregnancy       
 IUD vs Expectant 
management 
Cheng 2008 Askalani 1987 (RCT) Egypt Both the intervention and 
comparison intervention 
were delivered at family 
planning clinics. 
Not reported. 
 Levonorgestrel split 
dose 24 hr vs 12 
hour  
Cheng 2008 Ngai 2005 (RCT) China None provided. Not reported. 
 Levonorgestrel 
single dose vs 
Levonorgestrel split 
dose 
Cheng 2008 Arowojolu 2002 (RCT) Nigeria Both the intervention and 
comparison intervention 
were delivered at family-
planning clinics at 
University College Hospital 
and Planned Parenthood 
Federation of Nigeria. 
Not reported. 
 Levonorgestrel vs 
Mid-dose 
mifepristone (25-
50mg) 
Cheng 2008 Han 1999a (RCT), Hu X 
2003 (RCT), Li A 2000 
(RCT), Li J 2005 (RCT), 
Liang 2001 (RCT), Liao, 
2003 (RCT), Qi M 2003 
(RCT), Su 2001 (RCT), 
Sun 2000 (RCT), Sun P 
2003 (RCT), Wang Q 
2000 (RCT), Wang Y 
2003 (RCT), Xu 2000 
(RCT), Xu Z 2000 (RCT), 
China In eleven of the studies 
the intervention and 
comparison intervention 
were delivered at hospital 
clinics, in three at family 
planning clinics and in one 
at a reproductive medicine 
clinic. 
Not reported. 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which 
respective 
studies 
conducted 
Contextual information Length of follow-
up 
Zhang JQ 2000 (RCT) 
 Levonorgestrel vs 
Low-dose 
mifepristone 
(<25mg) 
Cheng 2008 Li W 2002 (RCT), Lin 
2000 (RCT), Liu 2000 
(RCT), Pei 2001 (RCT), 
Sheng A 2002 (RCT), 
Wang C 2000 (RCT), Wu 
1999a (RCT) 
China In five of the studies the 
intervention and 
comparison intervention 
were delivered at family 
planning clinics (one study 
specified as urban), one at 
a family planning hospital, 
and one at a research 
institute for family 
planning. 
Not reported. 
 Levonorgestrel vs 
Anordrin 
Cheng 2008 Xu Z 2000 (RCT) China Both the intervention and 
comparison intervention 
were delivered at a family-
planning clinic. 
Not reported. 
 Low-dose 
mifepristone 
(<25mg) vs Low-dose 
mifepristone 
(≤10mg) 
Cheng 2008 Zhang L 2005 (RCT) China Both the intervention and 
comparison intervention 
were delivered at a 
hospital clinic. 
Not reported. 
 Mid-dose 
mifepristone (25-
50mg) vs Low-dose 
mifepristone 
(<25mg) 
Cheng 2008 Cao 1999 (RCT), Cheng 
1999a (RCT), Ding G 
2005 (RCT), Du J 2002 
(RCT), Fan HL 2001 
(RCT), Han L 2001 
(RCT), Lai Z 2004 (RCT), 
Qi 2000b (RCT), Sang 
China In four of the studies the 
intervention and 
comparison intervention 
were delivered at a family 
planning clinic (one study 
specified as urban), six at 
a gynaecology clinic, one 
Not reported. 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which 
respective 
studies 
conducted 
Contextual information Length of follow-
up 
1999 (RCT), Tan L 2003 
(RCT), Wang J 2006 
(RCT), Wang L 2004 
(RCT), Wang SZ 2001 
(RCT), Wei RH 2002 
(RCT), Xiao 2002 (RCT), 
Zhang Y 1998 (RCT), 
Zhao J 2003 (RCT), Zuo 
1999 (RCT) 
at an outpatient clinic, 
three at a MCH hospital, 
and four at a hospital 
clinic. One study did not 
report the location of the 
treatment. 
 Mid-dose 
mifepristone (50mg) 
vs Mid-dose 
mifepristone (25mg) 
Cheng 2008 Cao 1999 (RCT), Chen R 
2002 (RCT), Cheng 
1999a (RCT), Fang 2000 
(RCT), Han 1996 (RCT), 
Li 2000 (RCT), Li H 2000 
(RCT), Lou C 2002 
(RCT), Tan 1999 (RCT), 
Xie 1998 (RCT), Yang F 
2003 (RCT), Zhang JQ 
2000 (RCT), Zhao J 2003 
(RCT) 
China In three of the studies the 
intervention and 
comparison intervention 
were delivered at a family 
planning clinic, five at a 
hospital, and three at a 
MCH hospital. Two studies 
did not report the location 
of the treatment. 
Not reported. 
 High-dose 
mifepristone 
(>50mg) vs Low-dose 
mifepristone 
(<25mg) 
Cheng 2008 Cao 1999 (RCT), Ding G 
2005 (RCT), Tan L 2003 
(RCT), Zhang Y 2002 
(RCT) 
China In one of the studies the 
intervention and 
comparison intervention 
were delivered at a family 
planning clinic, two at a 
hospital clinic and one at a 
MCH hospital. 
Not reported. 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which 
respective 
studies 
conducted 
Contextual information Length of follow-
up 
 High-dose 
mifepristone 
(>50mg) vs Mid-dose 
mifepristone (25-
50mg) 
Cheng 2008 Cao 1999 (RCT), Ding G 
2005 (RCT), Li H 2000 
(RCT), Qian 1999 (RCT), 
Tan L 2003 (RCT), Xie 
1998 (RCT), Zhang Y 
2002 (RCT), Zheng A 
2005 (RCT). 
China In two of the studies the 
intervention and 
comparison intervention 
were delivered at a family 
planning clinic, three at a 
hospital clinic and two at a 
MCH hospital. One study 
did not report the location 
of the treatment. 
Not reported. 
 Mifepristone vs 
Danazol 
Cheng 2008 Yang 2001(RCT) China The intervention and 
comparison intervention 
were delivered at a MCH 
hospital. 
Not reported. 
 Mifepristone vs 
Anordrin 
Cheng 2008 Chen G 2001 (RCT), Fu X 
2000 (RCT), Han 1995 
(RCT), Liu L 2001 (RCT), 
Wang 1999 (RCT), Xu Z 
2000 (RCT), Yang 
2001(RCT) 
China In one of the studies, the 
intervention and 
comparison intervention 
were delivered at a family 
planning clinic. The 
remainder were delivered 
at a hospital clinic. 
Not reported. 
 Mifepristone alone 
(all doses) vs 
Mifepristone + 
anordrin (all doses)  
Cheng 2008 Han 1995 (RCT), Han 
1996 (RCT), Lou X 2005 
(RCT), Sang 1999 (RCT), 
Zhang YM 2002 (RCT) 
China In one of the studies, the 
intervention and 
comparison intervention 
were delivered at a family 
planning clinic and a 
hospital; the other  four 
were at a hospital clinic. 
Not reported. 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which 
respective 
studies 
conducted 
Contextual information Length of follow-
up 
 Mifepristone alone 
(all doses) vs 
Mifepristone + MTX 
(all doses)  
Cheng 2008 Chen H 2002 (RCT) China The intervention and 
comparison intervention 
were delivered at a 
hospital clinic. 
Not reported. 
 Mifepristone alone 
(all doses) vs 
Mifepristone + 
tamoxifen (all doses) 
Cheng 2008 He CH 2002 (RCT) China The intervention and 
comparison intervention 
were delivered at a family 
planning clinic. 
Not reported. 
 Mifepristone vs 
Mifepristone + 
misoprostol (all 
doses) 
Cheng 2008 Wu XZ 2002 (RCT) China None provided. Not reported. 
 Mifepristone (all 
doses) vs Cu-IUD 
Cheng 2008 Liu L 2002 (RCT) China The intervention and 
comparison intervention 
were delivered at a 
hospital clinic. 
Not reported. 
Discontinuation No comparisons Cheng 2008 N/A N/A N/A N/A 
 
Table 4.1h: Further information on spermicides in developing countries 
Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
Pregnancy       
 Collatex sponge 
(nonoxynol-9 1.15mg) 
Grimes Chi 1987 (RCT) Belgrade, 
Maribor (former 
None reported. 6 months 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
vs Neo sampoon 
tablet (menfegol 
60mg) 
2005 Yugoslavia), 
Taiwan and 
Bangladesh 
 Neo sampoon tablet 
(menfegol 60mg) vs 
Ortho or Emko 
vaginal tablet 
(100mg of nonoxynol-
9) 
Grimes 
2005 
Kazi 1992 (RCT), 
Lamptey 1985 (RCT), 
Abdelsalaam 1984 (RCT) 
Pakistan; 
Ghana; Egypt. 
None reported. 12 months 
 Ortho vaginal tablet 
nonoxynol-9 100mg 
vs Emko vaginal 
tablet nonoxynol-9 
100mg 
Grimes 
2005 
Lamptey 1985 (RCT), 
Younis 1985 (RCT) 
Ghana; Egypt None reported. 12 months 
 Neo sampoon tablet 
menfelgol 60mg vs 
Emko foam 
nonoxynol-9 8% 
Grimes 
2005 
Youssef 1987 (RCT), 
Andolsek 1988 (RCT) 
Egypt; 
Yugoslavia 
None reported. 12 months 
Discontinuation       
 Collatex sponge 
(nonoxynol-9 1.15mg) 
vs Neo sampoon 
tablet (menfegol 
60mg) 
Grimes 
2005 
Chi 1987 (RCT) Belgrade, 
Maribor (former 
Yugoslavia), 
Taiwan and 
Bangladesh 
None reported. 6 months 
 Vaginal foaming 
tablets nonxynol-9 
100mg vs menfegol 
60mg 
Grimes 
2005 
Chompootaweep 1990 
(RCT), Klufio 1988 (RCT) 
Thailand; 
Ghana 
None reported. 12 months 
What is the impact of contraceptive methods and mixes of contraceptive methods on contraceptive prevalence, unmet need for family planning, and unwanted and unintended 
pregnancies? 
122 
Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
 Neo sampoon tablet 
(menfegol 60mg) vs 
Ortho or Emko 
vaginal tablet 
(100mg of nonoxynol-
9) 
Grimes 
2005 
Kazi 1992 (RCT), 
Lamptey 1985 (RCT), 
Abdelsalaam 1984 (RCT) 
Pakistan; 
Ghana; Egypt 
None reported. 12 months 
 Ortho vaginal tablet 
nonoxynol-9 100mg 
vs Emko vaginal 
tablet nonoxynol-9 
100mg 
Grimes 
2005 
Lamptey 1985 (RCT), 
Younis 1985 (RCT) 
Ghana; Egypt None reported. 12 months 
 Neo sampoon tablet 
menfelgol 60mg vs 
Emko foam 
nonoxynol-9 8% 
Grimes 
2005 
Youssef 1987 (RCT), 
Andolsek 1988 (RCT) 
Egypt; 
Yugoslavia 
None reported. 12 months 
 
 
 
Table 4.1i: Further information on repeated use of pre- and post-coital hormonal contraception in developing countries 
Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
Pregnancy       
 Chinese LNG vs 
Hungarian LNG 
Halpern 
2010 
He 1991(RCT) China None reported. Not reported. 
 One LNG tablet Halpern Kesseru 1973 (non-RCT) Peru The intervention and Not reported. 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
immediately (but no 
later than 3 hours) 
after each sexual 
intercourse. Five 
groups: 0.15mg, 
0.25mg, 0.30mg, 
0.35mg, 0.40mg. 
2010 comparison intervention 
were delivered at a 
fertility outpatients in a 
research clinic. 
 One dose quinestanol 
acetate within 24 hrs 
of intercourse in 
following dose size: 
0.5mg, 0.6mg, 
0.75mg, 0.8mg, 
1.5mg, 2.0mg. 
Halpern 
2010 
Mischler 1974 (non-RCT) Mexico, Peru, 
Argentina, 
Chile 
None reported. Not reported. 
 Quinagestanol 
acetate 1.5mg vs 
LNG within 1 hour 
post-coitus. 
Halpern 
2010 
Moggia 1974 (non-RCT) Argentina The intervention and 
comparison intervention 
were delivered at a 
maternity and children's 
city hospital, Buenos Aires 
Not reported. 
 Quinagestanol 
acetate within 24 hrs 
of intercourse. Max 
of 1 dose/24hrs. 
Dose sizes as follows: 
0.2mg, 0.3mg, 
0.4mg, 0.5mg, 
0.75mg, 0.8mg. 
Halpern 
2010 
Rubio 1970 (non-RCT) Mexico, Peru, 
Chile 
None reported. Not reported. 
 Progestogens 
before/after coitus. 
Halpern 
2010 
Zanartu 1974 (non-RCT) Chile None reported. Not reported. 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
Four different types 
of progestogens: 
retroprogestogen 30-
40mg, clogestone 
1.0mg, 
norgestrienone 
0.5mg, ethynodiol 
0.5mg. 
 Groups: clogestone 
1.0mg 5/6 hours 
prior to intercourse, 
two clogestone 
0.6mg tablets 
(=1.2mg total) one 
before and one after 
coitus, two 
clogestone 1.0mg 
(total 2.0mg) one 
before, one after 
coitus. 
Halpern 
2010 
Zanartu 1976 (non-RCT) Chile None reported. Not reported. 
Continuation       
 Chinese LNG vs 
Hungarian LNG 
Halpern 
2010 
He 1991 (RCT) China None reported. Not reported. 
 One dose quinestanol 
acetate within 24 hrs 
of intercourse in 
following dose size: 
0.5mg, 0.6mg, 
0.75mg, 0.8mg, 
Halpern 
2010 
Mischler 1974 (non-RCT) Mexico, Peru, 
Argentina, 
Chile 
None reported. Not reported. 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
1.5mg, 2.0mg. 
 Quinagestanol 
acetate 1.5mg vs 
LNG within 1 hour 
post-coitus. 
Halpern 
2010 
Moggia 1974 (non-RCT) Argentina The intervention and 
comparison intervention 
were delivered at a 
maternity and children's 
city hospital, Buenos Aires 
Not reported. 
 Quinagestanol 
acetate within 24 hrs 
of intercourse. Max 
of 1 dose/24hrs. 
Dose sizes as follows: 
0.2mg, 0.3mg, 
0.4mg, 0.5mg, 
0.75mg, 0.8mg. 
Halpern 
2010 
Rubio 1970 (non-RCT) Mexico, Peru, 
Chile 
None reported. Not reported. 
Continuation Progestogens 
before/after coitus. 
Four different types 
of progestogens: 
retroprogestogen 30-
40mg, clogestone 
1.0mg, 
norgestrienone 
0.5mg, ethynodiol 
0.5mg. 
Halpern 
2010 
Zanartu 1974 (non-RCT) Chile None reported. Not reported. 
Continuation Groups: clogestone 
1.0mg 5/6 hours 
prior to intercourse, 
two clogestone 
0.6mg tablets 
Halpern 
2010 
Zanartu 1976 (non-RCT) Chile  Not reported. 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
(=1.2mg total) one 
before and one after 
coitus, two 
clogestone 1.0mg 
(total 2.0mg) one 
before, one after 
coitus. 
 
Table 4.1j: Further information on natural family planning in developing countries 
Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
Pregnancy       
 Ovulation method vs 
symptothermal 
method 
Grimes 
2004 
Medina 1980 (RCT) Colombia All participants entered a 
training programme lasting 
3 to 5 months. Thereafter, 
all participants were 
visited monthly by study 
personnel for follow-up 
and counselling. 
Not reported. 
 LAM with support vs 
LAM without support 
Van der 
Wijden 
2003 
Diaz 1988 (non-RCT) Chile None reported. Not reported. 
 LAM with support vs 
(Controls) used non-
hormonal IUD 2 
months post-partum 
and on-demand 
Van der 
Wijden 
2003 
Perez 1991 (non-RCT) Chile None reported. Not reported. 
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Outcome Intervention and 
comparison 
intervention 
Review ID Included studies (using 
study ID from review) 
Countries in 
which studies 
conducted 
Contextual information Length of 
follow-up 
feeding 
Discontinuation       
 Ovulation method vs 
symptothermal 
method 
Grimes 
2004 
Medina 1980 (RCT) Colombia All participants entered a 
training programme lasting 
3 to 5 months. Thereafter, 
all participants were 
visited monthly by study 
personnel for follow-up 
and counselling. 
Not reported. 
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Appendix 4.2: Overview of reviews tables 
Modern contraceptive methods 
Terminal methods 
Table 4.2a: Overview of reviews table for sterilisation in developing countries (data synthesised using meta-analysis) 
Outcome Intervention and comparison 
intervention 
Illustrative comparative risks (95% CI) Relative effect 
(95% CI) 
Number of 
participants 
(studies) 
Quality of 
the 
evidence 
  Assumed risk Corresponding risk    
  With comparator With intervention    
Pregnancy       
 Tubal ring vs Clip 8 per 1,000 9 per 1,000 (2 to 43) Peto OR: 1.09 
[0.22, 5.36] 
724 (2)  
MODERATE 
 Modified Pomeroy vs 
Electrocoagulation 
Cannot calculate Cannot calculate Peto OR: 4.47 
[0.07, 286.78] 
295(1)  
VERY LOW 
 Tubal ring vs Electrocoagulation Cannot calculate Cannot calculate Peto OR: 0.0 
[0.0, 0.0] 
160 (1)  
VERY LOW 
 Modified Pomeroy vs Clip Cannot calculate Cannot calculate Peto OR: 8.28 
[0.16, 419.87] 
148 (1)  
VERY LOW 
Discontinuation       
 N/A N/A N/A N/A N/A N/A 
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Spacing/temporary methods 
Table 4.2b: Overview of reviews table for oral contraceptives in developing countries (data synthesised using meta-analysis) 
Outcome Intervention and comparison intervention Illustrative comparative risks 
(95% CI) 
Relative effect 
(95% CI) 
Number of 
participant
s (studies) 
Quality of 
the 
evidence 
  Assumed 
risk 
Corresponding risk    
  With 
comparator 
With intervention    
Pregnancy       
 Triphasic LNG 50-70-125 µg/EE 30-40-30 µg 
vs monophasic LNG 150 µg/EE 30 µg (follow-
up = 6 cycles) 
32 per 1,000 21 per 1,000 (4 to 
121) 
RR: 0.65 [0.11, 
3.78] 
189 (1)  
VERY LOW 
 
 Triphasic LNG 50-70-125 µg/EE 30-40-30 µg 
vs monophasic LNG 150 µg/EE 30 µg (follow-
up = 12 cycles) 
1 per 1,000 1 per 1,000 (0 to 
11) 
RR: 1.00 [0.06, 
16.01] 
 
3,010 (3)  
LOW 
 
 Triphasic LNG 50-70-125 µg/EE 30-40-30 µg 
vs monophasic NET 600 µg/EE 35 µg 
22 per 1,000 21 per 1,000 (3 to 
149) 
RR: 0.94 [0.13, 
6.52] 
186 (1)  
VERY LOW 
 
 Triphasic LNG 50-70-125 µg/EE 30-40-30 µg 
vs monophasic NET 400 µg/EE 35 µg 
Cannot 
calculate 
Cannot calculate RR: 0.0 [0.0, 0.0] 1,200 (1)  
MODERATE 
 Triphasic GTD 50-70-100 µg/EE 30-40-30 µg 
vs monophasic DSG 150 µg/EE 30 µg 
12 per 1,000 12 per 1,000 (1 to 
189) 
RR: 1.00 [0.06, 
15.73] 
168 (1)  
VERY LOW 
 
 28-day cycle vs 1 year cycle (continuous) of 
50 µg ethinyl estradiol and 250 µg 
levonorgestrel (dosed vaginally)  
9 per 1,000 1 per 1,000 (0 to 9) Peto OR 0.14 
[0.02, 0.97] 
900 (1)  
LOW 
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Outcome Intervention and comparison intervention Illustrative comparative risks 
(95% CI) 
Relative effect 
(95% CI) 
Number of 
participant
s (studies) 
Quality of 
the 
evidence 
  Assumed 
risk 
Corresponding risk    
  With 
comparator 
With intervention    
 EE 20µg + desogestrel 150µg vs EE30µg + 
gestodene 75µg 
Cannot 
calculate 
Cannot calculate RR: 2.97 [0.12, 
72.52] 
416 (1)  
VERY LOW 
 EE 20µg + gestodene 75µg vs EE 30µg + 
gestodene 75µg 
Cannot 
calculate 
Cannot calculate RR: 0.0 [0.0, 0.0] 150 (1)  
VERY LOW 
 
  Monophasic norgestrel 0.3mg/EE 30mg (Lo-
femenal) vs Monophasic norethindrone 
acetate 1.5mg/EE 30 mcg (Lo-estrin) 
(second versus first-generation OCs) 
8 per 1,000 1 per 1,000 (0 to 8) RR: 0.12 [0.02, 
0.99] 
2,074 (2)  
MODERATE 
  Monophasic desogestrel 150 mcg + EE 
30mcg vs Monophasic gestodene 75mcg + EE 
30mcg (monophasics) 
1 per 1,000 1 per 1,000 (0 to 
20) 
RR: 1.13 [0.07, 
18.02] 
1,730 (3)  
LOW 
 Monophasic NE (norethindrone) 0.4mg + EE 
35mcg vs Monophasic LNG (levonorgestrel) 
150mcg + EE 30mcg (monophasics) 
Cannot 
calculate 
Cannot calculate RR: 0.0 [0.0, 0.0] 1,199 (1)  
LOW 
 Biphasic levonorgestrel/EE (preparation 
Alpha) vs triphasic levonorgestrel/EE 
(preparation Gamma) 
Cannot 
calculate 
Cannot calculate RR: 0.0 [0.0, 0.0] 313 (1)  
LOW 
 Biphasic levonorgestrel/EE (preparation 
Beta) vs triphasic levonorgestrel/EE 
(preparation Gamma) 
Cannot 
calculate 
Cannot calculate RR: 0.0 [0.0, 0.0] N/A  
LOW 
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Outcome Intervention and comparison intervention Illustrative comparative risks 
(95% CI) 
Relative effect 
(95% CI) 
Number of 
participant
s (studies) 
Quality of 
the 
evidence 
  Assumed 
risk 
Corresponding risk    
  With 
comparator 
With intervention    
Discontinuation       
 Triphasic LNG 50-70-125 µg/EE 30-40-30 µg 
vs monophasic LNG 150 µg/EE 30 µg (follow-
up = 6 cycles) 
183 per 
1,000 
176 per 1,000 (95 to 
322) 
RR: 0.96 [0.52, 
1.76] 
189 (1)  
VERY LOW 
 
 Triphasic LNG 50-70-125 µg/EE 30-40-30 µg 
vs monophasic LNG 150 µg/EE 30 µg (follow-
up = 12 cycles) 
522 per 
1,000 
548 per 1,000 (506 
to 595) 
RR: 1.05 [0.97, 
1.14] 
 
3,010 (3)  
LOW 
 
 Triphasic LNG 50-70-125 µg/EE 30-40-30 µg 
vs monophasic NET 600 µg/EE 35 µg 
189 per 
1,000 
174 per 1,000 (83 to 
367) 
RR: 0.94 [0.51, 
1.72] 
186 (1)  
VERY LOW 
 
 Triphasic LNG 50-70-125 µg/EE 30-40-30 µg 
vs monophasic NET 400 µg/EE 35 µg 
321 per 
1,000 
276 per 1,000 (231 
to 327) 
RR: 0.86 [0.72, 
1.02] 
1,200 (1)  
MODERATE 
 Triphasic GTD 50-70-100 µg/EE 30-40-30 µg 
vs monophasic DSG 150 µg/EE 30 µg (follow-
up = 6 cycles) 
60 per 1,000 60 per 1,000 (20 to 
200) 
RR: 1.00 [0.33, 
3.33] 
168 (1)  
LOW 
 Triphasic GTD 50-70-100 µg/EE 30-40-30 µg 
vs monophasic DSG 150 µg/EE 30 µg (follow-
up = 12 cycles) 
155 per 
1,000 
132 per 1,000 (62 to 
726) 
RR: 0.85 [0.40, 
1.78] 
168 (1)  
LOW 
 28-day cycle vs 1 year cycle 137 per 
1,000 
140 per 1,000 (96 to 
204) 
Peto OR 1.02 
[0.70, 1.49] 
900 (1)  
LOW 
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Outcome Intervention and comparison intervention Illustrative comparative risks 
(95% CI) 
Relative effect 
(95% CI) 
Number of 
participant
s (studies) 
Quality of 
the 
evidence 
  Assumed 
risk 
Corresponding risk    
  With 
comparator 
With intervention    
 EE 20µg + desogestrel 150µg vs EE30µg + 
gestodene 75µg 
232 per 
1,000 
267 per 1,000 (172 
to 418) 
RR: 1.11 [0.79, 
1.56] 
416 (1)  
LOW 
 EE 20µg + gestodene 75µg vs EE 30µg + 
gestodene 75µg 
257 per 
1,000 
216 per 1,000 (103 
to 452) 
RR: 0.87 [0.49, 
1.54] 
150 (1)  
LOW 
 Monophasic norgestrel 0.3mg/EE 30mg (Lo-
femenal) vs Monophasic norethindrone 
acetate 1.5mg/EE 30 mcg (Lo-estrin) 
(second versus first-generation OCs) 
305 per 
1,000 
241 per 1,000 (210 
to 278) 
RR: 0.79 [0.69, 
0.91] 
2,074 (2)  
MODERATE 
 Monophasic desogestrel 150 mcg + EE 30mcg 
vs Monophasic gestodene 75mcg + EE 30mcg 
(monophasics) 
121 per 
1,000 
144 per 1,000 (113 
to 183) 
RR: 1.19 [0.93, 
1.51] 
1,730 (3)  
MODERATE 
 Monophasic NE (norethindrone) 0.4mg + EE 
35mcg vs Monophasic LNG (levonorgestrel) 
150mcg + EE 30mcg (monophasics) 
321 per 
1,000 
254 per 1,000 (212 
to 302) 
RR: 0.79 [0.66, 
0.94] 
1,199 (1)  
LOW 
 Biphasic levonorgestrel/EE (preparation 
Alpha) vs triphasic levonorgestrel/EE 
(preparation Gamma) 
321 per 
1,000 
353 per 1,000 (125 
to 992) 
Peto OR: 1.10 
[0.39, 3.09] 
 
313 (1)  
LOW 
 Biphasic levonorgestrel/EE (preparation 
Beta) vs triphasic levonorgestrel/EE 
(preparation Gamma) 
46 per 1,000 71 per 1,000 (27 to 
188) 
Peto OR: 1.54 
[0.58, 4.09] 
 
298 (1)  
LOW 
 
Appendix 4.2: Overview of reviews tables 
133 
Table 4.2c: Overview of reviews table for oral contraceptives in developing countries (data synthesised using narrative synthesis) 
Outcome Intervention and comparison intervention Narrative synthesis Number of 
participant
s (studies) 
Quality of 
the 
evidence 
Pregnancy     
 Low dose mifepristone vs levonorgestrel Pregnancy rate was lower with mifepristone when 
compared to levonorgestrel (OR0.71; 95% ci 0.07-6.95) 
p=0.77. No strong evidence of effect (p21) 
97 (1)  
LOW 
 Norethisterone vs levonorgestrel 150+ 
ethinyl estradiol combination pill 
Descriptive provided. p=0.007 (test unknown); 
Norethisterone 350mg, N=130; pregnancy=13.2%; 
Levonorgestrel 30 mg, N=128, pregnancy=9.5%; 
Norethisterone 1mg/mestraw 150 mg, N=123, 
pregnancy=8.3%; Levonorgestrol 150/ethinyl estradiol 
30mg, N=137, pregnancy=2.7% 
518 (1)  
VERY LOW 
 Progestin-only pill ( 6 weeks post-partum 
start) vs progestin-only pill (6 months post-
partum start) 
Total N=200; (51% loss to follow up); no pregnancies in 
either group 
200 (1)  
VERY LOW 
 Quin-Ng vs Quin-Lng 2-year cumulative pregnancy rate of Quin-Ng pill was 3.9 
per 100 and 3.3 per 100 for Quin-Lng. Pearl indices were 
2.9 and 1.8 per 100 women-years for Quin-Ng and Quin-
Lng pills respectively. Of the 14 pregnancies in Quin-Ng 
users and of the 10 in Quin-Lng users, 11 and 6 
pregnancies were method failures respectively, which 
gave Pearl indices for perfect use of 2.3 per 100 women 
years for Quin-Ng and 1.1 per 100 women years for Quin-
Lng pills (p<0.01) 
712 (1) Cannot 
calculate 
Discontinuation     
 Norethisterone v levonorgestrel 150+ ethinyl 
estradiol combination pill 
Discontinuation at 360 days. All causes, p=0.805.  518 (1)  
VERY LOW 
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Outcome Intervention and comparison intervention Narrative synthesis Number of 
participant
s (studies) 
Quality of 
the 
evidence 
Continuation     
 Progestron only pill v 6 months post-partum Continuation rates similar between groups. Note: 51% 
losses to follow-up. Unclear how missing data was dealt 
with. 
200 (1)  
VERY LOW 
 Quin-Ng vs Quin-Lng 1 and 2 year net cumulative continuation rates for Quin-
Lng pills of 87 and 78 per 100 respectively, and for Quin-
Lng pills 74 and 64 per 100 respectively. The difference 
between the two pills appeared to be due to 
discontinuation for side effects other than bleeding 
problems. 
712 (1) Cannot 
calculate 
 
Table 4.2d: Overview of reviews table for intrauterine devices in developing countries (data synthesised using meta-analysis) 
Outcome Intervention and comparison intervention Illustrative comparative risks 
(95% CI) 
Relative effect 
(95% CI) 
Number of 
participant
s (studies) 
Quality 
of the 
evidence 
  Assumed 
risk 
Corresponding risk    
  With 
comparator 
With intervention    
Pregnancy       
 TCu380A vs MLCu375 8 per 1,000 2 per 1,000 (1 to 6) RR: 0.25 [0.08, 
0.75] 
3,617 (4)  
MODERAT
E 
Continuation       
 TCu380A vs MLCu375 943 per 952 per 1,000 (943 RR: 1.01 [1.00, 3,617 (4)  
MODERAT
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Outcome Intervention and comparison intervention Illustrative comparative risks 
(95% CI) 
Relative effect 
(95% CI) 
Number of 
participant
s (studies) 
Quality 
of the 
evidence 
  Assumed 
risk 
Corresponding risk    
  With 
comparator 
With intervention    
1,000 to 971) 1.03] E 
 
Table 4.2e: Overview of reviews table for intrauterine devices in developing countries (data synthesised using narrative synthesis) 
Outcome Intervention and comparison intervention Narrative synthesis Number of 
participant
s (studies) 
Quality 
of the 
evidence 
Pregnancy     
 LNG-20 ius vs non-hormonal IUD >250 MM2 3 yr: Rar=0.11 (0.01, 2.12) Baveja 1989 2,118 (1)  
MODERAT
E 
 LNG-20 ius v non-hormonal ≤250 mm2 IUD To present data for Baveja 1989 only, used life-table 
differences rather than rate ratios. For 1 year = -0.90 
(-2.01 to 0.21), 2 year = −0.90 (−2.01 to −0.21), 3 year 
= −0.56 (−1.30, 0.18). 
2,118 (1)  
MODERAT
E 
 LNG-20 ius vs subdermal implants 1 yr: 3.01 (0.13,75.56) 2 yr:3.06 (0.12,75.56); 3 
yrs:3.00 (0.12,73.53)- no strong evidence of effect 
200 (1)  
LOW 
 Immediate post-partum insertion: Delta T vs 
Delta loop 
12-month pregnancy rates (per 100 women) were 2.1 
for the Delta-loop and 0 for the Delta T. No statistical 
significance was reported on unwanted pregnancies. 
246 (1)  
LOW 
 Immediate post-partum insertion TCu 380 A 
(hand insertion) VS Tcu 380 A(instrument 
12-month continuation rates (per 100 women) were 
84.9 for TCu200 and 77.1 for IPCS-52. Unable to 
extract 36-month continuation rates due to lack of 
400 (1)  
LOW 
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Outcome Intervention and comparison intervention Narrative synthesis Number of 
participant
s (studies) 
Quality 
of the 
evidence 
insertion) table column headers. Statistical significance only 
tested at 36 months. 
 MLCu 375 vs Tcu380A (Follow-up = 1 year) Rate difference = 0.75 [0.13, 1.37] 3,371 (2)  
HIGH 
 MLCu 375 vs Tcu380A (Follow-up = 2 years) Rate difference = 1.50 [0.09, 2.91] (exp = MLCu375, 
Tcu 380A) 
1,894 (1)  
HIGH 
 MLCu250 vs Tcu 380A Rate difference = 1.00 [0.24, 1.76] (Exp - MLCu250, 
Con - TCu380A) 
2,043 (1)  
MODERAT
E 
 TCu380S vs TCu380A (Follow-up = 1 year) Rate difference = 0.10 [−0.33, 0.53] (Exp - TCu380S, 
Con - TCu380A) 
1,568 (1)  
MODERAT
E 
 TCu380S vs TCu380A (Follow-up = 2 years) Rate difference = −0.18 [−0.73, 0.37] (Exp - TCu380S, 
Tcu 380A) 
1,568 (1)  
MODERAT
E 
 TCu380S vs TCu380A (Follow-up = 3 years) Rate difference = −0.90 [−2.21, 0.41] (Exp - TCu380S, 
Con - TCu380A) 
1,568 (1)  
MODERAT
E 
 Tcu220 vs Tcu 380A (Follow-up = 1 year) Rate difference = −0.20 [−1.47, 1.07] (Exp - TCu220, 
Con - TCu380A) 
1,811 (2)  
MODERAT
E 
 Tcu220 vs Tcu 380A (Follow-up = 2 years) Rate difference = −1.00 [−1.98, −0.02] (Exp - TCu220, 
Con - TCu380A) 
954 (1)  
MODERAT
E 
 Tcu220 vs Tcu 380A (Follow-up = 3 years) Rate difference = −0.70 [−1.84, +0.44] (Exp - TCu220, 
Con - TCu380A) 
954 (1)  
MODERAT
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Outcome Intervention and comparison intervention Narrative synthesis Number of 
participant
s (studies) 
Quality 
of the 
evidence 
E 
 Tcu200 vs TCu380A (Follow-up = 1 year) Rate difference = 1.06 [−0.90, 3.02] 2,842 (3)  
MODERAT
E 
 Tcu200 vs TCu380A (Follow-up = 2 years) Rate difference = 0.72 [−1.65, 3.09] 2,842 (3)  
MODERAT
E 
 Tcu200 vs TCu380A (Follow-up = 3 years) Rate difference = 0.60 [−0.93, 2.13] 964 (1)  
MODERAT
E 
 TCu220 vs MLCu375 (Follow-up = 1 year) Rate difference = 0.44 [−1.17, 2.05]. Exp = TCu220, 
Con - MLCu375) 
768 (1)  
LOW 
  TCu380A vs GyneFix frameless IUD The pregnancy rate (SE) at 3 years was 0.0(0.0) for 
the frameless group and 0.3(0.3) for the TCu380A 
group. The rate ratio was 0.32(0.01-7.91) and the rate 
difference −0.34 (−1.01-0.33). 
606 (1)  
LOW 
Discontinuation     
 c-2 LNG-20 v non-hormonal ≤250 mm2 IUD 2 yr rate ratio: 0.93 (0.80-1.07) Baveja 1989 2,118 (1)  
MODERAT
E 
 c-4: LNG-20 vs subdermal implants 1 yr rate ratio: 0.97 (0.72-1.31) 200 (1)  
LOW 
 MLCu250 vs Tcu 380A (Follow-up = 1 year) Rate difference = −1.50 [−1.26, 4.26]. Exp = MLCu250, 
Con - TCu380A) 
2,043 (1)  
MODERAT
E 
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Outcome Intervention and comparison intervention Narrative synthesis Number of 
participant
s (studies) 
Quality 
of the 
evidence 
 Tcu220 vs Tcu 380A (Follow-up = 1 year) Rate difference = −3.00 [−7.21, 1.21]. Exp = TCu220, 
Con - TCu380A) 
857 (1)  
MODERAT
E 
 Tcu200 vs TCu380A (Follow-up = 1 year) Rate difference = 1.00 [−2.96, 4.96]. Exp = TCu200, 
Con - TCu380A) 
1,678 (1)  
MODERAT
E 
Continuation     
 Immediate post-partum insertion: Delta T vs 
Delta loop 
12-month continuation rates (per 10 women) were 
93.3 for the Delta Loop and 90.7 for Delta T. No test 
of statistical significance was reported 
246 (1)  
LOW 
 Immediate post-partum insertion by hand 
TCu 200 Vs progestasert 
12-month continuation rates (per 100 women) were 
86.3 for the Tcu 200 and 59.9 for the progestasert 
(significantly different) 
400 (1)  
LOW 
 Immediate post-partum insertion by 
instrument Tcu 200 vs progestastert 
12-month continuation rates (per 100 women) were 
86.1 for the Tcu 200 and 57.2 for the progestasert 
(significantly different) 
400 (1)  
LOW 
 Immediate post-partum insertion Tcu 200 vs 
IPCS-52 mg 
12-month continuation rates (per 100 women) were 
73.8 for the Tcu 200 and 57.3 for the IPCS-52 . Unable 
to extract 36-month continuation rates (per 100 
women) from table due to lack of headers. Statistical 
significance only tested at 36 months 
400 (1)  
LOW 
 MLCu 375 vs Tcu380A Rate difference −2.20 [−5.39, 0.99]. Exp = MLCu375, 
Con - TCu380A) 
1,477 (1)  
MODERAT
E 
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Outcome Intervention and comparison intervention Narrative synthesis Number of 
participant
s (studies) 
Quality 
of the 
evidence 
Continuation  TCu380S vs TCu380A (Follow-up = 1 year) Rate difference = −5.50 [−9.11, −1.89]. Exp = 
TCu380S, Con - TCu380A) 
1568(1)  
MODERAT
E 
Continuation Tcu200 vs TCu380A Rate difference = −3.00 [−12.84, 6.84]]. Exp = 
TCu380A, Con - TCu200) 
200(1)  
MODERAT
E 
Continuation TCu380A vs GyneFix frameless IUD Continuation rates (SE) at 3 years were 90.7(1.7) in 
the frameless group and 85.3(2.0) in the TCu380A 
group. The rate ratio was 1.06 (1.00-1.13) and the 
rate difference 5.48 (0.33-10.63). The continuation 
rates tended to be higher with Gynefix, significantly 
in the second and third years. The differences in 
continuation rates is explained mainly by the 
differences in the expulsions, which were lower with 
the frameless device. At the end of 1st year, the 
figures given are 95% with Gynefix and 92% with 
TCu380A (RR 1.04 (1-1.08); RD 5.48 (0.33-10.63). It is 
not clear in the review if this data refers to 
continuation or expulsion. 
606(1)  
LOW 
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Table 4.2f: Overview of reviews table for injectables in developing countries (data synthesised using meta-analysis) 
Outcome Intervention and comparison intervention Illustrative comparative risks 
(95% CI) 
Relative effect 
(95% CI) 
Number of 
participant
s (studies) 
Quality of 
the 
evidence 
  Assumed 
risk 
Corresponding risk    
  With 
comparator 
With intervention    
Pregnancy       
 NET-EN 50mg/E2V 5mg vs DMPA 25mg/E2C 
5mg 
2 per 1,000 3 per 1,000 (1 to 
11) 
Peto OR: 1.95 
[0.53, 7.20] 
3,915 (1)  
MODERAT
E 
 NET-EN 50mg/E2V 5mg vs NET-EN 200mg 9 per 1,000 3 per 1,000 (0 to 
16) 
Peto OR: 0.30 
[0.05, 1.75] 
849 (1)  
LOW 
 NET-EN 50mg/E2V 5mg vs Non-hormonal IUD 30 per 1,000 7 per 1,000 (1 to 
74) 
Peto OR: 0.22 
[0.02, 2.47] 
148 (1)  
VERY LOW 
Discontinuation       
 DMPA 150mg IM every 3 months vs NET-EN 
200mg IM every 2 months 
461 per 
1,000 
461 per 1,000 (406 
to 521) 
RR: 1.00 [0.88, 
1.13] 
2,467 (10)  
MODERAT
E 
 NET-EN 50mg/E2V 5mg vs DMPA 25mg/E2C 
5mg 
257 per 
1,000 
193 per 1,000 (172 
to 216) 
Peto OR: 0.75 
[0.67, 0.84] 
4,272 (2)  
MODERAT
E 
 DMPA 25mg/E2C 5mg vs DMPA 150mg 222 per 
1,000 
497 per 1,000 (317 
to 777) 
Peto OR 2.24 
[1.43, 3.50] 
360 (1)  
LOW 
 NET-EN 50mg/E2V 5mg vs NET-EN 200mg 357 per 
1,000 
503 per 1,000 (382 
to 664) 
Peto OR: 1.41 
[1.07, 1.86] 
849 (1)  
LOW 
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Table 4.2g: Overview of reviews table for intrauterine devices versus injectables in developing countries (data synthesised using meta-analysis) 
Outcome Intervention and comparison 
intervention 
Illustrative comparative risks  Relative effect 
(95% CI) 
Number of 
participants 
(studies) 
Quality of 
the 
evidence 
  Assumed risk Corresponding risk    
  With comparator With intervention    
Pregnancy       
 IUD vs depot progestogen 68 per 1,000 32 per 1,000 RR: 0.47 [0.25, 
0.85] 
937 (1)  
MODERAT
E
Discontinuation       
 IUD vs depot progestogen 36 per 170 6 per 168 RR: 0.17 [0.07, 
0.39] 
338 (1)  
MODERAT
E  
 IUD vs Mixed hormonal 
contraception 
83 per 313 146 per 286 RR: 4.20 [3.06, 
5.78] 
599 (1)  
MODERAT
E  
 
Table 4.2h: Overview of reviews table for implants in developing countries (data synthesised using narrative synthesis) 
Outcome Intervention and comparison intervention Narrative synthesis Number of 
participants 
(studies) 
Quality 
of the 
evidence 
Pregnancy     
 Implanon vs Norplant (Follow-up = 1 year) The authors state that they did meta-analysis on all 
data, but tables not provided for effectiveness. It 
just says ‘no difference in effectiveness between the 
two implants’ - no pregnancies (and hence no table!) 
in either the Implanon or Norplant groups after 26, 
1,219 (3)  
LOW 
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Outcome Intervention and comparison intervention Narrative synthesis Number of 
participants 
(studies) 
Quality 
of the 
evidence 
972 and 28, 108 women months of follow-up 
respectively. This includes all studies regardless of 
location. Using data on number of participants from 
only developing country trials = 0 pregnancies in 
either group (Norplant = 610, Implanon = 609). 
 Implanon vs Norplant (Follow-up = 2 years) See 1-year follow-up. 1,219 (3)  
LOW 
 Implanon vs Norplant (Follow-up = 3 years) See 1-year follow-up. 1,219 (3)  
LOW 
 Implanon vs Norplant (Follow-up = 4 years) See 1-year follow-up. 1,219 (3)  
LOW 
Continuation     
 Implanon vs Norplant (Follow-up = 1 year) 91.6% continued to use Implanon and 92.4% 
continued to use Norplant. 
1,219 (3)  
LOW 
 Implanon vs Norplant (Follow-up = 2 years) 82.5% continued to use Implanon and 81.4% 
continued to use Norplant. 
1,219 (3)  
LOW 
 Implanon vs Norplant (Follow-up = 3 years) 67.4% continued to use Implanon and 72.5% 
continued to use Norplant. 
1,219 (3)  
LOW 
 Implanon vs Norplant (Follow-up = 4 years) 17.1% continued to use Implanon and 16.9% 
continued to use Norplant. 
1,219 (3)  
LOW 
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Table 4.2i: Overview of reviews table for emergency contraception in developing countries (data synthesised using meta-analysis) 
Outcome Intervention and comparison intervention Illustrative comparative risks 
(95% CI) 
Relative effect 
(95% CI) 
Number of 
participants 
(studies) 
Quality 
of the 
evidence 
  Assumed 
risk 
Corresponding risk    
  With 
comparator 
With intervention    
Pregnancy       
 IUD vs Expectant management 220 per 
1,000 
20 per 1,000 (7 to 
57) 
RR: 0.09 [0.03, 
0.26] 
300(1)  
LOW 
 Levonorgestrel split dose 24 hr vs 12 hour  20 per 1,000 20 per 1,000 (11 to 
36) 
RR: 0.98 [0.53, 
1.82] 
2,060 (1)  
MODERAT
E 
 Levonorgestrel single dose vs Levonorgestrel 
split dose 
13 per 1,000 7 per 1,000 (2 to 
24) 
RR: 0.54 [0.16, 
1.85] 
1,118 (1)  
MODERAT
E 
 Levonorgestrel vs Mid-dose mifepristone 
(25-50mg) 
14 per 1,000 28 per 1,000 (18 to 
44) 
RR: 2.01 [1.27, 
3.17] 
3,743 (15)  
LOW 
 Levonorgestrel vs Low-dose mifepristone 
(<25mg) 
13 per 1,000 27 per 1,000 (14 to 
50) 
RR: 2.05 [1.11, 
3.81] 
1,647 (7)  
LOW 
 Levonorgestrel vs Anordrin 35 per 1,000 23 per 1,000 (4 to 
136) 
RR: 0.67 [0.11, 
3.89] 
172 (1)  
VERY 
LOW 
 Low-dose mifepristone (<25mg) vs Low-dose 
mifepristone (≤10mg) 
9 per 1,000 9 per 1,000 (1 to 
146) 
RR: 1.04 [0.07, 
16.37] 
220 (1)  
VERY 
LOW 
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Outcome Intervention and comparison intervention Illustrative comparative risks 
(95% CI) 
Relative effect 
(95% CI) 
Number of 
participants 
(studies) 
Quality 
of the 
evidence 
  Assumed 
risk 
Corresponding risk    
  With 
comparator 
With intervention    
 Mid-dose mifepristone (25-50mg) vs Low-
dose mifepristone (<25mg) 
16 per 1,000 11 per 1,000 (8 to 
15) 
RR: 0.66 [0.47, 
0.91] 
11,432 (19)  
MODERAT
E 
 Mid-dose mifepristone (50mg) vs Mid-dose 
mifepristone (25mg) 
16 per 1,000 12 per 1,000 (7 to 
20) 
RR: 0.72 [0.41, 
1.27] 
3,123 (13)  
LOW 
 High-dose mifepristone (>50mg) vs Low-dose 
mifepristone (<25mg) 
32 per 1,000 6 per 1,000 (1 to 
29) 
RR: 0.19 [0.04, 
0.90] 
1,726 (4)  
LOW 
 High-dose mifepristone (>50mg) vs Mid-dose 
mifepristone (25-50mg) 
17 per 1,000 14 per 1,000 (7 to 
30) 
RR: 0.83 [0.39, 
1.77] 
1,890 (8)  
LOW 
 Mifepristone vs Danazol 42 per 1,000 8 per 1,000 (1 to 
70) 
RR: 0.20 [0.02, 
1.67] 
241 (1)  
VERY 
LOW 
 Mifepristone vs Anordrin 40 per 1,000 10 per 1,000 (4 to 
25) 
RR: 0.26 [0.11, 
0.63] 
1,035 (7)  
LOW 
 Mifepristone alone (all doses) vs 
Mifepristone + anordrin (all doses)  
12 per 1,000 16 per 1,000 (9 to 
29) 
RR: 1.32 [0.72, 
2.41] 
3,038 (5)  
LOW 
 Mifepristone alone (all doses) vs 
Mifepristone + MTX (all doses)  
20 per 1,000 60 per 1,000 (3 to 
1,000) 
RR: 3.00 [0.13, 
71.92] 
100 (1)  
VERY 
LOW 
 Mifepristone alone (all doses) vs 
Mifepristone + tamoxifen (all doses) 
5 per 1,000 15 per 1,000 (2 to 
143) 
RR: 3.00 [0.31, 
28.60] 
400 (1)  
LOW 
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Outcome Intervention and comparison intervention Illustrative comparative risks 
(95% CI) 
Relative effect 
(95% CI) 
Number of 
participants 
(studies) 
Quality 
of the 
evidence 
  Assumed 
risk 
Corresponding risk    
  With 
comparator 
With intervention    
 Mifepristone vs Mifepristone + misoprostol 
(all doses) 
7 per 1,000 23 per 1,000 (5 to 
112) 
RR: 3.49 [0.73, 
16.65] 
599 (1)  
LOW 
 Mifepristone (all doses) vs Cu-IUD Cannot 
calculate 
Cannot calculate RR: 1.51 [0.06, 
36.67] 
185 (1)  
VERY 
LOW 
Discontinuation No comparisons N/A N/A N/A N/A N/A 
 
Table 4.2j: Overview of reviews table for spermicides in developing countries (data synthesised using narrative synthesis) 
Outcome Intervention and comparison intervention Narrative synthesis Number of 
participants 
(studies) 
Quality 
of the 
evidence 
Pregnancy     
 Collatex sponge (nonoxynol-9 1.15mg) vs 
Neo sampoon tablet (menfegol 60mg) 
Pregnancy rates varied widely by site: rates were 5 x 
higher in Taiwan than Belgrade. Bangladesh was 
excluded due to losses. Life-table pregnancy rates at 
12 months ranged from 3.8-18.2/100 women with 
sponge, and 6.2-29.9 with Neo Sampoon tablet. Non-
significant. 
1,299 (1)  
LOW 
 Neo sampoon tablet (menfegol 60mg) vs 
Ortho or Emko vaginal tablet (100mg of 
nonoxynol-9) 
No significant differences. In Kazi 1992, the 12-
month rates were 15.2 for menfegol and 22.5 for 
Ortho. Lamptey 1985 provided Pearl Index: 10.6 for 
menfegol, 13.8 for Ortho, 17.9 for Emko. 
672 (3)  
MODERAT
E 
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Outcome Intervention and comparison intervention Narrative synthesis Number of 
participants 
(studies) 
Quality 
of the 
evidence 
 Ortho vaginal tablet nonoxynol-9 100mg vs 
Emko vaginal tablet nonoxynol-9 100mg 
The 12-month life-table pregnancy rates were nearly 
identical in Lamptey and Younis. 
440 (2)  
MODERAT
E ( 
 Neo sampoon tablet menfelgol 60mg vs 
Emko foam nonoxynol-9 8% 
Life-table pregnancy rates were similar for the two 
methods in both trials. 
620 (2)  
MODERAT
E ( 
Discontinuation     
 Collatex sponge (nonoxynol-9 1.15mg) vs 
Neo sampoon tablet (menfegol 60mg) 
Discontinuation rates were non-significant. 1,299 (1)  
LOW 
 Vaginal foaming tablets nonxynol-9 100mg 
vs menfegol 60mg 
Life-table discontinuation rates for discomfort were 
not significantly different. In Klufio the 12 month 
discontinuation rates for medical reasons were 9.0 
for menfegol, 0 for nonoxynol-9 - a significant 
difference. 
272 (2)  
LOW 
 Neo sampoon tablet (menfegol 60mg) vs 
Ortho or Emko vaginal tablet (100mg of 
nonoxynol-9) 
Abdelsalaam: 6-month discontinuations for 
discomfort were similar to those for medical and 
product-related reasons. Kazi: 12-month 
discontinuation rates were similar for both groups. 
Lamptey: Significant difference in 12-month 
discontinuation rates for discomfort: 0 for menfegol, 
2.7 for Ortho, 12.8 for Emko. 
672 (3)  
LOW 
 Ortho vaginal tablet nonoxynol-9 100mg vs 
Emko vaginal tablet nonoxynol-9 100mg 
Lamptey: Emko = 12.8, Ortho = 2.7 discontinuation 
rate for discomfort at 12 months (significant 
difference). Younis: Emko = 5.6, Ortho = 11.6 
discontinuation rate for discomfort at 12 months 
(not a significant difference). 
440 (2)  
LOW 
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Outcome Intervention and comparison intervention Narrative synthesis Number of 
participants 
(studies) 
Quality 
of the 
evidence 
 Neo sampoon tablet menfelgol 60mg vs 
Emko foam nonoxynol-9 8% 
Discontinuation rates due to discomfort were 
similar. Overall rates were higher in Andolsek 
compared to Youssef. 
620 (2)  
LOW 
 
Table 4.2k: Overview of reviews table for repeated use of pre- and post-coital hormonal contraception in developing countries (data synthesised 
using narrative synthesis) 
Outcome Intervention and comparison intervention Narrative synthesis Number of 
participants 
(studies) 
Quality 
of the 
evidence 
Pregnancy     
 Chinese LNG vs Hungarian LNG 5/361. Pearl index = 16.6 (number of pregnancies = 
5). <6 months follow-up. 
361(1)  
MODERAT
E (see 
provision) 
 One dose quinestanol acetate within 24 hrs 
of intercourse in following dose size: 0.5mg, 
0.6mg, 0.75mg, 0.8mg, 1.5mg, 2.0mg. 
Pearl index by dose (note where two indices are 
given for one dose, these came from different trial 
sites, which could not be combined due to lack of 
information about number of pregnancies): (i) 0.5 
mg = 36 (ii) 0.6mg = 38 (iii) 0.75mg = 23.1 (iv) 
0.75mg = 20.2 (v) 1.5mg = 5.4 (vi) 1.5m = 0.8 (vii) 
2mg = 1.2. Length of follow-up not provided. 
2,792 (1)  
VERY 
LOW 
 Quinagestanol acetate 1.5mg vs LNG within 
1 hour post-coitus. 
LNG: discontinued without pregnancy 25-31%, used > 
6 months 42-78%, range for duration up to 30 
months, mean duration 9 months/cycles. 
 
 
899 (1)  
VERY 
LOW 
What is the impact of contraceptive methods and mixes of contraceptive methods on contraceptive prevalence, unmet need for family planning, and unwanted and unintended 
pregnancies? 
148 
Outcome Intervention and comparison intervention Narrative synthesis Number of 
participants 
(studies) 
Quality 
of the 
evidence 
 Quinagestanol acetate within 24 hrs of 
intercourse. Max of 1 dose/24hrs. Dose sizes 
as follows: 0.2mg, 0.3mg, 0.4mg, 0.5mg, 
0.75mg, 0.8mg. 
Pearl indices for doses as follows: (i) 0.2mg = 168 (ii) 
0.3mg = 36 (iii) 0.4mg = 16.6 (iv) 0.5mg = 10.3 (v) 
0.8mg = 0. No intended duration of follow-up. Same 
participants also in Mischler 1974. 
317 (1)  
VERY 
LOW 
 Progestogens before/after coitus. Four 
different types of progestogens: 
retroprogestogen 30-40mg, clogestone 
1.0mg, norgestrienone 0.5mg, ethynodiol 
0.5mg. 
Pearl indices as follows: Retroprogestogen = 4.5, 
Ethynodiol = 36.9, Norgestrienone = 2.6, Clogestone 
= 2.5. No intended duration of follow-up given. 
1,805 (1)  
VERY 
LOW 
 
 
 Groups: clogestone 1.0mg 5/6 hours prior to 
intercourse, two clogestone 0.6mg tablets 
(=1.2mg total) one before and one after 
coitus, two clogestone 1.0mg (total 2.0mg) 
one before, one after coitus. 
Pearl indices by Clogestone dose: 1.0mg = 17, 1.2mg 
= 15, 2.0mg = 15. 
756 (1)  
VERY 
LOW 
Continuation     
 One dose quinestanol acetate within 24 hrs 
of intercourse in following dose size: 0.5mg, 
0.6mg, 0.75mg, 0.8mg, 1.5mg, 2.0mg. 
Non-LNG drugs. Mean duration use: 4.8 
month/cycles. Follow-up less than 6 months. 
2,792 (1)  
VERY 
LOW 
 Quinagestanol acetate 1.5mg vs LNG within 
1 hour post-coitus. 
LNG - discontinued without pregnancy 11%, used > 6 
months 37%, range 1-26 months, mean use 9.2 
months. 
899 (1)  
VERY 
LOW 
 Quinagestanol acetate within 24 hrs of 
intercourse. Max of 1 dose/24hrs. Dose sizes 
as follows: 0.2mg, 0.3mg, 0.4mg, 0.5mg, 
0.75mg, 0.8mg. 
Non-LNG drugs. Range for use - up to 14 months, 
mean duration 4.2 months. Follow-up less than 6 
months. 
317 (1)  
VERY 
LOW 
 Progestogens before/after coitus. Four 
different types of progestogens: 
Non-LNG drugs. Mean duration 5.5 months. Follow- 1,805 (1)  
VERY 
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Outcome Intervention and comparison intervention Narrative synthesis Number of 
participants 
(studies) 
Quality 
of the 
evidence 
retroprogestogen 30-40mg, clogestone 
1.0mg, norgestrienone 0.5mg, ethynodiol 
0.5mg. 
up less than 6 months. LOW 
 Groups: clogestone 1.0mg 5/6 hours prior to 
intercourse; two clogestone 0.6mg tablets 
(=1.2mg total) one before and one after 
coitus; two clogestone 1.0mg (total 2.0mg) 
one before, one after coitus. 
Non-LNG drugs. Mean duration 5.4 months. Follow-
up less than 6 months. 
756 (1)  
VERY 
LOW 
 
Traditional methods 
Table 4.2l: Overview of reviews table for natural family planning in developing countries (data synthesised using narrative synthesis) 
Outcome Intervention and comparison intervention Narrative synthesis Number of 
participant
s (studies) 
Quality 
of the 
evidence 
Pregnancy     
 Ovulation method vs symptothermal method Pregnancy rates could not be determined because of 
high drop-out. 
N/A  
VERY 
LOW 
 LAM with support vs LAM without support  The life-table pregnancy rate (using the standard 
definition of amenorrhea) was 0.45 (one pregnancy in 
1,671 woman-months accumulated(WMAC) for the 
women using the LAM, compared with zero (none in 
690 WMAC) for the controls, who were fully 
breastfeeding, amenorrhoeic women not using any 
other method of contraception). 
 
676 (1)  
VERY 
LOW 
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Outcome Intervention and comparison intervention Narrative synthesis Number of 
participant
s (studies) 
Quality 
of the 
evidence 
 LAM with support vs (Controls) used non-
hormonal IUD 2 months post-partum and on-
demand feeding 
Life-table pregnancy rate after 6 months was 2.45 
(using standard definition of the end of amenorrhea) 
and 0.45 (using 'any bleeding' to mark the end of 
amenorrhea). 
735 (1)  
VERY 
LOW 
Discontinuation Ovulation method vs symptothermal method ‘Most randomised participants dropped out before 
beginning the observation period: 149 of 279 couples 
(53%) assigned to the ovulation method discontinued 
during training, in contrast to 176 of 287 assigned to 
the symptothermal method (61%). Eleven women 
assigned to the ovulation method and 32 assigned to 
the symptothermal method were excluded from 
analysis because of non-compliance during the 
training phase, and one more in each group was 
excluded during the active observation phase. Only a 
minority of participants entered the follow-up phase: 
130 assigned to the ovulation method and 111 to the 
symptothermal method. Of these, 86 (31%) and 82 
(30%) dropped out during the follow-up phase. With 
the training and follow-up phases combined, 72 
women assigned to the ovulation method became 
pregnant compared with 71 assigned to the 
alternative method. The corresponding numbers of 
participants who discontinued because of lack of 
interest or dissatisfaction with the method were 63 
and 69, respectively. 
N/A  
VERY 
LOW 
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The rankings in this table relate to 225 nations for which comparative data were compiled in 2009. Figures are in US dollars. 
Argentina Two studies carried out during 1974 and 2000 were included in the systematic reviews included in this OoR. The GDP per capita in 
1980 and 2000 were $4,857 and $9,203. In 2009, Argentina ranked 82th in GDP per capita. The population policy has ever been 
promoting fertility control. Yet fertility has been low compared to many developing countries. During 1970-74 the total fertility 
rate was 3.1, which dropped to 2.28 in 2003. In 2009, Argentina ranked 106th in fertility.  
Bangladesh Only one study, published in 1987, was included in a systematic review included in the OoR, In 1987, GDP per capita was $440. In 
2009 Bangladesh ranked 197th rank in GDP per capita. Contraceptive prevalence among married women increased from 8% in the 
mid-1970s to about 60% in 2004. Fertility decreased from an average of more than six children per woman in 1975 to slightly more 
than three children per woman in 2004. Recent studies have shown that virtually all women were aware of modern family 
planning methods. In 2000, the most popular method was pills (23%) followed by female sterilisation (7%) and injectables (7%). In 
2009 Bangladesh ranked 81st in total fertility rate. In 2009, the family planning effort was 56%, which was lower than the Asia 
average of 54%. Thus, despite low economic status contraceptive use is increasing and fertility is falling. 
Brazil 
 
Only one study, published in 1995, was included in a systematic review included in this OoR. In 1995, GDP per capita was $6,466. 
In 2009 Brazil’s economic ranking was 102nd. The most common family planning method was female sterilisation (53%), followed 
by the pill (27%). Use of other modern methods was low (below 5%). The total fertility rate during 1990-95 was 2.45. In 2009, 
Brazil ranked 116th (2.21) in total fertility. The family planning effort was 39%, which was lower than the average for Latin 
America of 50%.  
Colombia One study, carried out in 1980, was included in a systematic review included in this OoR. The GDP per capita in 1980 was $2,446. 
Contraceptive prevalence among currently married women in 1990 was 47% (for modern family planning methods). The most 
popular method in 1990 was oral pills (18%), followed by IUD (11%) and female sterilisation (8%). The total fertility rate in 1990 
was 2.8, which dropped to 2.46 in 2009. In 2009, Colombia ranked 98th in total fertility rate. In 2009 the family planning effort 
was 50%, which is the same as the Latin America average.  
Chile 
 
Studies carried out during 1991 and 1998 were included in the systematic reviews included in the OoR. In 1991, GDP per capita 
was $5,287, which increased to $9,037 in 1998. In 2009, Chile ranked  76th in GDP per capita. Chile began family planning 
programmes in 1962. In 1991, the total fertility rate was 2.6 and in 1998 it was 2.2. And in 2009, Chile ranked 139th (1.92) in 
total fertility rate. Contraceptive prevalence in early 1990 was about 56%. In 2009, the family planning effort was 65%, higher 
than the average for Latin America (50%). 
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China 
 
Studies conducted during 1987, 1991, 1993, 1995, 1996 and 1998-2006 were included in the systematic reviews included in this 
OoR. In 1987, GDP per capita was $1,026, which increased to $1,999 in 1998. In 2009 China ranked 136th in GDP per capita. In 
1992, female sterilisation (42%) and IUD (40%) were the major family planning methods used by couples. In 1990-95, the total 
fertility rate was 1.8. In 2009 China ranked 157th (1.79) in total fertility. In 2009, the family planning effort was 72%, which is 
higher than the Asia average of 54%.  
Egypt  
 
 
Two studies included in the OoR relate to the years 1984 and 1995. The GDP per capita in those years was $1,871 and $2,995 
respectively. In 2009, Egypt ranked 135th in GDP per capita. During 1984, contraceptive prevalence in Egypt was around 37% 
among currently married women. The pill and IUDs were the most popular family planning methods, and each accounted for 
about around 15%; use of other family planning methods was very low. By 1990, contraceptive prevalence had increased to 47%. 
Among currently married women, knowledge about contraception was near universal in 1990. The ideal number of children 
reported by women was 4 children in 1984 and 2.9 children during the early 1990s. There were corresponding declines in fertility: 
the total fertility rate declined from 4.0 in 1984 to around 2.9 children in the early 1990s. Unmet need for family planning during 
the 1990s was around 20% and was an important factor in the high fertility. The overall family planning effort in 1994 was about 
61%, which was higher than the Middle East/North Africa average of 52%. Thus, the studies took place in a context of a relatively 
improving economic situation and declining fertility.  
Ecuador 
 
One study, carried out in 1999, was included in the systematic review selected in this OoR. In 1999, GDP per capita was $4,574. In 
2009, the GDP per capita ranking was 117th. Family planning programmes were introduced in the mid-1960s. Contraceptive 
prevalence increased from 56% in 1994 to 66% in 1999. In 1994, female sterilisation was the most popular family planning method 
(35%), followed by IUDs (21%) and the pill (18%). Other modern family planning methods accounted for less than 5%. Among family 
planning users, about 22% used traditional methods. The total fertility rate during 1975-80 was 5.4, which declined to 3.10 in 
2000. In 2009, the family planning effort was 53%, which was slightly higher than the Latin America average (50%). 
Ghana 
 
 
Studies included in the OoR relate to the years 1985, 1987, 1988, and 1999. GDP per capita of Ghana in these years was $524, 
$573, $673, $924 and $954 respectively. In 2009, Ghana ranked 196th in GDP per capita. Fertility remained high (around 6 
children) up to the mid-1980s. In 1988, the total fertility rate was 6.4, which dropped to 4.4 in 1998. In 1998, knowledge about 
contraception was 93% among currently married women. Contraceptive prevalence increased from 10% in 1988 to 13% in 1999. 
The fertility decline was reflected in the ideal number of children, which declined from 5.5 in 1988 to 4.8 in 1998. The family 
planning effort scores also increased, from 10% in 1972 to 47% in 2009. Ghana’s family planning effort in 2009 was same as the 
Sub-Saharan Africa average (47%). 
Guatemala 
 
Only one study, published in 1999, was included in the systematic review included in this OoR. In 1999, GDP per capita was 
$3,857. The first family planning clinic opened in Guatemala City in 1965. As in many Latin American countries, female 
sterilisation was the most common family planning method. In 1999, about 33% of contraceptive users were sterilisation adopters, 
followed by injectables (14%) and the pill (12%). The total fertility rate in 1999 was about 5 children; of these, about 4 were 
wanted, reflecting substantial demand for having children. In 2009, the family planning effort was 43%, which was lower than the 
Latin American average (50%). 
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India Three studies, carried out during 1990, 1992, and 1994, were included in the systematic review included in this OoR. GDP per 
capita in these years was $869, $943 and $1054 respectively. The official family planning programmes began in 1951. In 1992-93, 
contraceptive prevalence was 36%, which had risen to 49% by 2005-06. The most popular family planning method was female 
sterilisation: in 1992-3, about 27% of currently married women were sterilised. In 2009, the total fertility rate was 2.78. The 
family planning effort was 54% in 2009, which was the same as the average for the Asia region.  
Indonesia Three studies, carried out during 1984, 1987 and 1992, were included in the systematic reviews included in this OoR. In 1987, the 
pill was the most popular method (15%), followed by IUDs (13%) and injectables. In 1997, the most popular method was 
injectables (about 22%), followed by the pill (15%) and IUDs (8%). Contraceptive prevalence rose from 19% in 1976 to 60% in 2003. 
The total fertility rate dropped from 5.6 in 1968 to 2.4 in 2003. In 2009, the family planning effort was 60%, which was higher 
than Asian average of 54%. 
Kenya 
 
 
One study, published in 2005, was included in the systematic review selected for this OoR. In 2005, GDP per capita was $1,433. In 
2009, Kenya ranked 185th position in GDP per capita. The total fertility rate in 1989 was 6.7 children per woman, which dropped 
to 4.9 in 2003. During this period, contraceptive use increased from 27% to 41% among currently married women. Among the 
contraceptive methods, injectables was the most popular, followed by the pill, sterilisation, IUDs and condoms. Wanted fertility 
remained at around 4 children during 1993-2003. However, during this period, unwanted pregnancy declined from about 2 
children to just over 1 child. Family planning services were first made available in the 1950s by private doctors and from 1962 by 
the Family Planning Association of Kenya. The family planning effort score increased from 20% in 1972 to 49% in 2009, which was 
slightly higher than the average for the Sub-Saharan Africa region (47%).  
Malaysia One study, published in 1993, was included in the OoR. In 1993, GDP per capita was $6,361. In 2009 Malaysia ranked 75th in GDP 
per capita. Malaysia’s national family planning programme started in 1966 to promote the health of mothers and children. 
Between 1966 and 2008, the total fertility rate declined from 5.7 to 2.3. During this period, contraceptive prevalence increased 
from 8% to 50%. In 2009 the family planning effort score was 62%, which was higher than the Asia average of 54%. 
Mexico 
 
Two studies, published in 1993 and 1999, were included in systematic reviews included in this OoR. In 1993, GDP per capita was 
$6,238, which increased to $9,939 in 1999. During the 1960s, average fertility was about 7 children. Fertility started to decline 
from 1960. In 1993, total fertility was 3.04 and in 2000 it was 2.40. In 1995, female sterilisation was the most popular method 
(41%), followed by IUDs (22%) and the pill (13%). In 2009, the family planning effort was 52%, which was slightly higher than the 
Latin America average of 50%.  
Nepal One study, carried out in 1995, was included in a systematic review selected for this OoR. Family planning activities in Nepal 
started as early as the 1950s. The total fertility rated declined from 7.1 in 1971 to 4.1 in 2001. Contraceptive prevalence in 1976 
was 2.6%, which rose to 35.4% in 2001. In 1996, unmet need for family planning was 28.5%, which increased to 39% in 2001. In 
2001, the most popular family planning method was condoms (38%), followed by implants (21%), pills (16%) and female 
sterilisation (7%). In 2009, Nepal’s family planning effort score was 57%, which was higher than the Asia average of 54%. 
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Nigeria One study, carried out in 2002, was included in the systematic review included in this OoR. GDP per capita in 2002 was $1,456. In 
2009, Nigeria ranked 175th in GDP per capita. In 2002, the total fertility rate was 5.4. The most popular family planning method 
was oral pills (34%), followed by IUDs (23%), injectables (20%), condoms (11%) and sterilisation (9%). In 2002, the contraceptive 
prevalence rate was 8% among currently married women. In 2009, the family planning effort in Nigeria was 34%, which was lower 
than the Sub-Saharan Africa average (47%). 
Pakistan One study, published in 1992, was included in a systematic review included in this OoR. GDP per capita in 1992 was $1,429. In 
2009, Pakistan ranked 170th in GDP per capita data. Pakistan’s official family planning programme started in 1960. Despite this 
early start, fertility declined slower than in many Asian countries. The total fertility rate in 1992 was 5.4, which declined to 4.1 
in 2006. Knowledge about family planning methods is near universal. Contraceptive prevalence increased from 12% in 1990-91 to 
28% in 2000-01. The most prominent family planning methods are female sterilisation, condoms, injectables and pills. Unmet 
need for family planning in Pakistan is 25%, and most of it is among the poorest and those with lower levels of education. Family 
planning is generally weak at all levels and the method mix is skewed towards few methods. The family planning effort score in 
2009 was 46%, which was lower than the Asia average of 54%. 
Peru Two studies, carried out during 1973 and 1978, were included in the systematic reviews included in this OoR. The GDP per capita 
in 1980 was $2,963. In 1991-2, contraceptive prevalence was 33%. The most popular method was IUDs (13%), followed by female 
sterilisation (8%) and pills (6%). Total fertility in 1991-2 was 3.5, which dropped to 2.8 in 2000. In 2009, the family planning effort 
score was 41%, which was lower than the Latin America average of 50%. 
Philippines 
 
Three studies, published in 1985, 1989 and 1994, were included in the systematic reviews selected for this OoR. In 1989, GDP per 
capita was $1,674. In 2009, Philippines ranked 160th in GDP per capita. The total fertility rate declined from 6 children in 1975-
80 to 3.34 in 2000-05. In 1995, about 45% of the births were unplanned. In 2009, the family planning effort score was 30%, which 
was substantially lower than the Asia average of 54%. 
Poland One study, carried out in 1995, was included in the systematic review included in this OoR. GDP per capita in 1995 was $7,256. 
The total fertility rate dropped from 2.07 in 1989 to 1.22 in 2003. In 1991, contraceptive prevalence in Poland was 49%.  
Thailand 
 
Two studies, conducted in 1998 and 1990, were included in the systematic reviews selected in this OoR. GDP per capita in 1998 
and 1990 was $2,207 and $2,903 respectively. The total fertility rate in during 1995-2000 was 1.86. In 1996, the most popular 
method of family planning was the pill (32%), followed by female sterilisation (31%). Other modern family planning methods 
accounted for less than 5%.  
Taiwan 
 
One study, published in 1987, was included in the systematic review included in this OoR. GDP per capita in 1989 was $8,985. In 
2009, Taiwan ranked 42nd in GDP per capita. The most popular family planning method in 1992 was female sterilisation (33%), 
followed by IUDs (27%), barrier methods (22%) and pills (6%). In 2003, the total fertility rate was 1.57.  
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Turkey  One study, carried out in 1985, was included in the systematic review included in this OoR. GDP per capita in 1985 was 
$3,838.Total fertility in 1984 was around 3.9, which dropped to 2.12 in 2009. Contraceptive prevalence in 1993 was around 63%. 
In 2009, the family planning effort was 53%, which was slightly higher than the Middle East/North Africa average of 52%. 
Vietnam One study, carried out in 1996, was included in the systematic review included in this OoR. GDP per capita in 1996 was $1,106. In 
1997, the total fertility rate was 2.3. Contraceptive prevalence in 1994 was around 65%. Among currently married women, about 
40% used IUDs, followed by sterilisation (7%), condoms (5%) and the pill (4%). In 2009, the family planning effort score was 71%, 
which was substantially higher than the Asia average of 54%. 
Zambia One study, carried out in 2007, was included in the systematic review included in this OoR. GDP per capita in 2007 was $1,380. 
The contraceptive prevalence rate in 2007 was 26%. Unmet need for family planning in the same period was 27%. In 2007, the 
most popular family planning method was the pill (27%), followed by injections (21%), condoms (12%) and female sterilisation 
(5%). The total fertility rate was 6.2 in 2007. Government clinics/pharmacies are the main source of contraception (about 70%). In 
2009, the family planning effort was 45%, which was lower than the Sub-Saharan Africa average (47%). 
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